PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
1796924-0	1991	Effects of successive doses of nizatidine, cimetidine and ranitidine on serum gastrin level and gastric acid secretion.	Ranitidine	58-68	gastrin	Rattus norvegicus	78-85
1796924-2	1991	In the present experiment, the effects of single s.c. administration of nizatidine, cimetidine and ranitidine on serum gastrin levels were studied in fasted rats.	Ranitidine	99-109	gastrin	Rattus norvegicus	119-126
1796924-4	1991	Cimetidine and ranitidine at respective doses of 250 and 100 mg/kg markedly increased serum gastrin levels 3 and 6 h after administration.	Ranitidine	15-25	gastrin	Rattus norvegicus	92-99
1874162-6	1991	Thus, the serum gastrin concentration was increased in response to ranitidine-evoked blockade of the gastric acid output; the rise in gastrin was associated with a transient drop in blood calcium.	Ranitidine	67-77	gastrin	Rattus norvegicus	16-23
1874162-6	1991	Thus, the serum gastrin concentration was increased in response to ranitidine-evoked blockade of the gastric acid output; the rise in gastrin was associated with a transient drop in blood calcium.	Ranitidine	67-77	gastrin	Rattus norvegicus	134-141
1685675-9	1991	Fasting and meal-stimulated plasma gastrin concentrations were increased on the final treatment day with ranitidine and famotidine but had returned to pretreatment levels two days after treatment.	Ranitidine	105-115	gastrin	Homo sapiens	35-42
2056280-6	1991	The histamine-mediated decrease in TNF-alpha synthesis was not affected by indomethacin, nor by diphenhydramine, an H1 receptor antagonist, but was reversed by cimetidine or ranitidine, H2 receptor antagonists, in a dose-dependent manner.	Ranitidine	174-184	tumor necrosis factor	Homo sapiens	35-44
1862300-0	1991	24-hour intragastric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in patients with reflux esophagitis.	Ranitidine	94-104	gastrin	Homo sapiens	40-47
1675461-2	1991	Cimetidine, rantidine, famotidine, and nizantidine are histamine H2-receptor antagonists that block this action of histamine, reducing gastric acid output and concentration under both basal and stimulated conditions.	Ranitidine	12-21	histamine receptor H2	Homo sapiens	55-76
1888830-1	1991	Ranitidine hydrochloride, a histamine H2-receptor antagonist, was intravenously administered to 61 pregnant women at a dose of 50 mg as premedication for caesarean section; its effects on gastric secretion were studied in the mother and the newborn.	Ranitidine	0-24	histamine receptor H2	Homo sapiens	28-49
2046687-3	1991	These changes are seen with the histamine H2 receptor antagonists loxtidine, SKF 93479, ICI 162,846 and ranitidine; with the hypolipidaemic agents clofibrate, ciprofibrate and benzofibrate; with sodium bicarbonate and pentagastrin; and with omeprazole, a potent inhibitor of the parietal cell proton pump mechanism.	Ranitidine	104-114	histamine receptor H 2	Rattus norvegicus	32-53
2043287-1	1991	Ranitidine was first marketed in 1981; since then many patients have been treated such that much experience has been accumulated on the safety of this histamine H2-receptor antagonist in the treatment of gastroduodenal disease.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	151-172
1680274-4	1991	Using H1 receptor (cetirizin and loderix) and H2 receptor (cimetidine and ranitidine) specific antagonists, an H1-dependent stimulation of IL-6 binding by CESS cells was found.	Ranitidine	74-84	interleukin 6	Homo sapiens	139-143
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	223-233	interleukin 2	Mus musculus	29-33
2023098-5	1991	Spontaneous and in vitro interleukin-2- and interferon-alpha-stimulated natural killer cell activity improved in the ranitidine-treated patients in contrast to a decrease in nontreated patients (#p less than 0.03, #p less than 0.01, #p less than 0.02 between groups, respectively).	Ranitidine	117-127	interleukin 2	Homo sapiens	25-38
2023098-6	1991	Furthermore, T-cell blastogenesis to phytohemagglutinin stimulation and soluble interleukin-2 receptors in serum increased in ranitidine-treated patients compared with nontreated patients (#p less than 0.01).	Ranitidine	126-136	interleukin 2	Homo sapiens	80-93
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	297-307	interleukin 2	Mus musculus	29-33
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	297-307	interleukin 2	Mus musculus	123-127
1989762-10	1991	Mean calculated gastric pHi was 7.30 +/- 0.11 in the untreated group and 7.39 +/- 0.03 in the ranitidine-treated group (p less than .03).	Ranitidine	94-104	glucose-6-phosphate isomerase	Homo sapiens	24-27
1682955-5	1991	In the presence of 100 mumol/l histamine the Ki values (mumol/l) for the histamine H2 receptor antagonists averaged 1.45 (cimetidine), 0.10 (ranitidine), and 0.02 (famotidine).	Ranitidine	141-151	histamine receptor H2	Homo sapiens	73-94
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	297-307	interleukin 2	Mus musculus	123-127
1974182-2	1990	Histamine H2-receptor antagonists (e.g. cimetidine, ranitidine and more recently famotidine and nizatidine) have revolutionised the treatment of peptic acid disorders, but their role is currently challenged by muscarinic-M1-receptor antagonists (e.g. pirenzepine), proton pump inhibitors (e.g. omeprazole), prostaglandin analogues and site-protective drugs (e.g. colloidal bismuth subcitrate and sucralfate).	Ranitidine	52-62	histamine receptor H2	Homo sapiens	0-21
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	297-307	interleukin 2	Mus musculus	123-127
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	297-307	interleukin 2	Mus musculus	29-33
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	297-307	interleukin 2	Mus musculus	123-127
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	297-307	interleukin 2	Mus musculus	123-127
2147942-6	1990	The antimetastatic effect of IL-2 was potentiated by histamine; in some experiments, combined treatment with a low dose of IL-2 (6000 U/kg) and histamine completely eliminated metastasis, whereas concomitant treatment with ranitidine abrogated antimetastatic effects of IL-2; animals treated with ranitidine and IL-2 displayed the same level of enhanced metastasis as those treated with ranitidine alone.	Ranitidine	297-307	interleukin 2	Mus musculus	123-127
2084458-1	1990	The effect of ranitidine on both induced (phenobarbital) and uninduced cytochrome P450 enzymes was investigated in mice using the [14C]-labeled antipyrine breath test.	Ranitidine	14-24	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	71-86
2390929-5	1990	Plaunotol in combination with ranitidine significantly increased secretin release and inhibited gastrin release after a meal.	Ranitidine	30-40	gastrin	Homo sapiens	96-103
2390929-6	1990	Intravenous infusion of secretin resulted in significant suppression of postprandial gastrin release exaggerated by ranitidine.	Ranitidine	116-126	gastrin	Homo sapiens	85-92
1675024-9	1991	Since acid blockade by proton pump inhibitors or H2-receptor blockers dose-dependently increase serum gastrin levels, patients with ranitidine-resistant peptic ulceration receiving long-term treatment with high-dose omeprazole have been followed up with serial gastric biopsy specimens for up to 5 years.	Ranitidine	132-142	gastrin	Homo sapiens	102-109
1981005-4	1990	The patient"s serum IgE concentration increased markedly to 2590 IU/ml 10 days after admission, and skin tests for cimetidine and ranitidine were positive.	Ranitidine	130-140	immunoglobulin heavy constant epsilon	Homo sapiens	20-23
1965331-4	1990	Glyceryl trinitrate-induced cyclic GMP stimulation remained unaltered by ranitidine (0.1 mmol/l), which has a much lower affinity for the cytochrome P-450 enzyme system.	Ranitidine	73-83	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	138-154
2103756-0	1990	Gastric histology and plasma gastrin response to a meal in patients with duodenal ulcer disease after five years treatment with ranitidine.	Ranitidine	128-138	gastrin	Homo sapiens	29-36
2241595-1	1990	This prospective multicentric randomized open trial was designed to evaluate the efficacy of ranitidine 150 mg bid vs 300 mg nocte in the short-term (4 weeks) treatment of duodenal ulcer in 15 Brazilian centers.	Ranitidine	93-103	BH3 interacting domain death agonist	Homo sapiens	111-114
2343160-6	1990	Also, the increase in serum gastrin concentration following intraperitoneal injection of the histamine H2-receptor antagonist ranitidine was associated with a drop in blood Ca2+ and also the ranitidine-evoked hypocalcemia could be prevented by gastrectomy.	Ranitidine	126-136	gastrin	Rattus norvegicus	28-35
2343160-6	1990	Also, the increase in serum gastrin concentration following intraperitoneal injection of the histamine H2-receptor antagonist ranitidine was associated with a drop in blood Ca2+ and also the ranitidine-evoked hypocalcemia could be prevented by gastrectomy.	Ranitidine	126-136	histamine receptor H 2	Rattus norvegicus	93-114
2343160-6	1990	Also, the increase in serum gastrin concentration following intraperitoneal injection of the histamine H2-receptor antagonist ranitidine was associated with a drop in blood Ca2+ and also the ranitidine-evoked hypocalcemia could be prevented by gastrectomy.	Ranitidine	191-201	gastrin	Rattus norvegicus	28-35
2343160-6	1990	Also, the increase in serum gastrin concentration following intraperitoneal injection of the histamine H2-receptor antagonist ranitidine was associated with a drop in blood Ca2+ and also the ranitidine-evoked hypocalcemia could be prevented by gastrectomy.	Ranitidine	191-201	histamine receptor H 2	Rattus norvegicus	93-114
2093018-6	1990	Basal serum gastrin levels, which were already elevated by the previous high-dose ranitidine treatment, rose to 4 times normal levels after 4 months of treatment with omeprazole.	Ranitidine	82-92	gastrin	Homo sapiens	12-19
1972605-4	1990	After pretreatment with ranitidine, a specific histamine H2-receptor antagonist, the diastolic pressure rise no longer sufficed to maintain a constant systolic pressure during LBNP.	Ranitidine	24-34	histamine receptor H2	Homo sapiens	47-68
1983349-4	1990	During oral dosing with ranitidine 300 mg, compared with intravenous saline, the pentagastrin infusion returned acidity towards normal (67 to 293 pmol.h/L; P less than 0.001) and lowered gastrin (209 to 135 pmol.h/L; P less than 0.001).	Ranitidine	24-34	gastrin	Homo sapiens	86-93
35578169-11	2022	While the structurally similar H2R antagonist tiotidine displayed equivalent anti-inflammatory activity, the H2R antagonists cimetidine or ranitidine were ineffective even at very high dosages.	Ranitidine	139-149	histamine receptor H2	Mus musculus	109-112
2401392-0	1990	Effect of 20 weeks" ranitidine treatment on plasma gastrin levels and gastric enterochromaffin-like cell density in the rat.	Ranitidine	20-30	gastrin	Rattus norvegicus	51-58
2401393-2	1990	It has been argued that short-acting, surmountable histamine H2-receptor blockers such as ranitidine do not cause carcinoids.	Ranitidine	90-100	histamine receptor H 2	Rattus norvegicus	51-72
2401393-3	1990	In this study, female rats (n = 100) were treated for 2 years with the histamine H2-receptor blocker ranitidine, 2 g/kg/day in the diet.	Ranitidine	101-111	histamine receptor H 2	Rattus norvegicus	71-92
2150668-8	1990	The effect of histamine on NK cell responsiveness to IL-2 was mediated by H2-type histamine receptors, as judged by mimicry exerted by the specific H2 receptor agonist dimaprit, but not by an H2-receptor-inactive derivative of this compound, N-methyldimaprit, and blocking by the H2 receptor antagonist ranitidine.	Ranitidine	303-313	interleukin 2	Homo sapiens	53-57
33803769-5	2021	Some of these ranitidine analogs also possessed potent inhibitory activities of acetylcholinesterase (AChE), which is another therapeutic target in AD.	Ranitidine	14-24	acetylcholinesterase (Cartwright blood group)	Homo sapiens	80-100
33803769-5	2021	Some of these ranitidine analogs also possessed potent inhibitory activities of acetylcholinesterase (AChE), which is another therapeutic target in AD.	Ranitidine	14-24	acetylcholinesterase (Cartwright blood group)	Homo sapiens	102-106
33803769-6	2021	These ranitidine analogs, by addressing both Abeta aggregation and AChE, offer insight into the key chemical features of a new type of multi-target directed ligands for the pharmaceutical treatment of AD.	Ranitidine	6-16	acetylcholinesterase (Cartwright blood group)	Homo sapiens	67-71
34986535-10	2021	Compared with the model control group, FD groups and ranitidine group significantly reduced the levels of TNF-alpha, IL-1beta, IL-6 in serum and the MDA content in the gastric tissues, and increased the activity of SOD, CAT and GSH in gastric tissues (all <0.05).	Ranitidine	53-63	tumor necrosis factor	Rattus norvegicus	106-115
34986535-10	2021	Compared with the model control group, FD groups and ranitidine group significantly reduced the levels of TNF-alpha, IL-1beta, IL-6 in serum and the MDA content in the gastric tissues, and increased the activity of SOD, CAT and GSH in gastric tissues (all <0.05).	Ranitidine	53-63	interleukin 1 alpha	Rattus norvegicus	117-125
34986535-10	2021	Compared with the model control group, FD groups and ranitidine group significantly reduced the levels of TNF-alpha, IL-1beta, IL-6 in serum and the MDA content in the gastric tissues, and increased the activity of SOD, CAT and GSH in gastric tissues (all <0.05).	Ranitidine	53-63	interleukin 6	Rattus norvegicus	127-131
34986535-10	2021	Compared with the model control group, FD groups and ranitidine group significantly reduced the levels of TNF-alpha, IL-1beta, IL-6 in serum and the MDA content in the gastric tissues, and increased the activity of SOD, CAT and GSH in gastric tissues (all <0.05).	Ranitidine	53-63	catalase	Rattus norvegicus	220-223
34470951-7	2021	A, C, and E was 100 times higher than that from crystalline ranitidine hydrochloride under forced degradation at 110  C for 1 h. Surprisingly, crystalline Imp.	Ranitidine	60-84	inositol monophosphatase 1	Homo sapiens	155-158
2277968-2	1990	Furthermore, we have demonstrated in eight patients with reflux oesophagitis that 2-week treatment courses with 300 mg ranitidine twice daily and 300 mg four times daily progressively decreased 24-h intraoesophageal acidity but only moderately elevated basal and meal-stimulated serum gastrin concentrations, significantly below gastrin values obtained after a 2-week treatment course with 20mg omeprazole once daily.	Ranitidine	119-129	gastrin	Homo sapiens	285-292
2277968-2	1990	Furthermore, we have demonstrated in eight patients with reflux oesophagitis that 2-week treatment courses with 300 mg ranitidine twice daily and 300 mg four times daily progressively decreased 24-h intraoesophageal acidity but only moderately elevated basal and meal-stimulated serum gastrin concentrations, significantly below gastrin values obtained after a 2-week treatment course with 20mg omeprazole once daily.	Ranitidine	119-129	gastrin	Homo sapiens	329-336
3529778-0	1986	The role of ranitidine infusion on glucose, insulin and C-peptide serum levels induced by oral glucose tolerance test in healthy subjects.	Ranitidine	12-22	insulin	Homo sapiens	56-65
3529778-1	1986	In 9 healthy subjects we evaluated the effect of a constant ranitidine infusion (100 mg) on glucose (mg/dl), insulin (microU/ml) and C-peptide (ng/ml) serum levels promoted by oral glucose tolerance test (75 g).	Ranitidine	60-70	insulin	Homo sapiens	133-142
34170952-1	2021	Ranitidine HCl, a selective, competitive histamine H2-receptor antagonist with a short biological half-life, low bioavailability and narrow absorption window, is an ideal candidate for gastro-retentive drug delivery system (GRDDS).	Ranitidine	0-14	histamine receptor H2	Homo sapiens	41-62
35134455-2	2022	The considered ligands are clinical drugs with different binding constants to albumin: relatively strong binders (naproxen, ibuprofen, warfarin with 105 to 107 binding constant values) and weak binders (isoniazid, ranitidine with 103 to 104 binding constant values).	Ranitidine	214-224	albumin	Homo sapiens	78-85
35441176-14	2022	While the structurally similar H2R antagonist tiotidine displayed equivalent anti-inflammatory activity, the H2R antagonists cimetidine or ranitidine were ineffective even at very high dosages.	Ranitidine	139-149	histamine receptor H2	Mus musculus	109-112
2751854-3	1989	Ranitidine induces an improvement in scores of subjective and objective symptoms, a decrease in total serum IgE levels, and no significant variations in Parietaria IgE antibody levels.	Ranitidine	0-10	immunoglobulin heavy constant epsilon	Homo sapiens	108-111
2590612-7	1989	Coadministration of ranitidine significantly raised intragastric pH and reduced aspirin induced bleeding to 1.5 microliters 10 min-1 (1.0-2.3 microliters 10 min-1) after 5 days and 1.6 (1.0-2.5 microliters 10 min-1) after 12 days (P less than 0.05).	Ranitidine	20-30	CD59 molecule (CD59 blood group)	Homo sapiens	127-132
2590612-7	1989	Coadministration of ranitidine significantly raised intragastric pH and reduced aspirin induced bleeding to 1.5 microliters 10 min-1 (1.0-2.3 microliters 10 min-1) after 5 days and 1.6 (1.0-2.5 microliters 10 min-1) after 12 days (P less than 0.05).	Ranitidine	20-30	CD59 molecule (CD59 blood group)	Homo sapiens	157-162
2590612-7	1989	Coadministration of ranitidine significantly raised intragastric pH and reduced aspirin induced bleeding to 1.5 microliters 10 min-1 (1.0-2.3 microliters 10 min-1) after 5 days and 1.6 (1.0-2.5 microliters 10 min-1) after 12 days (P less than 0.05).	Ranitidine	20-30	CD59 molecule (CD59 blood group)	Homo sapiens	157-162
2697116-1	1989	In a randomized double-blind study the gastroduodenal tolerability of 300 mg ASS daily has been evaluated in the presence of 150 mg ranitidine bid or placebo in 20 healthy volunteers using upper GI-endoscopy.	Ranitidine	132-142	BH3 interacting domain death agonist	Homo sapiens	143-146
2697116-6	1989	Concomitant administration of 150 mg ranitidine bid afforded almost full protection against 300 mg ASS daily both on day 7 and day 14 (1.9 +/- 0.6 and 2.1 +/- 0.8, respectively) (p less than 0.05).	Ranitidine	37-47	BH3 interacting domain death agonist	Homo sapiens	48-51
2697116-7	1989	Our data suggest that coadministration of ranitidine 150 mg bid reduces almost completely gastroduodenal lesions evoked by acetylsalicylic acid 300 mg daily.	Ranitidine	42-52	BH3 interacting domain death agonist	Homo sapiens	60-63
2688344-5	1989	Perioperative ranitidine diminished the expected postoperative reduction in DTH responses (p less than 0.0001), as well as in spontaneous NK-cell activity (p less than 0.03) and in vitro IL-2 stimulated NK-cell activity (p less than 0.02).	Ranitidine	14-24	interleukin 2	Homo sapiens	187-191
2570382-2	1989	A comparison between the latter and the other cases treated with a variety of drugs (aprotinin, cimetidine, ranitidine) led to the following conclusions: 1) somatostatin significantly improves the clinical course of acute oedematous pancreatitis with circumscribed necrosis; 2) it makes no difference to the development of cases with diffuse necrosis and haemorrhage.	Ranitidine	108-118	somatostatin	Homo sapiens	157-169
2573049-6	1989	These results do not correlate with the in vitro data, where ORF-17578 and ranitidine were the most potent entities with respect to acetylcholinesterase inhibition (approximately 1-2 X 10(-6) M), followed by nizatidine greater than cimetidine greater than famotidine.	Ranitidine	75-85	acetylcholinesterase	Mus musculus	132-152
2573049-7	1989	The sulfoxide metabolites of ranitidine and cimetidine were approximately one-tenth as potent as their parent compounds with respect to inhibition of acetylcholinesterase.	Ranitidine	29-39	acetylcholinesterase	Mus musculus	150-170
2482713-1	1989	The activity of gamma-glutamyl transpeptidase (gamma-GT) in duodenal mucosa both in healthy rats and in rats experimentally ulcerated with indomethacin increases significantly after oral administration of pirenzepine as well as ranitidine but not after oral administration of sucralphate.	Ranitidine	228-238	gamma-glutamyltransferase 1	Rattus norvegicus	16-45
2482713-1	1989	The activity of gamma-glutamyl transpeptidase (gamma-GT) in duodenal mucosa both in healthy rats and in rats experimentally ulcerated with indomethacin increases significantly after oral administration of pirenzepine as well as ranitidine but not after oral administration of sucralphate.	Ranitidine	228-238	gamma-glutamyltransferase 1	Rattus norvegicus	47-55
2482713-2	1989	These increase in gamma-GT activity may contribute to the cytoprotective effects already described for pirenzepine and ranitidine.	Ranitidine	119-129	gamma-glutamyltransferase 1	Rattus norvegicus	18-26
2667937-2	1989	Ranitidine, a histamine H2-receptor antagonist, is now well established as a potent inhibitor of gastric acid secretion effective in the treatment and prophylaxis of gastrointestinal lesions aggravated by gastric acid secretion.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	14-35
2753306-5	1989	The half-life effect of ranitidine (t1/2 E) was significantly (p less than or equal to 0.05) greater than t1/2 E of cimetidine whereas their plasma half-lives (t1/2) were similar.	Ranitidine	24-34	interleukin 1 receptor like 1	Homo sapiens	36-42
2753306-6	1989	The ratio t1/2 E/t1/2 was significantly (p less than or equal to 0.05) lower with cimetidine than with ranitidine.	Ranitidine	103-113	CD6 molecule	Homo sapiens	10-21
2568738-3	1989	We studied the effect of cimetidine, ranitidine and famotidine on the monoxygenase, the oxidase and the peroxidase action of cytochrome P-450.	Ranitidine	37-47	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	125-141
2756157-6	1989	In both groups, there was a great increase in plasma gastrin, somewhat greater after omeprazole than after ranitidine.	Ranitidine	107-117	gastrin	Rattus norvegicus	53-60
2568738-5	1989	Ranitidine and famotidine (both pharmacodynamically more potent than cimetidine) only slightly affected cytochrome P-450 activities.	Ranitidine	0-10	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	104-120
2565384-0	1989	Acute effects of ranitidine, famotidine and omeprazole on plasma gastrin in the rat.	Ranitidine	17-27	gastrin	Rattus norvegicus	65-72
2565384-7	1989	Differences in peak gastrin levels between compounds disappeared at increased dose levels of 500 mg/kg for ranitidine, 200 or 2000 mg/kg for famotidine and 140 mg/kg for omeprazole.	Ranitidine	107-117	gastrin	Rattus norvegicus	20-27
2470453-14	1989	The H2 receptor antagonist ranitidine (2 mumol 1(-1)) did not inhibit basal acid secretion, but acid outputs with gastrin and all histamine agonists were reduced.	Ranitidine	27-37	gastrin	Rattus norvegicus	114-121
2734586-4	1989	There was very good correlation between plasma gastrin levels and HDC activity for both compounds, although higher oxyntic mucosal HDC activity was found during ranitidine treatment.	Ranitidine	161-171	histidine decarboxylase	Rattus norvegicus	131-134
2734586-5	1989	The higher HDC activity in the ranitidine-treated rats indicated the presence of a histamine H2-receptor on the ECL cells.	Ranitidine	31-41	histidine decarboxylase	Rattus norvegicus	11-14
2734586-5	1989	The higher HDC activity in the ranitidine-treated rats indicated the presence of a histamine H2-receptor on the ECL cells.	Ranitidine	31-41	histamine receptor H 2	Rattus norvegicus	83-104
2467982-1	1989	Ranitidine, procainamide and its active N-acetyl metabolite (NAPA) are renally secreted bases which can compete for carrier-mediated transport processes.	Ranitidine	0-10	NSF attachment protein alpha	Homo sapiens	61-65
2542384-2	1989	The effects of H2-receptor antagonists, cimetidine and ranitidine, on plasma aldosterone response to angiotensin II (AII) were examined in six healthy subjects.	Ranitidine	55-65	angiotensinogen	Homo sapiens	101-115
2542384-9	1989	A significant correlation was observed between AII and PA with placebo (P less than 0.01) and ranitidine (P less than 0.01), but not with cimetidine (P greater than 0.05).	Ranitidine	94-104	angiotensinogen	Homo sapiens	47-50
2467982-2	1989	The effect of ranitidine on the disposition of procainamide and NAPA was evaluated in 13 healthy men.	Ranitidine	14-24	NSF attachment protein alpha	Homo sapiens	64-68
2905866-0	1988	Histamine H2-receptor blocking activity of ranitidine and lamtidine analogues containing aminomethyl-substituted aliphatic systems.	Ranitidine	43-53	histamine receptor H 2	Rattus norvegicus	0-21
2490777-5	1989	A limit of detection of 3 ng ml-1 was obtained for a 100-microliters injection of ranitidine.	Ranitidine	82-92	interleukin 17F	Homo sapiens	29-33
2646846-1	1989	Hepatic cytochrome-P-450-linked microsomal metabolism is inhibited by cimetidine, and to a lesser extent by ranitidine.	Ranitidine	108-118	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	8-24
2566988-0	1989	Histamine H2-receptor blocking activity of ranitidine analogues containing 3-amino-4-alkylaminofurazan moieties.	Ranitidine	43-53	histamine receptor H2	Homo sapiens	0-21
2513641-6	1989	Serum gastrin levels were already elevated approximately 2-fold during the initial high-dose ranitidine treatment and rose a further 2-fold at 2-3 months of omeprazole treatment.	Ranitidine	93-103	gastrin	Homo sapiens	6-13
3243180-3	1988	We recently observed a 66-year-old man whose steady-state serum phenytoin concentration increased 40 percent during one month after the addition to his regimen of ranitidine 150 mg bid.	Ranitidine	163-173	BH3 interacting domain death agonist	Homo sapiens	181-184
2904394-4	1988	Dosing with ranitidine 300 mg at 21:00 h also caused a simultaneous significant decrease of morning acidity (-32%; p less than 0.05) with a significant increase of plasma gastrin concentration (+36%; p less than 0.05), but the antisecretory effects of nizatidine 150 or 300 mg at 21:00 h were only observed during the night, with no effect during the morning.	Ranitidine	12-22	gastrin	Homo sapiens	171-178
3181674-2	1988	In intact rats plasma gastrin levels were increased during a 20-wk treatment course with either omeprazole or ranitidine.	Ranitidine	110-120	gastrin	Rattus norvegicus	22-29
2856577-0	1988	A new rapid HPLC assay for the simultaneous determination of two histamine H2-receptor antagonists, cimetidine and ranitidine, in human plasma.	Ranitidine	115-125	histamine receptor H2	Homo sapiens	65-86
2900598-0	1988	New ranitidine analogues containing the 2-aminobenzimidazole moiety: in vivo and in vitro histamine H2-receptor blocking activity.	Ranitidine	4-14	histamine receptor H 2	Rattus norvegicus	90-111
3245740-7	1988	These results seem to cast a doubt on the generally held ACh release hypothesis for the action mechanism of metoclopramide on one hand, and suggest, on the other hand, that cholinesterase inhibition contributes to some extent to the gastrokinetic effects of metoclopramide and ranitidine.	Ranitidine	277-287	butyrylcholinesterase	Rattus norvegicus	173-187
3245740-6	1988	In rat fundus homogenates, metoclopramide and ranitidine showed a significant cholinesterase inhibition.	Ranitidine	46-56	butyrylcholinesterase	Rattus norvegicus	78-92
3183868-10	1988	Our results suggest that pretreatment serum PG I levels in children with PUD may predict fairly accurately which will not relapse after attaining ulcer healing by a short-term ranitidine course.	Ranitidine	176-186	biglycan	Homo sapiens	44-48
2899659-2	1988	that were without effect per se on the secretion of gastric acid in pylorus ligated (Shay) rats, potentiated the antisecretory effects of the histamine H2 receptor antagonists cimetidine and ranitidine in this model but not those of the muscarine receptor antagonist pirenzepine nor those of the proton pump inhibitor omeprazole.	Ranitidine	191-201	histamine receptor H 2	Rattus norvegicus	142-163
2900546-5	1988	Within the dose-response range of the inhibition of gastric acid secretion, cimetidine and ranitidine increased significantly the serum gastrin levels, but famotidine and TZU-0460 did not.	Ranitidine	91-101	gastrin	Rattus norvegicus	136-143
2899931-4	1988	Histamine and three of these drugs, namely cimetidine, ranitidine and famotidine, were weak inhibitors of this cytochrome P-450-catalysed O-deethylation, but mifentidine was a potent competitive inhibitor with a Ki in the range 40-70 microM.	Ranitidine	55-65	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	111-127
3346844-2	1988	Ranitidine is thought to spare phase I hepatic metabolism mediated by cytochrome P-450, unlike its counterpart H2-receptor antagonist cimetidine.	Ranitidine	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-86
3394579-3	1988	In the HGT-1 human gastric cancer cell line, famotidine and ranitidine showed long lasting, irreversible actions probably related to a slow rate of dissociation from the histamine H2-receptor.	Ranitidine	60-70	solute carrier family 25 member 16	Homo sapiens	7-12
3394579-3	1988	In the HGT-1 human gastric cancer cell line, famotidine and ranitidine showed long lasting, irreversible actions probably related to a slow rate of dissociation from the histamine H2-receptor.	Ranitidine	60-70	histamine receptor H2	Homo sapiens	170-191
3410170-9	1988	Serum gastrin levels were already elevated during the initial high-dose ranitidine treatment (106 +/- 15.4 pg/ml).	Ranitidine	72-82	gastrin	Homo sapiens	6-13
2896770-0	1988	Pharmacological profile of new histamine H2-receptor antagonists related to cimetidine, ranitidine and lamtidine.	Ranitidine	88-98	histamine receptor H 2	Rattus norvegicus	31-52
3127265-9	1988	Gastrin levels reflected changes in intragastric pH over the 24 h time frame and were noted to increase during ranitidine and enteral nutrition.	Ranitidine	111-121	gastrin	Homo sapiens	0-7
2440285-1	1987	Anti-IgE induced histamine release from isolated basophils after Cimetidine and Ranitidine administration was evaluated in 22 patients with atopic bronchial asthma.	Ranitidine	80-90	immunoglobulin heavy constant epsilon	Homo sapiens	5-8
2892407-5	1987	The histamine (H2)-receptor antagonists cimetidine and ranitidine have also been used successfully as prophylactic therapy when enough time is available prior to operation to make preoperative dosing practical.	Ranitidine	55-65	histamine receptor H2	Homo sapiens	4-27
3428700-0	1987	Cimetidine and ranitidine on basal and ACTH-stimulated steroidogenesis.	Ranitidine	15-25	proopiomelanocortin	Homo sapiens	39-43
3695537-3	1987	Rats were dosed orally for 4 days with the histamine H2-receptor antagonist ranitidine or the H+,K+-sensitive ATPase inhibitor omeprazole, and examined on day 5 for effects on gastric acid secretion and serum gastrin.	Ranitidine	76-86	histamine receptor H 2	Rattus norvegicus	43-64
3695537-5	1987	Large, single daily doses of ranitidine (1000-2000 mg/kg/day) had no effect on 24-hr acid or gastrin secretion; however, ranitidine did inhibit next-day acid secretion with associated increases in serum gastrin when administered in three divided doses.	Ranitidine	121-131	gastrin	Rattus norvegicus	203-210
3630858-0	1987	Effects of ranitidine on the enzyme cholinesterase and the rat anococcygeus muscle.	Ranitidine	11-21	butyrylcholinesterase	Rattus norvegicus	36-50
3630858-1	1987	Ranitidine in lower doses, (100 ng and 1 microgram) accelerated the rate of reaction of the enzyme acetylcholinesterase with the substrate acetylthiocholine.	Ranitidine	0-10	acetylcholinesterase	Rattus norvegicus	99-119
3647281-2	1987	Subcutaneous pretreatment with a histamine H2-receptor blocking agent, ranitidine, in a dose of 5 mg/kg given 2 h before and at the time of kainic acid injection, partially decreased the edema formation in the thalamus.	Ranitidine	71-81	histamine receptor H 2	Rattus norvegicus	33-54
3340272-4	1988	Intracerebroventricular infusion of the H2 receptor antagonists cimetidine (CIM: 100 micrograms) or ranitidine (RAN: 125 micrograms) abolished the PRL response to HA (p less than 0.01), while intracerebroventricular infusion of the H1 receptor antagonist mepyramine (MEP; 100 micrograms) inhibited the response only 40% (p less than 0.05).	Ranitidine	100-110	RAN, member RAS oncogene family	Rattus norvegicus	112-115
3340272-4	1988	Intracerebroventricular infusion of the H2 receptor antagonists cimetidine (CIM: 100 micrograms) or ranitidine (RAN: 125 micrograms) abolished the PRL response to HA (p less than 0.01), while intracerebroventricular infusion of the H1 receptor antagonist mepyramine (MEP; 100 micrograms) inhibited the response only 40% (p less than 0.05).	Ranitidine	100-110	prolactin	Rattus norvegicus	147-150
2891837-5	1987	Pretreatment with three histamine H2 receptor antagonists (cimetidine, ranitidine, BMY-25271), prevented both of these effects in a dose-related manner.	Ranitidine	71-81	histamine receptor H2	Canis lupus familiaris	24-45
2821082-0	1987	Effect of ranitidine on the aldosterone response to angiotensin II in healthy subjects.	Ranitidine	10-20	angiotensinogen	Homo sapiens	52-66
3497460-2	1987	Cimetidine and ranitidine increase interleukin-2 production.	Ranitidine	15-25	interleukin 2	Mus musculus	35-48
3497460-3	1987	The effect of cimetidine and ranitidine (histamine type-2 receptor antagonists) on the production of interleukin-2 (IL-2) by mitogen-activated, normal murine spleen cells was studied in vitro.	Ranitidine	29-39	interleukin 2	Mus musculus	101-114
3497460-3	1987	The effect of cimetidine and ranitidine (histamine type-2 receptor antagonists) on the production of interleukin-2 (IL-2) by mitogen-activated, normal murine spleen cells was studied in vitro.	Ranitidine	29-39	interleukin 2	Mus musculus	116-120
3497460-5	1987	Ranitidine (10(-4) mol/L to 10(-6) mol/L) also increased IL-2 production to a maximal 5.6 +/- 1.2 U, as compared with media controls of 1 U.	Ranitidine	0-10	interleukin 2	Mus musculus	57-61
2979226-3	1987	Median integrated 24-hour intragastric acidity was decreased significantly from 1148 to 490 and 36 mmol.hour litre-1 during treatment with ranitidine and omeprazole, respectively, whilst median intragastric 24-hour plasma gastrin was raised significantly from 328 to 799 and 1519 pmol.hour litre-1 respectively.	Ranitidine	139-149	gastrin	Homo sapiens	222-229
2891536-0	1987	Effect of 6-hourly intermittent intravenous boluses of oxmetidine and ranitidine on gastric acidity and serum prolactin.	Ranitidine	70-80	prolactin	Homo sapiens	110-119
2438708-3	1987	The prolongation of the decay phase of the synaptic current induced by the "selective" H2-antagonist Ranitidine, and to a lesser extent and at higher concentrations by Cimetidine, resembles that of the cholinesterase inhibitors.	Ranitidine	101-111	butyrylcholinesterase	Mus musculus	202-216
2882981-1	1987	Famotidine is a new histamine H2-receptor antagonist which has been demonstrated to be more potent than cimetidine and ranitidine in inhibiting gastric acid secretion.	Ranitidine	119-129	histamine receptor H 2	Rattus norvegicus	20-41
2895455-5	1987	The interaction that occurs with theophylline and warfarin when the cytochrome P-450 enzyme system is inhibited by cimetidine and ranitidine requires monitoring.	Ranitidine	130-140	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-84
3587694-0	1987	[Blood fibrinogen as a prognostic index in ulcer therapy with ranitidine].	Ranitidine	62-72	fibrinogen beta chain	Homo sapiens	7-17
3653228-15	1987	group had urine output during the study period with renal ranitidine clearance values of 9.9 +/- 9.9 ml X min-1.	Ranitidine	58-68	CD59 molecule (CD59 blood group)	Homo sapiens	106-111
2443458-2	1987	The histamine H2-receptor antagonists cimetidine, ranitidine and tiotidine suppressed NK cell cytotoxicity (NKCC) at a high concentration (10(-3) M).	Ranitidine	50-60	histamine receptor H2	Homo sapiens	4-25
3559884-0	1986	The inhibition of acetylcholinesterase by ranitidine: a study on the guinea pig ileum.	Ranitidine	42-52	acetylcholinesterase	Cavia porcellus	18-38
3818148-5	1986	Mean integrated gastrin responses after pirenzepine and ranitidine alone as well as pirenzepine plus ranitidine were not significantly different from placebo.	Ranitidine	56-66	gastrin	Homo sapiens	16-23
3559884-1	1986	The present work was performed to investigate if the stimulating effect of ranitidine on the intestinal smooth muscle is connected with a possible inhibition of the acetylcholinesterase.	Ranitidine	75-85	acetylcholinesterase	Cavia porcellus	165-185
3559884-6	1986	This acetylcholinesterase activity was inhibited by ranitidine and this inhibition was weaker than that caused by physostigmine.	Ranitidine	52-62	acetylcholinesterase	Cavia porcellus	5-25
2872895-4	1986	Preincubation of HGT-1 cells for 10 min with H2 antagonists at 2 microM concentration resulted in 90-100% inactivation (SKF 93479 and oxmetidine) and 65% inactivation (ranitidine) which persisted for 30 min, even after a washout period.	Ranitidine	168-178	solute carrier family 25 member 16	Homo sapiens	17-22
3023203-0	1986	Dose related in vitro effects of ranitidine and cimetidine on basal and ACTH-stimulated steroidogenesis.	Ranitidine	33-43	proopiomelanocortin	Homo sapiens	72-76
3023203-3	1986	Cimetidine and ranitidine at 320 and 1000 micrograms/ml inhibited ACTH-stimulated corticosterone and cortisol synthesis and cimetidine decreased basal cortisol synthesis.	Ranitidine	15-25	proopiomelanocortin	Homo sapiens	66-70
2874977-3	1986	Recent studies have demonstrated that treatment with the currently available histamine H2-receptor antagonists (cimetidine, ranitidine) with or without an anticholinergic agent will control gastric acid secretion in almost all patients.	Ranitidine	124-134	histamine receptor H2	Homo sapiens	77-98
3722819-7	1986	Furthermore, the enhancement was completely antagonized by the specific histamine H2-receptor antagonists cimetidine and ranitidine.	Ranitidine	121-131	histamine receptor H2	Homo sapiens	72-93
2874096-3	1986	The potency of inhibitory activity of H2-antagonists on acetylcholinesterase estimated from median inhibitory dose were in the following order of decreasing activity: ranitidine greater than TZU-0460 greater than cimetidine greater than YM-11170, whereas that on pseudocholinesterase were TZU-0460 greater than ranitidine greater than cimetidine greater than YM-11170.	Ranitidine	167-177	acetylcholinesterase (Cartwright blood group)	Homo sapiens	56-76
2874096-3	1986	The potency of inhibitory activity of H2-antagonists on acetylcholinesterase estimated from median inhibitory dose were in the following order of decreasing activity: ranitidine greater than TZU-0460 greater than cimetidine greater than YM-11170, whereas that on pseudocholinesterase were TZU-0460 greater than ranitidine greater than cimetidine greater than YM-11170.	Ranitidine	311-321	acetylcholinesterase (Cartwright blood group)	Homo sapiens	56-76
3510144-3	1986	After 10 wk of treatment, plasma gastrin levels were high in unoperated rats treated with the high omeprazole dose and with ranitidine, and low in antrectomized controls.	Ranitidine	124-134	gastrin	Rattus norvegicus	33-40
2874962-0	1986	[Ranitidine: a new histamine H2 receptor blockader].	Ranitidine	1-11	histamine receptor H2	Homo sapiens	19-40
3531308-1	1986	Treatment of duodenal ulcer with the histamine H2-receptor antagonist, ranitidine, was assessed in a double-blind, randomized, multicenter trial in which patients were treated for two consecutive 4-week periods with ranitidine 150 mg b.i.d.	Ranitidine	71-81	histamine receptor H2	Homo sapiens	37-58
2868965-7	1986	Plasma and antral gastrin concentrations were elevated in rats treated with high-dose ranitidine (700 mumol/kg daily), but to a lesser extent than during omeprazole therapy, and somatostatin concentrations were unchanged.	Ranitidine	86-96	gastrin	Rattus norvegicus	18-25
2878726-5	1986	Treatment with 35 micrograms of enprostil BID plus 300 mg of ranitidine BID for two and 11 weeks was associated with an increased number of duodenal G-cells, a decrease in antral D-cells, and a decrease in the number of antral serotonin-containing cells.	Ranitidine	61-71	BH3 interacting domain death agonist	Homo sapiens	72-75
2869182-5	1986	Response was blocked by histamine H2 receptor antagonists (rantidine, famotidine).	Ranitidine	59-68	histamine receptor H2	Homo sapiens	24-45
3003475-1	1986	GABA-evoked contractions of the guinea pig ileum were significantly potentiated by the histamine H2-receptor antagonist ranitidine in concentrations above 10 microM.	Ranitidine	120-130	histamine H2 receptor	Cavia porcellus	87-108
2878726-9	1986	The serum concentrations of total gastrin, G-17, and G-34 were reduced with enprostil and with ranitidine.	Ranitidine	95-105	gastrin	Homo sapiens	34-41
3702129-0	1986	[Chronological effect of histamine H2 receptor antagonist ranitidine as serum gastrin response in gastric ulcer patients].	Ranitidine	58-68	histamine receptor H2	Homo sapiens	25-46
3792673-9	1986	Treatment with high-dose (700 mumol/kg daily) ranitidine also caused an elevation in the G cell population and the antral and plasma content of gastrin, but to a lesser extent than that observed during omeprazole treatment.	Ranitidine	46-56	gastrin	Rattus norvegicus	144-151
3702129-0	1986	[Chronological effect of histamine H2 receptor antagonist ranitidine as serum gastrin response in gastric ulcer patients].	Ranitidine	58-68	gastrin	Homo sapiens	78-85
2866002-2	1985	Using histamine as agonist, pKB values have been estimated for burimamide, metiamide, cimetidine, ranitidine, oxmetidine and famotidine on both the gastric and guinea-pig isolated right atrium assays.	Ranitidine	98-108	thymoma viral proto-oncogene 2	Mus musculus	28-31
3081918-0	1986	Effect of a short-term oral administration of cimetidine and ranitidine on the basal and thyrotropin-releasing hormone-stimulated serum concentrations of prolactin, thyrotropin and thyroid hormones in healthy volunteers.	Ranitidine	61-71	thyrotropin releasing hormone	Homo sapiens	89-118
3081918-0	1986	Effect of a short-term oral administration of cimetidine and ranitidine on the basal and thyrotropin-releasing hormone-stimulated serum concentrations of prolactin, thyrotropin and thyroid hormones in healthy volunteers.	Ranitidine	61-71	prolactin	Homo sapiens	154-163
3081918-7	1986	Both cimetidine and ranitidine induced a significant increase in basal prolactin (PRL) values.	Ranitidine	20-30	prolactin	Homo sapiens	71-80
3460171-5	1986	Gastrin levels were increased in unoperated rats treated with the high omeprazole dose and with ranitidine, whereas they were lowered in antrectomized controls.	Ranitidine	96-106	gastrin	Rattus norvegicus	0-7
2424035-3	1986	This response was reduced by the histamine H2-receptor antagonist ranitidine (IC50 = 3 X 10(-6) mol/l).	Ranitidine	66-76	histamine receptor H2	Homo sapiens	33-54
2869436-8	1985	The H2-antagonist ranitidine, however, proved a good antagonist of responses to histamine and the H1- and H2-agonists, despite an unrelated excitatory action which may be linked to inhibition of cholinesterase.	Ranitidine	18-28	butyrylcholinesterase	Rattus norvegicus	195-209
2410935-0	1985	Effects of eight-week treatment with oral ranitidine on plasma level changes of gastrin, histamine and serotonin in duodenal ulcer patients.	Ranitidine	42-52	gastrin	Homo sapiens	80-87
4056078-1	1985	The aim of these studies was to further delineate pharmacokinetic characteristics of ranitidine, a new histamine H2-receptor antagonist.	Ranitidine	85-95	histamine receptor H2	Homo sapiens	103-124
4021474-6	1985	In the present study we found that daily intraperitoneal administration of appropriate doses of the H-2 antagonists cimetidine (2 and 10 mg/kg/day) and ranitidine (2 and 10 mg/kg/day) resulted in maintenance of normal cell-mediated immunity in burned animals.	Ranitidine	152-162	histocompatibility-2, MHC	Mus musculus	100-103
3878237-1	1985	We assessed the effects of ranitidine and cimetidine (histamine H2-receptor antagonists) on the serum concentrations of parathyroid hormone (PTH) in 22 patients with end-stage chronic renal failure.	Ranitidine	27-37	parathyroid hormone	Homo sapiens	120-139
2864753-4	1985	In contrast, two other histamine H2-receptor antagonists, cimetidine and ranitidine, caused only minor changes in these parameters of cytotoxicity.	Ranitidine	73-83	histamine receptor H 2	Rattus norvegicus	23-44
2410935-2	1985	Elevated plasma gastrin and histamine levels, as well as intragastric pH were found after four weeks of ranitidine treatment, only in patients whose ulcers had healed.	Ranitidine	104-114	gastrin	Homo sapiens	16-23
2410935-4	1985	It is suggested that the increases in plasma gastrin, histamine and serotonin levels could be due to gastric and duodenal acid reductions by ranitidine.	Ranitidine	141-151	gastrin	Homo sapiens	45-52
2856908-7	1985	Plasma gastrin levels were increased by cimetidine and ranitidine, both in the interdigestive and in the postprandial state.	Ranitidine	55-65	gastrin	Homo sapiens	7-14
2858046-1	1985	Scrambled DC current applied to the hind paws of rats caused an analgesic response that was inhibited by the histamine H2-receptor antagonists cimetidine, ranitidine and oxmetidine, but not by high doses of naloxone (the opiate antagonist), or other transmitter receptor antagonists.	Ranitidine	155-165	histamine receptor H 2	Rattus norvegicus	109-130
3992022-5	1985	Activities of hepatic cytochrome P-450-dependent metabolizing enzymes such as aminopyrine- and TMO N-demethylase and aniline hydroxylase activity were decreased by pretreatment of rats with cimetidine, whereas in the rats pretreated with ranitidine, these enzyme activities were not changed.	Ranitidine	238-248	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	22-38
2986474-7	1985	However, in the subjects who had received ranitidine on the night prior to surgery, the fasting serum gastrin was significantly higher (p less than 0.01) than the values in the remaining subjects, the mean (SEM) values being 60.3 (6.3) pg/ml in those not receiving ranitidine and 111.3 (19.5) pg/ml in those who had been given ranitidine.	Ranitidine	42-52	gastrin	Homo sapiens	102-109
2986474-7	1985	However, in the subjects who had received ranitidine on the night prior to surgery, the fasting serum gastrin was significantly higher (p less than 0.01) than the values in the remaining subjects, the mean (SEM) values being 60.3 (6.3) pg/ml in those not receiving ranitidine and 111.3 (19.5) pg/ml in those who had been given ranitidine.	Ranitidine	265-275	gastrin	Homo sapiens	102-109
2986474-7	1985	However, in the subjects who had received ranitidine on the night prior to surgery, the fasting serum gastrin was significantly higher (p less than 0.01) than the values in the remaining subjects, the mean (SEM) values being 60.3 (6.3) pg/ml in those not receiving ranitidine and 111.3 (19.5) pg/ml in those who had been given ranitidine.	Ranitidine	265-275	gastrin	Homo sapiens	102-109
3990446-12	1985	Similar effects were observed with ranitidine, another histamine H2-receptor blocker.	Ranitidine	35-45	histamine receptor H2	Mus musculus	55-76
6097454-0	1984	Cimetidine and ranitidine: their interaction with human and pig liver microsomes and with purified cytochrome P-450.	Ranitidine	15-25	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	99-115
2857236-0	1985	CSF concentrations of ranitidine.	Ranitidine	22-32	colony stimulating factor 2	Homo sapiens	0-3
6095662-7	1984	Presently, there are rare reports of gynecomastia, bradycardia, inhibition of acetylcholinesterase, headache, lethargy, diarrhea, and rash in patients receiving ranitidine.	Ranitidine	161-171	acetylcholinesterase (Cartwright blood group)	Homo sapiens	78-98
6096071-3	1984	Like cimetidine, ranitidine binds to cytochrome P-450 in the liver where it appears to exert an inhibitory effect, but to a lesser extent than cimetidine.	Ranitidine	17-27	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-53
6096071-13	1984	The reported interactions of ranitidine with warfarin, metoprolol, nifedipine, theophylline and fentanyl appear to be due to inhibition of cytochrome P-450.	Ranitidine	29-39	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	139-155
6093392-0	1984	[Experiences with the histamine-H2-receptor antagonist ranitidine in the prevention of stress ulcers].	Ranitidine	55-65	histamine receptor H2	Homo sapiens	22-43
6093392-2	1984	For this reason the new developed histamine-H2-receptor blocker ranitidine was used in an open prospective study in 50 cases.	Ranitidine	64-74	histamine receptor H2	Homo sapiens	34-55
3991575-1	1985	In 11 patients with advanced renal failure, chronic treatment with ranitidine decreased plasma immunoreactive parathormone (PTH) without affecting phosphate reabsorption or urinary excretion of cyclic AMP.	Ranitidine	67-77	parathyroid hormone	Homo sapiens	124-127
6097454-1	1984	Cimetidine and ranitidine interact with microsomes from human and pig liver and with purified cytochrome P-450 in the ligand-type manner.	Ranitidine	15-25	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	94-110
6329591-0	1984	[Effects of the intravenous administration of cimetidine and ranitidine on the secretion of prolactin, FSH and LH in healthy males].	Ranitidine	61-71	prolactin	Homo sapiens	92-101
6330716-1	1984	Depression and anxiety were measured during the course of a double-blind, placebo-controlled trial of the histamine H2-receptor antagonist, ranitidine (150 mg twice daily), in patients suffering from duodenal ulcer but free of systemic disease.	Ranitidine	140-150	histamine receptor H2	Homo sapiens	106-127
6329222-3	1984	In order to identify the mechanism of these apparently cholinomimetic actions, the effects of ranitidine on AChE and BuChE were studied.	Ranitidine	94-104	acetylcholinesterase (Cartwright blood group)	Homo sapiens	108-112
6329222-6	1984	It appears that ranitidine exerts an inhibition of the "mixed" type on both AChE and BuChE, but the dissociation constants for BuChE were markedly higher than those for AChE.	Ranitidine	16-26	acetylcholinesterase (Cartwright blood group)	Homo sapiens	76-80
6329222-6	1984	It appears that ranitidine exerts an inhibition of the "mixed" type on both AChE and BuChE, but the dissociation constants for BuChE were markedly higher than those for AChE.	Ranitidine	16-26	acetylcholinesterase (Cartwright blood group)	Homo sapiens	169-173
6329222-7	1984	Since AChE inhibition occurs in the same concentration range potentiating the twitch responses on the ileal myenteric preparation, it may explain the cholinomimetic effect of ranitidine.	Ranitidine	175-185	acetylcholinesterase (Cartwright blood group)	Homo sapiens	6-10
6088162-0	1984	[Changes in serum prolactin during short-term treatment with cimetidine and ranitidine in males with ulcer].	Ranitidine	76-86	prolactin	Homo sapiens	18-27
6089451-1	1984	Of four H2 blockers, cimetidine, tiotidine, oxmetidine and ranitidine, all except ranitidine showed ligand (type II) interactions with oxidized cytochrome P-450.	Ranitidine	59-69	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	144-160
6089451-1	1984	Of four H2 blockers, cimetidine, tiotidine, oxmetidine and ranitidine, all except ranitidine showed ligand (type II) interactions with oxidized cytochrome P-450.	Ranitidine	82-92	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	144-160
6089451-3	1984	All H2 blockers except for ranitidine (up to 400 microM) produced a concentration-dependent inhibitory effect of the metabolic intermediate (MI)-cytochrome P-450 complex formation which is displayed during metabolism of tofenacine in PB hepatic microsomes in vitro.	Ranitidine	27-37	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	145-161
6149751-3	1984	In studies on structure-activity relationships of histamine H2-receptor antagonists, cyanoguanidines and 2-nitro-1,1-ethendiamines, which contain the heterocyclic rings of ranitidine and cimetidine twofold, were prepared and tested for their H2-antihistaminic activity on the isolated guinea-pig atrium and on the histamine stimulated acid secretion of the anaesthetized rat.	Ranitidine	172-182	histamine H2 receptor	Cavia porcellus	50-71
6322709-8	1984	The relative effects of cimetidine and ranitidine on the elimination of cytochrome P-450 metabolized drugs such as theophylline indicate a useful property of ranitidine as compared with cimetidine.	Ranitidine	39-49	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6322709-8	1984	The relative effects of cimetidine and ranitidine on the elimination of cytochrome P-450 metabolized drugs such as theophylline indicate a useful property of ranitidine as compared with cimetidine.	Ranitidine	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
6326400-1	1984	An inhibition of acetylcholinesterase activity by ranitidine and cimetidine as described by Hansen and Bertl (Z. Gastroenterol.	Ranitidine	50-60	acetylcholinesterase (Cartwright blood group)	Homo sapiens	17-37
6318101-1	1983	In vitro, the reaction, in acidified solution, of the histamine H2 receptor antagonist ranitidine with excess nitrite, yielded nitroso derivative(s) eliciting a dose-dependent amount of unscheduled DNA synthesis in primary cultures of rat hepatocytes.	Ranitidine	87-97	histamine receptor H 2	Rattus norvegicus	54-75
6097456-4	1984	Plasma cortisol and prolactin levels were lower after ranitidine at the beginning of the test but their values were not significantly different after ambulation during ranitidine therapy.	Ranitidine	54-64	prolactin	Homo sapiens	20-29
6145677-0	1984	Comparative study with oxmetidine and ranitidine on acid secretion and gastrin release in the dog.	Ranitidine	38-48	gastrin	Canis lupus familiaris	71-78
6317325-1	1983	Ranitidine is a selective, competitive histamine H2-receptor antagonist recently approved by the Food and Drug Administration for use in the short-term treatment of active duodenal ulcers and gastric hypersecretory conditions.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	39-60
6305470-2	1983	Ranitidine, a new histamine H2-receptor antagonist, reversed all symptoms and healed the stomal ulcer without side effects, thus obviating the need for further surgery.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	18-39
6311451-1	1983	The possible intragastric nitrosation of ranitidine to genotoxic derivatives has been investigated in rats and mice given, by gavage, high single doses of this histamine H2 receptor antagonist along with NaNO2.	Ranitidine	41-51	histamine receptor H2	Mus musculus	160-181
6146158-1	1983	Serum prolactin (PRL ng/ml) was measured in 7 male patients on cimetidine (CMT) and in 13 on ranitidine (RNT) before therapy and 5, 10, 15 and 30 days after; at the same intervals FSH (ng/ml), LH (ng/ml) and testosterone (ng/ml) were measured in 5 patients too, in order to ascertain hypothalamic, pituitary, gonadal dysfunction caused by H2 histamine blockers.	Ranitidine	93-103	prolactin	Homo sapiens	6-15
6301262-1	1983	A multicenter trial of oral ranitidine 150 mg bid was conducted in 41 patients with duodenal and 30 with gastric ulcers.	Ranitidine	28-38	BH3 interacting domain death agonist	Homo sapiens	46-49
6308490-2	1983	The increase of plasma prolactin levels induced by third-ventricle injection of histamine was blocked by intraventricular injection of ranitidine, an H2-antagonist, but not by systemic administration of mepyramine, an H1-antagonist.	Ranitidine	135-145	prolactin	Rattus norvegicus	23-32
6308490-8	1983	Ranitidine was able to prevent the prolactin response to 4-methylhistamine.	Ranitidine	0-10	prolactin	Rattus norvegicus	35-44
6137111-0	1983	[Side effects and safety of the new histamine H2 receptor antagonist ranitidine in the long-term treatment of patients with stomach and duodenal ulcers].	Ranitidine	69-79	histamine receptor H2	Homo sapiens	36-57
6305638-4	1983	Cimetidine (80 mg/kg) and ranitidine (30 mg/kg), when injected ia as a single bolus, induced prompt increases (P less than 0.01) in PRL.	Ranitidine	26-36	prolactin	Rattus norvegicus	132-135
6136952-1	1983	Ranitidine is a new histamine H2-receptor antagonist that includes a furan ring structure, whereas other H2-receptor antagonists include an imidazole ring.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	20-41
6135642-0	1983	[Effect of ranitidine on secretion of gastric intrinsic factor and absorption of vitamin B 12].	Ranitidine	11-21	cobalamin binding intrinsic factor	Homo sapiens	38-62
6299642-1	1983	Ranitidine is a potent histamine H2-receptor blocker that inhibits histamine- and pentagastrin-induced gastric acid secretion.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	23-44
6135642-1	1983	The effects of ranitidine, a new potent histamine H2-receptor antagonist, on gastric intrinsic factor (IF) secretion and protein-bound cobalamin absorption were evaluated in 6 patients with duodenal ulcer, before, during and after discontinuation of ranitidine therapy.	Ranitidine	15-25	cobalamin binding intrinsic factor	Homo sapiens	77-101
6130143-6	1983	Dose-dependent gastrin release was unaffected by cimetidine, an imidazole compound, and augmented by tiotidine and ranitidine, the two nonimidazole compounds.	Ranitidine	115-125	gastrin	Canis lupus familiaris	15-22
6858410-4	1983	The histamine H2-receptor blocker Ranitidine (0.25 mg/kg b.w.)	Ranitidine	34-44	histamine receptor H2	Homo sapiens	4-25
6133718-0	1983	Characterization of cimetidine, ranitidine, and related structures" interaction with cytochrome P-450.	Ranitidine	32-42	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	85-101
6133815-4	1983	This study confirms that oral PGE2 has a protective action on gastric mucosa exposed to aspirin and that this property is also shared by ranitidine, a potent histamine H2-receptor antagonist.	Ranitidine	137-147	histamine receptor H2	Homo sapiens	158-179
6140286-13	1983	Differences between cimetidine and ranitidine on drug metabolism appear to exist both because the cytochrome P-450 binding affinity for ranitidine is about 10 times lower than cimetidine and because the daily ranitidine dose is 1/4 that of cimetidine.	Ranitidine	35-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6129812-1	1983	Review of a 5 year clinical experience with the histamine H2-receptor antagonists metiamide, cimetidine, and ranitidine in 20 patients with Zollinger-Ellison syndrome disclosed a treatment failure rate of 50 percent.	Ranitidine	109-119	histamine receptor H2	Homo sapiens	48-69
6131752-1	1983	The in vitro reaction of nitrite with the histamine H2-receptor antagonist ranitidine, in acidified solutions or in human gastric juice, resulted in the formation of genotoxic derivatives, mainly eliciting base-pair substitutions in his-Salmonella typhimurium and trp- Escherichia coli and inducing an increased lethality in DNA repair-deficient bacteria.	Ranitidine	75-85	histamine receptor H2	Homo sapiens	42-63
6141973-2	1983	Both types of H2-R antagonists, ranitidine and cimetidine, were equally associated with production of yeasts.	Ranitidine	32-42	histamine receptor H2	Homo sapiens	14-18
6140286-13	1983	Differences between cimetidine and ranitidine on drug metabolism appear to exist both because the cytochrome P-450 binding affinity for ranitidine is about 10 times lower than cimetidine and because the daily ranitidine dose is 1/4 that of cimetidine.	Ranitidine	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6140286-13	1983	Differences between cimetidine and ranitidine on drug metabolism appear to exist both because the cytochrome P-450 binding affinity for ranitidine is about 10 times lower than cimetidine and because the daily ranitidine dose is 1/4 that of cimetidine.	Ranitidine	136-146	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	98-114
6298933-2	1982	Thirty-eight patients with erosive-ulcerative reflux esophagitis were treated in an open trial with the histamine-H2-receptor antagonist ranitidine (150 mg twice daily).	Ranitidine	137-147	histamine receptor H2	Homo sapiens	104-125
6134841-1	1983	A teratogenicity study was carried out in Crj: CD (SD) rats orally administered ranitidine hydrochloride, a histamine H2-receptor antagonist, at dose levels of 50, 200 and 800 mg/kg/day as base weight for a period of 11 days from day 7 to day 17 of gestation.	Ranitidine	80-104	histamine receptor H 2	Rattus norvegicus	108-129
6134842-1	1983	A perinatal and postnatal study was carried out in the Crj:CD (SD) rats orally administered ranitidine hydrochloride, a histamine H2-receptor antagonist, at dose levels of 50, 200, and 800 mg/kg/day as base for a period of time from day 17 of gestation to day 21 after delivery.	Ranitidine	92-116	histamine receptor H 2	Rattus norvegicus	120-141
6134843-1	1983	Ranitidine hydrochloride, a histamine H2-receptor antagonist, was orally given to pregnant rabbits of Japanese White strain from day 6 to 18 of gestation at doses of 25, 100 and 400 mg/kg/day, as ranitidine base, and teratogenicity of the drug was studied.	Ranitidine	0-24	histamine H2 receptor	Oryctolagus cuniculus	28-49
6134844-1	1983	Chronic toxicity of ranitidine hydrochloride, a new histamine H2-receptor antagonist, was studied using Sprague Dawley rats.	Ranitidine	20-44	histamine receptor H 2	Rattus norvegicus	52-73
6134846-1	1983	A fertility study was carried out in Crj: CD (SD) rats orally administered ranitidine hydrochloride, a histamine H2-receptor antagonist, at dose levels of 50, 200 and 800 mg/kg/day in base weight.	Ranitidine	75-99	histamine receptor H 2	Rattus norvegicus	103-124
6129316-7	1983	The order of potency as histamine H2-receptor and gastric antisecretory antagonists was cimetidine less than etintidine less than ranitidine less than tiotidine.	Ranitidine	130-140	histamine receptor H2	Canis lupus familiaris	24-45
6133022-0	1983	[Effect of 4-week oral administration of ranitidine, a new histamine H2-receptor antagonist, on pancreatic exocrine secretion in rats].	Ranitidine	41-51	histamine receptor H 2	Rattus norvegicus	59-80
6291889-3	1982	In vitro addition of cimetidine (0.12 mg/ml) and ranitidine (0.06 mg/ml) again led to prolongation of plasmatic thrombin time only after cimetidine, reaching double the initial value.	Ranitidine	49-59	coagulation factor II, thrombin	Homo sapiens	112-120
6126246-0	1982	Effect of chronic ranitidine treatment on secretion of intrinsic factor.	Ranitidine	18-28	cobalamin binding intrinsic factor	Homo sapiens	55-71
6125203-9	1982	Upon oral administration, ranitidine exerted no effect on gastric emptying of the meal but slightly decreased the gastrin response to the meal.	Ranitidine	26-36	gastrin	Homo sapiens	114-121
6128216-1	1982	Ranitidine is a new histamine H2-receptor antagonist which, unlike cimetidine, does not contain an imidazole group.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	20-41
6288312-1	1982	Ranitidine is a histamine H2-receptor antagonist that differs structurally from cimetidine.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	16-37
6288312-3	1982	Ranitidine had an absorption lag time of approximately 30 min, an absorption half-life (t 1/2) of approximately 40 min, and an elimination t 1/2 of 3 hr, all differing from those of cimetidine.	Ranitidine	0-10	CD6 molecule	Homo sapiens	88-114
6288312-3	1982	Ranitidine had an absorption lag time of approximately 30 min, an absorption half-life (t 1/2) of approximately 40 min, and an elimination t 1/2 of 3 hr, all differing from those of cimetidine.	Ranitidine	0-10	interleukin 1 receptor like 1	Homo sapiens	88-91
6126962-1	1982	Ranitidine and oxmetidine are newly developed histamine H2-receptor antagonists without any antiandrogenic activity and probably without drug interactions.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	46-67
6124297-0	1982	Effect of chronic ranitidine treatment on secretion of intrinsic factor.	Ranitidine	18-28	cobalamin binding intrinsic factor	Homo sapiens	55-71
6125462-0	1982	Effect of acute oral and intravenous administration of ranitidine on prolactin, thyrotropin and gonadotropin serum levels.	Ranitidine	55-65	prolactin	Homo sapiens	69-78
6123238-0	1982	Cholinergic-like effects of the new histamine H2-receptor antagonist ranitidine.	Ranitidine	69-79	histamine receptor H2	Homo sapiens	36-57
6282071-0	1982	Pharmacological interactions between ranitidine, cimetidine, metiamide and tiotidine at histamine H2-receptor sites in guinea-pig atria.	Ranitidine	37-47	histamine H2 receptor	Cavia porcellus	88-109
6118248-2	1981	The effect of different doses of the newly developed histamine H2 receptor antagonist ranitidine on the sodium taurocholate-induced decrease of the potential difference across the human gastric mucosa was investigated in 18 healthy persons.	Ranitidine	86-96	histamine receptor H2	Homo sapiens	53-74
6293900-5	1982	Finally, 6 healthy fasting subjects were given a 1-hour intravenous infusion of gastrin after pretreatment with ranitidine.	Ranitidine	112-122	gastrin	Homo sapiens	80-87
6293900-6	1982	Plasma GIP responses after the meal on the days with ranitidine alone or together with the gastrin infusion did not differ significantly from that found on the control day.	Ranitidine	53-63	gastric inhibitory polypeptide	Homo sapiens	7-10
6124064-2	1982	Ranitidine interacts with liver microsomes from rats pretreated with different inducers of cytochrome P-450 to produce substrate difference optical spectra with a peak at 426-429 nm and a trough at 390-400 nm.	Ranitidine	0-10	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	91-107
6124064-4	1982	Cytochrome P-450 reduced with dithionite in the presence of ranitidine produced substrate difference spectra with a peak at 447 nm.	Ranitidine	60-70	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	0-16
6124064-6	1982	Ks values for the interaction of ranitidine with cytochrome P-450 (not reduced), calculated from double reciprocal plots, were in the range 1.4-2.8 mM.	Ranitidine	33-43	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	49-65
6124064-14	1982	spectra of cytochrome P-450 from phenobarbital-pretreated rats, in the presence of ranitidine, reveal two types of interaction depending on the ranitidine concentration.	Ranitidine	83-93	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	11-27
6124064-14	1982	spectra of cytochrome P-450 from phenobarbital-pretreated rats, in the presence of ranitidine, reveal two types of interaction depending on the ranitidine concentration.	Ranitidine	144-154	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	11-27
6276054-3	1981	Ranitidine (100 and 200 mg) and cimetidine (300 mg) caused a significant increase in PRL secretion, whereas saline and ranitidine (50 mg) did not.	Ranitidine	0-10	prolactin	Homo sapiens	85-88
6276054-5	1981	A dose-response relationship between ranitidine and PRL was established, and a dose of 65 mg ranitidine was found to be the minimal effective PRL-releasing dose.	Ranitidine	37-47	prolactin	Homo sapiens	52-55
6276054-5	1981	A dose-response relationship between ranitidine and PRL was established, and a dose of 65 mg ranitidine was found to be the minimal effective PRL-releasing dose.	Ranitidine	93-103	prolactin	Homo sapiens	142-145
6120885-0	1981	[Effects of ranitidine, a new histamine H2-receptor antagonist, on secretagogue-stimulated gastric secretion in Heidenhain pouch dogs (author"s transl)].	Ranitidine	12-22	histamine receptor H2	Canis lupus familiaris	30-51
6120886-0	1981	[Effects of ranitidine, a new histamine H2-receptor antagonist, on histamine- and aspirin-induced gastric ulcers in rats and dogs (author"s transl)].	Ranitidine	12-22	histamine receptor H 2	Rattus norvegicus	30-51
6121473-1	1981	This study was undertaken to determine gastric acid surface and to examine the local effect f ranitidine, a histamine H2-receptor antagonist, on the gastric acid response to histamine.	Ranitidine	94-104	histamine receptor H2	Canis lupus familiaris	108-129
6117040-0	1981	[Ranitidine, a new histamine H2 receptor antagonist.	Ranitidine	1-11	histamine receptor H2	Homo sapiens	19-40
6117040-2	1981	The new developed histamine H2-receptor antagonist ranitidine has proven to be a more potent and longer acting anti-secretory compound than cimetidine both after intravenous as well as oral administration.	Ranitidine	51-61	histamine receptor H2	Homo sapiens	18-39
6119281-0	1981	[Effects of ranitidine, a new histamine H2-receptor antagonist, on secretagogue-stimulated gastric secretion in rats: comparison with cimetidine (author"s transl)].	Ranitidine	12-22	histamine receptor H 2	Rattus norvegicus	30-51
6119770-2	1981	Experiments using guinea-pig isolated right atrium and ileum preparations have shown that ranitidine is a selective, potent, and competitive histamine H2-receptor antagonist.	Ranitidine	90-100	histamine H2 receptor	Cavia porcellus	141-162
6118237-0	1981	The treatment of "cimetidine resistant" peptic ulcers by ranitidine hydrochloride: a new histamine H2-receptor antagonist.	Ranitidine	57-81	histamine receptor H2	Homo sapiens	89-110
6119781-0	1981	The new histamine H2-receptor antagonist ranitidine.	Ranitidine	41-51	histamine receptor H2	Homo sapiens	8-29
6119781-2	1981	The antisecretory effects of a new histamine H2-receptor antagonist ranitidine hydrochloride 150 mg, have been tested on basal and pentagastrin-stimulated acid secretion in healthy volunteers 5 and 10 h after oral administration.	Ranitidine	68-92	histamine receptor H2	Homo sapiens	35-56
6119783-0	1981	The effect of ranitidine and cimetidine on pentagastrin and insulin stimulated gastric secretion.	Ranitidine	14-24	insulin	Homo sapiens	60-67
6119786-4	1981	In the adrenal cell studies ranitidine infusion stimulated basal aldosterone secretion and inhibited the release of aldosterone in response to angiotensin II, but not to ACTH.	Ranitidine	28-38	angiotensinogen	Rattus norvegicus	143-157
6116654-0	1981	[Effects of a new histamine H2-receptor antagonist, ranitidine, on experimental acute gastric and duodenal ulcers (author"s transl)].	Ranitidine	52-62	histamine receptor H 2	Rattus norvegicus	18-39
6112034-0	1981	Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine.	Ranitidine	79-89	histamine receptor H 2	Rattus norvegicus	45-66
6167279-0	1981	The effect of ranitidine, a new histamine H 2-receptor antagonist, on the amylase/creatinine clearance ratio.	Ranitidine	14-24	histamine receptor H2	Homo sapiens	32-54
6117373-0	1981	The effect of ranitidine hydrochloride, a new histamine H2-receptor antagonist, on intrinsic factor secretion.	Ranitidine	14-38	histamine receptor H2	Homo sapiens	46-67
6117373-0	1981	The effect of ranitidine hydrochloride, a new histamine H2-receptor antagonist, on intrinsic factor secretion.	Ranitidine	14-38	cobalamin binding intrinsic factor	Homo sapiens	83-99
6117373-1	1981	The effect on intrinsic factor (IF) secretion of eight weeks" continuous treatment with a clinically relevant oral dose of ranitidine hydrochloride, a new histamine H2-receptor antagonist, has been studied in 11 patients with duodenal ulcer.	Ranitidine	123-147	histamine receptor H2	Homo sapiens	155-176
6108203-0	1980	[Ranitidine, a newly developed histamine H2-receptor antagonist.	Ranitidine	1-11	histamine receptor H2	Homo sapiens	31-52
6262889-0	1981	The new histamine H2-receptor antagonist ranitidine.	Ranitidine	41-51	histamine receptor H2	Homo sapiens	8-29
6262889-2	1981	The antisecretory effects of a new histamine H2-receptor antagonist, ranitidine hydrochloride, have been investigated on basal and pentagastrin-stimulated acid secretion in healthy volunteers 5 and 10 h after oral administration of 150 mg.	Ranitidine	69-93	histamine receptor H2	Homo sapiens	35-56
33931709-9	2021	However, ranitidine decreased numbers of B cells and IL-2Ralpha (CD25) expressing T cells that remained lower even after treatment cessation.	Ranitidine	9-19	interleukin 2 receptor subunit alpha	Homo sapiens	53-63
6108555-0	1980	Comparative effect of cimetidine and ranitidine on prolactin secretion.	Ranitidine	37-47	prolactin	Homo sapiens	51-60
6104417-0	1980	In vitro actions of ranitidine, a new histamine H2-receptor antagonist.	Ranitidine	20-30	histamine H2 receptor	Cavia porcellus	38-59
6104418-0	1980	Inhibition of gastric acid secretion in the dog by the histamine H2-receptor antagonists ranitidine and cimetidine.	Ranitidine	89-99	histamine receptor H2	Canis lupus familiaris	55-76
6108607-0	1980	Treatment of duodenal ulcer with ranitidine, a new histamine H2-receptor antagonist.	Ranitidine	33-43	histamine receptor H2	Homo sapiens	51-72
41699-1	1979	The dose-effect relationship of ranitidine, a recently developed selective histamine H2 receptor antagonist was tested on six healthy subjects after oral administration.	Ranitidine	32-42	histamine receptor H2	Homo sapiens	75-96
43178-0	1979	Ranitidine (AH 19065): a new potent, selective histamine H2-receptor antagonist [proceedings].	Ranitidine	0-10	histamine receptor H2	Homo sapiens	47-68
33704920-5	2021	The model further predicted that DDI effects of weak CYP3A inhibitors (fluoxetine and ranitidine) are weak, and effects of moderate inhibitors (erythromycin and verapamil) are moderate.	Ranitidine	86-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	53-58
6105117-1	1980	The pharmacokinetics and gastric antisecretory effects of a new histamine H2-receptor antagonist, ranitidine hydrochloride, have been investigated in healthy subjects.	Ranitidine	98-122	histamine receptor H2	Homo sapiens	64-85
33931709-9	2021	However, ranitidine decreased numbers of B cells and IL-2Ralpha (CD25) expressing T cells that remained lower even after treatment cessation.	Ranitidine	9-19	interleukin 2 receptor subunit alpha	Homo sapiens	65-69
33070288-7	2020	Ranitidine showed a significant pH-mediated DDI effect only in the fasted but not fed state.	Ranitidine	0-10	phenylalanine hydroxylase	Homo sapiens	32-34
33512513-0	2021	Ranitidine"s N-nitrosodimethylamine Problem May be Tip of the Iceberg.	Ranitidine	0-10	TOR signaling pathway regulator	Homo sapiens	51-54
32410382-7	2020	However, only the bidirectional-OCT2 model successfully predicted the minimal effect of ranitidine.	Ranitidine	88-98	POU class 2 homeobox 2	Homo sapiens	32-36
31951767-10	2020	Moreover, treatment with ranitidine, an H2 blocker (30 NMol, i.c.v) antagonized the neuroprotective actions of L-carnosine evidenced by decrease in MWM performance, increase in the level of AChE and oxidative stress, while decrease in GSH level in brain.	Ranitidine	25-35	acetylcholinesterase	Mus musculus	190-194
32142732-3	2020	Ranitidine decreases liver damage in Mdr2-/- (Abcb4 null) mice.	Ranitidine	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	37-41
32142732-3	2020	Ranitidine decreases liver damage in Mdr2-/- (Abcb4 null) mice.	Ranitidine	0-10	ATP-binding cassette, sub-family B (MDR/TAP), member 4	Mus musculus	46-51
31306812-8	2019	Ranitidine, when given along with L-DOPA, normalized the expression of GRK3 in the dopamine-depleted striatum thereby inhibiting LID in mice.	Ranitidine	0-10	G protein-coupled receptor kinase 3	Mus musculus	71-75
31542894-2	2020	To evaluate whether organic cation transporter (OCT) 1, OCT2 and multidrug and toxin extrusion (MATE) 1 and MATE2-K are involved in pharmacokinetics, competitions with ranitidine, a probe inhibitor of the cation transporters, were evaluated in transfected HEK293 cells.	Ranitidine	168-178	solute carrier family 22 member 1	Homo sapiens	20-54
31542894-2	2020	To evaluate whether organic cation transporter (OCT) 1, OCT2 and multidrug and toxin extrusion (MATE) 1 and MATE2-K are involved in pharmacokinetics, competitions with ranitidine, a probe inhibitor of the cation transporters, were evaluated in transfected HEK293 cells.	Ranitidine	168-178	solute carrier family 47 member 1	Homo sapiens	79-103
31542894-2	2020	To evaluate whether organic cation transporter (OCT) 1, OCT2 and multidrug and toxin extrusion (MATE) 1 and MATE2-K are involved in pharmacokinetics, competitions with ranitidine, a probe inhibitor of the cation transporters, were evaluated in transfected HEK293 cells.	Ranitidine	168-178	solute carrier family 47 member 2	Homo sapiens	108-115
31542894-4	2020	Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 +- 25 microM, 482 +- 105 microM, 134 +- 37 microM, and 35 +- 11 microM, respectively.	Ranitidine	0-10	solute carrier family 22 member 1	Homo sapiens	21-25
31542894-4	2020	Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 +- 25 microM, 482 +- 105 microM, 134 +- 37 microM, and 35 +- 11 microM, respectively.	Ranitidine	0-10	POU class 2 homeobox 2	Homo sapiens	27-31
31542894-4	2020	Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 +- 25 microM, 482 +- 105 microM, 134 +- 37 microM, and 35 +- 11 microM, respectively.	Ranitidine	0-10	solute carrier family 47 member 1	Homo sapiens	33-38
31542894-4	2020	Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 +- 25 microM, 482 +- 105 microM, 134 +- 37 microM, and 35 +- 11 microM, respectively.	Ranitidine	0-10	solute carrier family 47 member 2	Homo sapiens	44-49
31542894-8	2020	The renal effects apparently result from inhibition of MATE1 and/or MATE2-K by ranitidine as predicted by in vitro to in vivo extrapolation.	Ranitidine	79-89	solute carrier family 47 member 1	Homo sapiens	55-60
31542894-8	2020	The renal effects apparently result from inhibition of MATE1 and/or MATE2-K by ranitidine as predicted by in vitro to in vivo extrapolation.	Ranitidine	79-89	solute carrier family 47 member 2	Homo sapiens	68-75
32230733-4	2020	Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27.	Ranitidine	105-115	butyrylcholinesterase	Rattus norvegicus	47-61
31514880-5	2020	Determination of two histamine H2 receptor antagonist drugs, cimetidine and ranitidine, as the model analytes from the urine samples was done using the developed on-chip ion-pair based DLLME method followed by an HPLC-UV.	Ranitidine	76-86	histamine receptor H2	Homo sapiens	21-42
31306812-10	2019	These results demonstrate that ranitidine inhibits LID by normalizing the levels of GRK3, extracellular signal regulated kinase activation, and FosB accumulation in the dopamine-depleted striatum via HA H2R antagonism.	Ranitidine	31-41	G protein-coupled receptor kinase 3	Mus musculus	84-88
31306812-10	2019	These results demonstrate that ranitidine inhibits LID by normalizing the levels of GRK3, extracellular signal regulated kinase activation, and FosB accumulation in the dopamine-depleted striatum via HA H2R antagonism.	Ranitidine	31-41	FBJ osteosarcoma oncogene B	Mus musculus	144-148
31111054-8	2019	The levels of EGF and PGE2 in blood serum were markedly higher in hydrotalcite group than that in model group and ranitidine group in preventive experiment (574.39+-34.28 vs. 486.22+-41.73, 488.07+-24.44; P&lt;0.01, P&lt;0.01).	Ranitidine	114-124	epidermal growth factor like 1	Rattus norvegicus	14-17
31447554-5	2019	Results: The prepared Cat-CA/BS MCs could effectively retained in the stomach for 48 hours and successively released ranitidine hydrochloride, which could be used for the treatment of gastric ulcer.	Ranitidine	117-141	catalase	Homo sapiens	22-25
30657092-8	2018	The frequency of elevated serum IgA was significantly lower in IgA vasculitis patients with scrotal involvement versus without this manifestation (18% vs. 57%, p = 0.017), whereas glucocorticoid (93% vs. 49%, p &lt; 0.0001) and ranitidine use (63% vs. 30%, p = 0.003) were significantly higher in the former group.	Ranitidine	228-238	CD79a molecule	Homo sapiens	32-35
30362574-1	2019	OBJECTIVES: The aim of this research was to assess regional difference in the intestinal absorption of ranitidine HCl as an indicator for the potential effect of P-glycoprotein (P-gp) efflux transporters.	Ranitidine	103-117	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	162-176
30362574-1	2019	OBJECTIVES: The aim of this research was to assess regional difference in the intestinal absorption of ranitidine HCl as an indicator for the potential effect of P-glycoprotein (P-gp) efflux transporters.	Ranitidine	103-117	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	178-182
30362574-2	2019	METHODS: In situ rabbit intestinal perfusion was used to investigate absorption of ranitidine HCl, a substrate for P-gp efflux from duodenum, jejunum, ileum and colon.	Ranitidine	83-97	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	115-119
30362574-9	2019	CONCLUSIONS: The results indicate that P-gp transporters play a major role in determining regional difference in intestinal absorption of ranitidine HCl.	Ranitidine	138-152	ATP-dependent translocase ABCB1	Oryctolagus cuniculus	39-43
30901927-7	2019	The presence of the P-gp inhibitor verapamil significantly increased Papp,pig across the ileum of the P-gp substrates cimetidine and ranitidine (p &lt; 0.05).	Ranitidine	133-143	phosphoglycolate phosphatase	Sus scrofa	20-24
30657092-8	2018	The frequency of elevated serum IgA was significantly lower in IgA vasculitis patients with scrotal involvement versus without this manifestation (18% vs. 57%, p = 0.017), whereas glucocorticoid (93% vs. 49%, p &lt; 0.0001) and ranitidine use (63% vs. 30%, p = 0.003) were significantly higher in the former group.	Ranitidine	228-238	CD79a molecule	Homo sapiens	63-66
30158936-9	2018	This was not limited to the tumor setting since ranitidine-treated mice immunized with ovalbumin also demonstrated increased IgG antibody responses.	Ranitidine	48-58	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	87-96
30118850-1	2018	The aim of this study was to explore the influence of food on P-glycoprotein (P-gp) relative expression in both male and female rats, and its effect on intestinal permeation of P-gp substrates (ranitidine and ganciclovir) and a P-gp non-substrate (metformin).	Ranitidine	194-204	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	78-82
30118850-1	2018	The aim of this study was to explore the influence of food on P-glycoprotein (P-gp) relative expression in both male and female rats, and its effect on intestinal permeation of P-gp substrates (ranitidine and ganciclovir) and a P-gp non-substrate (metformin).	Ranitidine	194-204	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	177-181
30118850-1	2018	The aim of this study was to explore the influence of food on P-glycoprotein (P-gp) relative expression in both male and female rats, and its effect on intestinal permeation of P-gp substrates (ranitidine and ganciclovir) and a P-gp non-substrate (metformin).	Ranitidine	194-204	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	177-181
30158936-12	2018	Examination of NK cell populations revealed a significant decrease in the proportion of intermediately functionally mature NK cells populations (CD27+CD11b-) in ranitidine-treated tumor-bearing mice compared with untreated tumor-bearing controls.	Ranitidine	161-171	CD27 antigen	Mus musculus	145-149
30158936-12	2018	Examination of NK cell populations revealed a significant decrease in the proportion of intermediately functionally mature NK cells populations (CD27+CD11b-) in ranitidine-treated tumor-bearing mice compared with untreated tumor-bearing controls.	Ranitidine	161-171	integrin alpha M	Mus musculus	150-155
29145067-6	2017	Ranitidine (a histamine H2 receptor antagonist) alone did not affect pain intensity, whereas it prevented the antinociceptive activities of histamine, dimaprit (a histamine H2 receptor agonist) and morphine (an opiate receptor agonist).	Ranitidine	0-10	histamine receptor H 2	Rattus norvegicus	14-35
29490902-3	2018	The objectives of this study were to use a physiologically based pharmacokinetic modeling platform to 1) assess the impact of alterations in DT expression, toxin-drug interactions (TDIs), and free fraction (fu) on PK predictions for the organic cation transporter 2/multidrug and toxin extrusion protein 1 substrate metformin in RI populations; and 2) use available in vitro data to improve predictions of CLR for two actively secreted substrates, metformin and ranitidine.	Ranitidine	462-472	solute carrier family 22 member 2	Homo sapiens	237-305
29378195-8	2018	Treatment of HepG2 cells with other H1 receptor antagonists including fexofenadine, cetirizine, and diphenhydramine increased apo A-I levels in a dose-dependent manner while treatment with H2 receptor antagonists including cimetidine, famotidine, and ranitidine had no effect.	Ranitidine	251-261	apolipoprotein A1	Homo sapiens	126-133
28962836-0	2017	Effect of mutation of Phe 2436.44 of the histamine H2 receptor on cimetidine and ranitidine mechanism of action.	Ranitidine	81-91	histamine receptor H2	Homo sapiens	41-62
28962836-5	2017	We generated Phe 2436.44 Ala/Ser mutants of histamine H2 receptor and found that while the substitutions do not affect receptor expression or ligand signaling, are able to specifically alter cimetidine and ranitidine mechanisms of action from simply inactivating the receptor to produce a ligand-induced G-protein sequestering conformation, that interferes with the signaling of beta2-adrenoceptor.	Ranitidine	206-216	histamine receptor H2	Homo sapiens	44-65
29236753-0	2017	Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.	Ranitidine	73-83	POU class 2 homeobox 2	Homo sapiens	49-53
29236753-2	2017	Ranitidine was reported to be a substrate of the organic cation transporters OCT1 and OCT2.	Ranitidine	0-10	solute carrier family 22 member 1	Homo sapiens	77-81
29236753-2	2017	Ranitidine was reported to be a substrate of the organic cation transporters OCT1 and OCT2.	Ranitidine	0-10	POU class 2 homeobox 2	Homo sapiens	86-90
29236753-7	2017	AIM: In this study we analyzed the effects of genetic polymorphisms in OCT1 and OCT2 on the uptake of ranitidine and on its potency to inhibit uptake of other drugs.	Ranitidine	102-112	solute carrier family 22 member 1	Homo sapiens	71-75
29236753-7	2017	AIM: In this study we analyzed the effects of genetic polymorphisms in OCT1 and OCT2 on the uptake of ranitidine and on its potency to inhibit uptake of other drugs.	Ranitidine	102-112	POU class 2 homeobox 2	Homo sapiens	80-84
29236753-8	2017	METHODS AND RESULTS: We characterized ranitidine uptake using HEK293 and CHO cells stably transfected to overexpress wild type OCT1, OCT2, or their naturally occurring allelic variants.	Ranitidine	38-48	solute carrier family 22 member 1	Homo sapiens	127-131
29236753-9	2017	Ranitidine was transported by wild-type OCT1 with a Km of 62.9 muM and a vmax of 1125 pmol/min/mg protein.	Ranitidine	0-10	solute carrier family 22 member 1	Homo sapiens	40-44
29236753-10	2017	Alleles OCT1*5, *6, *12, and *13 completely lacked ranitidine uptake.	Ranitidine	51-61	solute carrier family 22 member 1	Homo sapiens	8-12
29236753-13	2017	The effects of OCT1 alleles on ranitidine uptake strongly correlated with the effects on morphine uptake suggesting common interaction mechanisms of both drugs with OCT1.	Ranitidine	31-41	solute carrier family 22 member 1	Homo sapiens	15-19
29236753-13	2017	The effects of OCT1 alleles on ranitidine uptake strongly correlated with the effects on morphine uptake suggesting common interaction mechanisms of both drugs with OCT1.	Ranitidine	31-41	solute carrier family 22 member 1	Homo sapiens	165-169
29236753-14	2017	Ranitidine inhibited the OCT1-mediated uptake of metformin and morphine at clinically relevant concentrations.	Ranitidine	0-10	solute carrier family 22 member 1	Homo sapiens	25-29
29236753-16	2017	OCT2 showed only a limited uptake of ranitidine that was not significantly affected by the Ala270Ser polymorphism.	Ranitidine	37-47	POU class 2 homeobox 2	Homo sapiens	0-4
29236753-17	2017	CONCLUSIONS: We confirmed ranitidine as an OCT1 substrate and demonstrated that common genetic polymorphisms in OCT1 strongly affect ranitidine uptake and modulate ranitidine"s potential to cause drug-drug interactions.	Ranitidine	26-36	solute carrier family 22 member 1	Homo sapiens	43-47
29236753-17	2017	CONCLUSIONS: We confirmed ranitidine as an OCT1 substrate and demonstrated that common genetic polymorphisms in OCT1 strongly affect ranitidine uptake and modulate ranitidine"s potential to cause drug-drug interactions.	Ranitidine	26-36	solute carrier family 22 member 1	Homo sapiens	112-116
29236753-17	2017	CONCLUSIONS: We confirmed ranitidine as an OCT1 substrate and demonstrated that common genetic polymorphisms in OCT1 strongly affect ranitidine uptake and modulate ranitidine"s potential to cause drug-drug interactions.	Ranitidine	133-143	solute carrier family 22 member 1	Homo sapiens	112-116
29236753-17	2017	CONCLUSIONS: We confirmed ranitidine as an OCT1 substrate and demonstrated that common genetic polymorphisms in OCT1 strongly affect ranitidine uptake and modulate ranitidine"s potential to cause drug-drug interactions.	Ranitidine	133-143	solute carrier family 22 member 1	Homo sapiens	112-116
29236753-18	2017	The effects of the frequent OCT1 polymorphisms on ranitidine pharmacokinetics in humans remain to be analyzed.	Ranitidine	50-60	solute carrier family 22 member 1	Homo sapiens	28-32
29530563-2	2018	For instance, the commonly-used solubilizing agent polyethylene glycol 400 (PEG 400) exhibits a sex-specific effect on the bioavailability of ranitidine in both humans and rats, mediated by the efflux transporter P-glycoprotein (P-gp).	Ranitidine	142-152	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	213-227
29530563-2	2018	For instance, the commonly-used solubilizing agent polyethylene glycol 400 (PEG 400) exhibits a sex-specific effect on the bioavailability of ranitidine in both humans and rats, mediated by the efflux transporter P-glycoprotein (P-gp).	Ranitidine	142-152	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	229-233
29530563-6	2018	In addition, while the P-gp inhibitor CsA increased the intestinal uptake of ranitidine in both male and female rats, a greater extent of intestinal transport modulation was observed in males compared to females.	Ranitidine	77-87	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	23-27
29145067-6	2017	Ranitidine (a histamine H2 receptor antagonist) alone did not affect pain intensity, whereas it prevented the antinociceptive activities of histamine, dimaprit (a histamine H2 receptor agonist) and morphine (an opiate receptor agonist).	Ranitidine	0-10	histamine receptor H 2	Rattus norvegicus	163-184
28991940-8	2017	The physician prescribed ranitidine 150 mg bid for the epigastric burning and explained, once more, the significance of the STD test results.	Ranitidine	25-35	BH3 interacting domain death agonist	Homo sapiens	43-46
30166899-5	2017	The most effective compound was CP-4, it produced 97.7% ulcer protection of control followed by CP-3, which produced 90.3% protection, while the standard drug ranitidine (100 mg/kg) produced 49.2% protection.	Ranitidine	159-169	surfactant protein D	Rattus norvegicus	32-36
29115998-2	2017	Effects of antisecretory therapy (famotidine or ranitidine, omeprazole) on serum gastrin concentration in dogs with chronic enteropathy (CE) and its biological variation (BV) are unknown.	Ranitidine	48-58	gastrin	Canis lupus familiaris	81-88
28819071-1	2017	Hepatic flavin-containing mono-oxygenase 3 (FMO3) metabolizes a broad array of nucleophilic heteroatom (e.g., N or S)-containing xenobiotics (e.g., amphetamine, sulindac, benzydamine, ranitidine, tamoxifen, nicotine, and ethionamide), as well as endogenous compounds (e.g., catecholamine and trimethylamine).	Ranitidine	184-194	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	0-42
28819071-1	2017	Hepatic flavin-containing mono-oxygenase 3 (FMO3) metabolizes a broad array of nucleophilic heteroatom (e.g., N or S)-containing xenobiotics (e.g., amphetamine, sulindac, benzydamine, ranitidine, tamoxifen, nicotine, and ethionamide), as well as endogenous compounds (e.g., catecholamine and trimethylamine).	Ranitidine	184-194	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	44-48
28709912-2	2017	As ranitidine is a substrate for the efflux transporter P-glycoprotein (P-gp), we hypothesized that the sex-related influence could be due to interactions between PEG 400 and P-gp.	Ranitidine	3-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	56-70
28709912-2	2017	As ranitidine is a substrate for the efflux transporter P-glycoprotein (P-gp), we hypothesized that the sex-related influence could be due to interactions between PEG 400 and P-gp.	Ranitidine	3-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	72-76
28709912-2	2017	As ranitidine is a substrate for the efflux transporter P-glycoprotein (P-gp), we hypothesized that the sex-related influence could be due to interactions between PEG 400 and P-gp.	Ranitidine	3-13	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	175-179
28709912-6	2017	Inhibition of P-gp by oral pre-treatment with cyclosporine A increased the bioavailability of the P-gp substrates (ampicillin and ranitidine) in males and females (p&lt;0.05), and to a greater extent in males, but had no influence on the bioavailability of metformin in either male or female rats.	Ranitidine	130-140	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	14-18
28709912-6	2017	Inhibition of P-gp by oral pre-treatment with cyclosporine A increased the bioavailability of the P-gp substrates (ampicillin and ranitidine) in males and females (p&lt;0.05), and to a greater extent in males, but had no influence on the bioavailability of metformin in either male or female rats.	Ranitidine	130-140	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	98-102
29132544-6	2017	On the other hand, blockade of histamine H2 receptors with cimetidine or ranitidine (1mg, 5mg, or 10mg/kg) significantly reduced these early pathophysiological events and attenuated nNOS expression in a dose-dependent manner.	Ranitidine	73-83	nitric oxide synthase 1	Rattus norvegicus	182-186
29474768-1	2017	Binding of clopidogrel to serum albumin has been characterized in the presence and absence of linoleic acid by equilibrium dialysis method where ranitidine and diazepam were used as specific probes.	Ranitidine	145-155	albumin	Homo sapiens	26-39
29132544-7	2017	Interestingly, TiO2-naowire delivery of cimetidine or ranitidine (5mg doses) exerted superior neuroprotective effects on SCI-induced nNOS expression and cord pathology.	Ranitidine	54-64	nitric oxide synthase 1	Rattus norvegicus	133-137
26784938-0	2016	The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.	Ranitidine	84-94	solute carrier family 47 member 1	Homo sapiens	4-9
27000965-7	2016	Biochemical analysis of fluoxetine- or ranitidine-pre-treated host tissues demonstrated reductions in tumor necrosis factor (TNF)-alpha and myeloperoxidase (MPO) levels and concomitant increases in gastric pH, nitric oxide (NO) and reduced glutathione (GSH) contents.	Ranitidine	39-49	myeloperoxidase	Rattus norvegicus	140-155
27000965-7	2016	Biochemical analysis of fluoxetine- or ranitidine-pre-treated host tissues demonstrated reductions in tumor necrosis factor (TNF)-alpha and myeloperoxidase (MPO) levels and concomitant increases in gastric pH, nitric oxide (NO) and reduced glutathione (GSH) contents.	Ranitidine	39-49	myeloperoxidase	Rattus norvegicus	157-160
27000965-7	2016	Biochemical analysis of fluoxetine- or ranitidine-pre-treated host tissues demonstrated reductions in tumor necrosis factor (TNF)-alpha and myeloperoxidase (MPO) levels and concomitant increases in gastric pH, nitric oxide (NO) and reduced glutathione (GSH) contents.	Ranitidine	39-49	tumor necrosis factor	Rattus norvegicus	102-135
26784938-2	2016	The goal of this study was to determine the association between metformin"s pharmacokinetics and pharmacodynamics and the genetic variants of MATE1 (rs2289669) and OCT2 (rs316019) before and after treatment with the potential MATE inhibitor, ranitidine.	Ranitidine	242-252	solute carrier family 47 member 1	Homo sapiens	142-147
26784938-2	2016	The goal of this study was to determine the association between metformin"s pharmacokinetics and pharmacodynamics and the genetic variants of MATE1 (rs2289669) and OCT2 (rs316019) before and after treatment with the potential MATE inhibitor, ranitidine.	Ranitidine	242-252	solute carrier family 22 member 2	Homo sapiens	164-168
26784938-5	2016	However, the renal clearance of metformin was significantly higher (15.2%) after ranitidine treatment in the MATE1 GG group compared with the MATE1 GA + AA group.	Ranitidine	81-91	solute carrier family 47 member 1	Homo sapiens	109-114
26784938-6	2016	Only the effect of MATE1 on the renal clearance of metformin after ranitidine treatment was significant (b = -0.465, p &lt;= 0.05) after including demographic data and the OCT2 genotype in the model.	Ranitidine	67-77	solute carrier family 47 member 1	Homo sapiens	19-24
26886308-1	2016	Mixing aqueous solutions of sodium diclofenac (DIC-Na) and ranitidine hydrochloride (RAN HCl) afforded an off-white solid (DIC-RAN) that was investigated from the microscopic, thermal, diffractometric, spectroscopic, and functional (chemometrics-assisted dissolution) points of view.	Ranitidine	59-83	RAN, member RAS oncogene family	Homo sapiens	85-88
27622015-9	2016	In keeping with ranitidine-induced changes in myeloid cell populations in non-tumor-bearing mice, ranitidine also delayed the onset of spontaneous tumor development, and decreased the number of tumors that developed in LKB1(-/-)/NIC mice.	Ranitidine	98-108	serine/threonine kinase 11	Mus musculus	219-223
26886308-1	2016	Mixing aqueous solutions of sodium diclofenac (DIC-Na) and ranitidine hydrochloride (RAN HCl) afforded an off-white solid (DIC-RAN) that was investigated from the microscopic, thermal, diffractometric, spectroscopic, and functional (chemometrics-assisted dissolution) points of view.	Ranitidine	59-83	RAN, member RAS oncogene family	Homo sapiens	127-130
26503124-9	2015	Ranitidine, allopurinol, and metformin together accounted for 76% of renally misprescribed medications in individuals with a CrCl of 30 to 49 mL/min.	Ranitidine	0-10	CRCL	Homo sapiens	125-129
26582357-2	2016	Here, zein is used as a sole excipient for drugs differing in hydrophobicity and isoelectric point: indomethacin, paracetamol and ranitidine.	Ranitidine	130-140	zein	Zea mays	6-10
27665770-9	2016	Ranitidine increased caspase-3/7 activity but did not affect the OCR.	Ranitidine	0-10	caspase 3	Homo sapiens	21-30
26474912-7	2015	We found that the microinjection of histamine (0.05, 0.5, and 5mug) into FN significantly attenuated the SGMD, in a dose-dependent manner, whereas, the microinjection of histamine H2 receptor antagonist, ranitidine, and glutamic acid decarboxylase antagonist, 3-mercaptopropionic acid (3-MPA) exacerbated the SGMD.	Ranitidine	204-214	histamine receptor H 2	Rattus norvegicus	170-191
22022004-8	2011	Ranitidine afforded 56% prevention in ulcer formation with 67%, 55% and 78% attenuation of the inhibition of mucus, CAT and SOD, respectively, by indomethacin.	Ranitidine	0-10	catalase	Rattus norvegicus	116-119
26775449-8	2015	Ranitidine hydrochloride suspensions in SyrSpend SF PH4 at room temperature and refrigerated conditions were stable for at least 30 days and 58 days, respectively.	Ranitidine	0-24	prolyl 4-hydroxylase, transmembrane	Homo sapiens	52-55
25461930-1	2014	Ranitidine (RNTD) is a widely prescribed histamine H2-receptor antagonist whose unambiguous presence in water sources appointed it as an emerging pollutant.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	41-62
25068521-4	2014	After exclusion of possible causes, hypomagnesaemia secondary to PPI was diagnosed and omeprazole was replaced by a histamine H2-receptor antagonist: ranitidine.	Ranitidine	150-160	histamine receptor H2	Homo sapiens	116-137
22581435-6	2012	Superoxide dismutase (SOD) and catalase (CAT) activities were both much higher in oleuropein-treated rats than the ethanol group, and although there was a moderate increase in SOD and CAT activities in ranitidine-treated rats, the differences were not significant.	Ranitidine	202-212	catalase	Rattus norvegicus	184-187
22687724-7	2012	Our results also indicated that intra-CA1 administration of L-arginine and L-NAME, in the presence or absence of ranitidine, exerted an anxiogenic effect.	Ranitidine	113-123	carbonic anhydrase 1	Mus musculus	38-41
25791352-1	2015	Ranitidine is a histamine H2-receptor antagonist that reduces gastric acid secretion.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	16-37
25791352-2	2015	We studied the flexibility of the ranitidine molecule with the special focus on the network of diverse intramolecular hydrogen bonds: N-H O, N-H N, C-H O, C-H N and N-H S. We performed static density functional theory calculations of global and local minima and analyzed their stability at finite temperature in the Car-Parrinello molecular dynamics simulations.	Ranitidine	34-44	nuclear receptor subfamily 4 group A member 3	Homo sapiens	141-160
24764253-4	2015	For comparison, the reference AChE inhibitors, tacrine and ranitidine, exhibit IC(50) values of 0.144 microM and 3.37 microM, respectively.	Ranitidine	59-69	acetylcholinesterase (Cartwright blood group)	Homo sapiens	30-34
24136594-7	2014	Best in vivo protection from terbufos sulfone-induced mortality was achieved, when K-27 was given before terbufos sulfone exposure (RR = 0.06), which was significantly (P &lt;= 0.05) superior to the pre-treatment with all other tested compounds, for example tacrine (RR = 0.21), pyridostigmine (RR = 0.28), physostigmine (RR = 0.29) and ranitidine (RR = 0.33).	Ranitidine	337-347	keratin 27	Rattus norvegicus	83-87
24103378-5	2013	The results showed that pre-training intra-CA1 administration of histamine (5mug/mouse), ranitidine (H2 receptor antagonist; at the doses of 0.25 and 0.5mug/mouse) and pyrilamine (H1 receptor antagonist; at the dose of 5mug/mouse) decreased memory formation.	Ranitidine	89-99	carbonic anhydrase 1	Mus musculus	43-46
24103378-10	2013	On the other hand, pre-training intra-CA1 injection of sub-threshold doses of ranitidine (0.0625mug/mouse) and pyrilamine (2.5mug/mouse) increased harmane-induced impairment of memory.	Ranitidine	78-88	carbonic anhydrase 1	Mus musculus	38-41
23982898-7	2013	Using these procedures to assess the receptors mediating histamine"s effects, the histamine H1 -receptor antagonists, pyrilamine and ketotifen, antagonized the punishing effect of histamine, but the histamine H2 -receptor antagonist ranitidine did not.	Ranitidine	233-243	histamine receptor H 2	Rattus norvegicus	199-221
23454087-5	2013	Cimetidine and ranitidine, both CYP inhibitors as well as H2 blockers, caused relaxation of the term and preterm mouse DA.	Ranitidine	15-25	peptidyl-prolyl isomerase G (cyclophilin G)	Mus musculus	32-35
23596793-10	2013	RESULTS: Compared with the model control group, the expression levels of SLC26A3 increased in the high dose WLP group and the ranitidine group with statistical difference (P &lt; 0.05).	Ranitidine	126-136	solute carrier family 26 member 3	Rattus norvegicus	73-80
23596793-11	2013	The expression levels of SLC26A6 increased in the high and middle dose WLP groups and the ranitidine group with statistical difference (P &lt; 0.05).	Ranitidine	90-100	solute carrier family 26 member 6	Rattus norvegicus	25-32
22607579-14	2012	Activity of ranitidine lasted about 12 h, whereas that of netazepide exceeded 24 h. CONCLUSIONS: In human: netazepide is an orally active gastrin antagonist, and gastrin has a major role in controlling gastric acidity.	Ranitidine	12-22	gastrin	Homo sapiens	162-169
22345389-2	2012	The method was based on the reaction of ranitidine with 4-fluoro-7-nitrobenzo-2-oxa-1,3-diazole forming yellow colored fluorescent product.	Ranitidine	40-50	OXA1L mitochondrial inner membrane protein	Homo sapiens	80-85
21922515-6	2012	Separate application of the selective histamine H(1) receptor antagonist mepyramine or the selective histamine H(2) receptor antagonist ranitidine partially suppressed the histamine-induced excitation, whereas a combination of ranitidine and mepyramine totally blocked the excitatory effect of histamine on motoneurons.	Ranitidine	136-146	histamine receptor H 2	Rattus norvegicus	101-124
21211106-9	2011	The extinction-induced phosphorylation of ERK1 was enhanced by histamine and dimaprit and blocked by ranitidine administered to dorsal CA1 after non-reinforced retrieval.	Ranitidine	101-111	mitogen activated protein kinase 3	Rattus norvegicus	42-46
21211106-9	2011	The extinction-induced phosphorylation of ERK1 was enhanced by histamine and dimaprit and blocked by ranitidine administered to dorsal CA1 after non-reinforced retrieval.	Ranitidine	101-111	carbonic anhydrase 1	Rattus norvegicus	135-138
19800360-3	2010	On the other hand, intra-CA1 administration of CB1 receptor antagonist, AM251 (25 and 50ng/mouse) or histamine, pyrilamine and ranitidine (5-10microg/mouse) decreased the amount of head-dipping and increased the first head-dip, suggesting an anxiogenic-like response.	Ranitidine	127-137	carbonic anhydrase 1	Mus musculus	25-28
20978762-8	2011	Histamine led to a slight increase in intracellular uptake of Cp (6)-his, whereas ranitidine, a histamine H2 receptor antagonist, and incubation at lower temperature (~15 C) led to its inhibition, suggesting that uptake of Cp (6)-his is receptor mediated.	Ranitidine	82-92	histamine receptor H2	Homo sapiens	96-117
21116686-2	2011	This study compares the antiulcer activities of lansoprazole (a proton pump inhibitor), PD-136450 (CCK(2)/gastrin receptor antagonist) and ranitidine (histamine H(2) receptor antagonist) on CRS-induced gastric ulcers in rats.	Ranitidine	139-149	histamine receptor H 2	Rattus norvegicus	151-174
19891965-2	2010	In the present study, the effect of microinjection of histamine, mepyramine (a histamine H(1) receptor antagonist) and ranitidine (a histamine H(2) receptor antagonist) into the dorsal hippocampus was investigated on a model of orofacial pain in rats.	Ranitidine	119-129	histamine receptor H 2	Rattus norvegicus	133-156
20026516-0	2010	Ranitidine as an alcohol dehydrogenase inhibitor in acute methanol toxicity in rats.	Ranitidine	0-10	aldo-keto reductase family 1 member A1	Rattus norvegicus	17-38
21382460-10	2011	The inhibition of ranitidine efflux by PEG 300 and 400 which interact with P-gp provides a mechanism that may account for the observations of ranitidine absorption enhancement by PEG 400 in vivo.	Ranitidine	18-28	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
21382460-10	2011	The inhibition of ranitidine efflux by PEG 300 and 400 which interact with P-gp provides a mechanism that may account for the observations of ranitidine absorption enhancement by PEG 400 in vivo.	Ranitidine	142-152	ATP binding cassette subfamily B member 1	Homo sapiens	75-79
20070855-11	2011	Treatment with 200 mg/kg ranitidine reduced AST, AST and ALP serum levels, while 200 and 40 mg/kg of cimetidine and famotidine, respectively, reduced AST and ALP serum levels.	Ranitidine	25-35	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	44-47
20070855-11	2011	Treatment with 200 mg/kg ranitidine reduced AST, AST and ALP serum levels, while 200 and 40 mg/kg of cimetidine and famotidine, respectively, reduced AST and ALP serum levels.	Ranitidine	25-35	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	49-52
20070855-11	2011	Treatment with 200 mg/kg ranitidine reduced AST, AST and ALP serum levels, while 200 and 40 mg/kg of cimetidine and famotidine, respectively, reduced AST and ALP serum levels.	Ranitidine	25-35	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	49-52
20552232-10	2010	The protein kinase A (PKA) inhibitor H89 (150 nM) and the H(2)-receptor antagonist ranitidine (100 muM) decreased  pH/min in gsk3 ( KI ) but not gsk3 ( WT ) and again abrogated the differences between the genotypes.	Ranitidine	83-93	glycogen synthase kinase 3 beta	Mus musculus	125-129
19907186-6	2010	In addition, the H1R antagonist olopatadine significantly blocked histamine-induced production of IL-6, whereas the H2R antagonist ranitidine did not.	Ranitidine	131-141	histamine receptor H2	Homo sapiens	116-119
19800360-3	2010	On the other hand, intra-CA1 administration of CB1 receptor antagonist, AM251 (25 and 50ng/mouse) or histamine, pyrilamine and ranitidine (5-10microg/mouse) decreased the amount of head-dipping and increased the first head-dip, suggesting an anxiogenic-like response.	Ranitidine	127-137	cannabinoid receptor 1 (brain)	Mus musculus	47-50
19723537-0	2009	Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis.	Ranitidine	54-64	histamine receptor H2	Homo sapiens	21-42
19723537-4	2009	Ranitidine also prevented the down-regulation of B-cell CLL/lymphoma 2 (BCL2) and the up-regulation of BCL2-associated X protein (BAX) by rotenone.	Ranitidine	0-10	BCL2 apoptosis regulator	Homo sapiens	49-70
19723537-4	2009	Ranitidine also prevented the down-regulation of B-cell CLL/lymphoma 2 (BCL2) and the up-regulation of BCL2-associated X protein (BAX) by rotenone.	Ranitidine	0-10	BCL2 apoptosis regulator	Homo sapiens	72-76
19723537-4	2009	Ranitidine also prevented the down-regulation of B-cell CLL/lymphoma 2 (BCL2) and the up-regulation of BCL2-associated X protein (BAX) by rotenone.	Ranitidine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	103-128
19723537-4	2009	Ranitidine also prevented the down-regulation of B-cell CLL/lymphoma 2 (BCL2) and the up-regulation of BCL2-associated X protein (BAX) by rotenone.	Ranitidine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
19723537-5	2009	Furthermore, ranitidine not only attenuated rotenone-induced cleavages of CASP9, poly(ADP-ribose) polymerase-1 (PARP) and CASP3, but also suppressed CASP3 enzyme activity.	Ranitidine	13-23	caspase 9	Homo sapiens	74-79
19723537-3	2009	Ranitidine blocked the rotenone-induced phosphorylation of c-Jun NH(2)-terminal protein kinase (JNK) and P38 MAPK (P38), and promoted the phosphorylation of extracellular signal-regulated protein kinase (ERK).	Ranitidine	0-10	mitogen-activated protein kinase 8	Homo sapiens	59-94
19723537-5	2009	Furthermore, ranitidine not only attenuated rotenone-induced cleavages of CASP9, poly(ADP-ribose) polymerase-1 (PARP) and CASP3, but also suppressed CASP3 enzyme activity.	Ranitidine	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	81-110
19723537-5	2009	Furthermore, ranitidine not only attenuated rotenone-induced cleavages of CASP9, poly(ADP-ribose) polymerase-1 (PARP) and CASP3, but also suppressed CASP3 enzyme activity.	Ranitidine	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	112-116
19723537-5	2009	Furthermore, ranitidine not only attenuated rotenone-induced cleavages of CASP9, poly(ADP-ribose) polymerase-1 (PARP) and CASP3, but also suppressed CASP3 enzyme activity.	Ranitidine	13-23	caspase 3	Homo sapiens	122-127
19723537-3	2009	Ranitidine blocked the rotenone-induced phosphorylation of c-Jun NH(2)-terminal protein kinase (JNK) and P38 MAPK (P38), and promoted the phosphorylation of extracellular signal-regulated protein kinase (ERK).	Ranitidine	0-10	mitogen-activated protein kinase 8	Homo sapiens	96-99
19723537-5	2009	Furthermore, ranitidine not only attenuated rotenone-induced cleavages of CASP9, poly(ADP-ribose) polymerase-1 (PARP) and CASP3, but also suppressed CASP3 enzyme activity.	Ranitidine	13-23	caspase 3	Homo sapiens	149-154
19723537-3	2009	Ranitidine blocked the rotenone-induced phosphorylation of c-Jun NH(2)-terminal protein kinase (JNK) and P38 MAPK (P38), and promoted the phosphorylation of extracellular signal-regulated protein kinase (ERK).	Ranitidine	0-10	mitogen-activated protein kinase 1	Homo sapiens	105-108
19723537-6	2009	These results indicate that ranitidine protects against rotenone-induced apoptosis, inhibiting phosphorylation of JNK and P38, and activation of CASPs in human dopaminergic SH-SY5Y cells.	Ranitidine	28-38	mitogen-activated protein kinase 8	Homo sapiens	114-117
19723537-6	2009	These results indicate that ranitidine protects against rotenone-induced apoptosis, inhibiting phosphorylation of JNK and P38, and activation of CASPs in human dopaminergic SH-SY5Y cells.	Ranitidine	28-38	mitogen-activated protein kinase 1	Homo sapiens	122-125
19723537-3	2009	Ranitidine blocked the rotenone-induced phosphorylation of c-Jun NH(2)-terminal protein kinase (JNK) and P38 MAPK (P38), and promoted the phosphorylation of extracellular signal-regulated protein kinase (ERK).	Ranitidine	0-10	mitogen-activated protein kinase 1	Homo sapiens	115-118
19723537-3	2009	Ranitidine blocked the rotenone-induced phosphorylation of c-Jun NH(2)-terminal protein kinase (JNK) and P38 MAPK (P38), and promoted the phosphorylation of extracellular signal-regulated protein kinase (ERK).	Ranitidine	0-10	mitogen-activated protein kinase 1	Homo sapiens	157-202
19723537-3	2009	Ranitidine blocked the rotenone-induced phosphorylation of c-Jun NH(2)-terminal protein kinase (JNK) and P38 MAPK (P38), and promoted the phosphorylation of extracellular signal-regulated protein kinase (ERK).	Ranitidine	0-10	mitogen-activated protein kinase 1	Homo sapiens	204-207
19318661-1	2009	BACKGROUND: Stress ulcer prophylaxis (SUP) using ranitidine, a histamine H2 receptor antagonist, has been associated with an increased risk of ventilator-associated pneumonia.	Ranitidine	49-59	histamine receptor H2	Homo sapiens	63-84
18480910-0	2008	Cucurbit[7]uril host-guest complexes of the histamine H2-receptor antagonist ranitidine.	Ranitidine	77-87	histamine receptor H2	Homo sapiens	44-65
19135254-1	2009	This study was designed to assess the overall ecotoxicity of ranitidine, a histamine H(2)-receptor antagonist that inhibits stomach acid production.	Ranitidine	61-71	histamine receptor H2	Homo sapiens	75-98
18971316-8	2009	Ranitidine, an hOCT1 inhibitor, reversed this hOCT1-mediated potentiation of cytotoxicity.	Ranitidine	0-10	solute carrier family 22 member 1	Homo sapiens	15-20
18971316-8	2009	Ranitidine, an hOCT1 inhibitor, reversed this hOCT1-mediated potentiation of cytotoxicity.	Ranitidine	0-10	solute carrier family 22 member 1	Homo sapiens	46-51
18393299-1	2009	Ranitidine hydrochloride (RAN-HCl), a known anti-ulcer drug, is the product of reaction between HCl and ranitidine base (RAN-B).	Ranitidine	0-24	RAN, member RAS oncogene family	Homo sapiens	26-29
18393299-1	2009	Ranitidine hydrochloride (RAN-HCl), a known anti-ulcer drug, is the product of reaction between HCl and ranitidine base (RAN-B).	Ranitidine	0-24	RAN, member RAS oncogene family	Homo sapiens	121-124
18393299-1	2009	Ranitidine hydrochloride (RAN-HCl), a known anti-ulcer drug, is the product of reaction between HCl and ranitidine base (RAN-B).	Ranitidine	104-114	RAN, member RAS oncogene family	Homo sapiens	26-29
18393299-1	2009	Ranitidine hydrochloride (RAN-HCl), a known anti-ulcer drug, is the product of reaction between HCl and ranitidine base (RAN-B).	Ranitidine	104-114	RAN, member RAS oncogene family	Homo sapiens	121-124
18783980-2	2009	This method is based on the reflectance measurements of the colored product produced from the spot test reaction between ranitidine and p-dimethylaminocinnamaldehyde (p-DAC), in acid medium, using filter paper as solid support.	Ranitidine	121-131	arylacetamide deacetylase	Homo sapiens	169-172
18483181-8	2008	In addition, inhibition of the acid secretory response to histamine by H2 receptor blockade with ranitidine proceeded more slowly in glands from Lasp-1-null mice.	Ranitidine	97-107	LIM and SH3 protein 1	Mus musculus	145-151
18390808-0	2008	p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine.	Ranitidine	181-191	mitogen-activated protein kinase 14	Homo sapiens	0-3
19457229-16	2009	In addition, fluvoxamine and ranitidine decreased the levels of the oxidant parameters, myeloperoxidase and malondialdeyhyde, in the stomach tissues of the rats when compared to indomethacin group.	Ranitidine	29-39	myeloperoxidase	Rattus norvegicus	88-103
18992283-4	2009	After pentagastrin-stimulation acid secretion was dose-dependently inhibited by intravenous administration of the gastrin receptor antagonist gastrazole, as well as ranitidine and esomeprazole by maximally 73+/-10%; 95+/-3%; 90+/-10%, respectively.	Ranitidine	165-175	gastrin	Rattus norvegicus	11-18
18938221-4	2008	Selective histamine H2 receptor antagonist ranitidine effectively blocked the histamine-evoked excitatory responses on the LVN neurons (n=4), but selective histamine H1 receptor antagonist triprolidine did not (n=4).	Ranitidine	43-53	histamine receptor H 2	Rattus norvegicus	10-31
18338907-3	2008	The goal of this work was to elucidate the synergistic influence of self-originating impurities and water vapor on the degradation kinetics of the histamine H2 receptor antagonist, ranitidine HCl.	Ranitidine	181-195	histamine receptor H2	Homo sapiens	147-168
18049114-9	2007	Ranitidine treatment also suppressed the proliferation of splenocytes and production of interleukin (IL)-2 and up-regulated IL-10 production.	Ranitidine	0-10	interleukin 2	Mus musculus	88-106
18043010-10	2008	injections of both the histamine H1 receptor antagonist pyrilamine (40 microg/mouse) and the histamine H2 receptor antagonist ranitidine (6.25 and 12.5 microg/mouse) prevented the improving effect of pre-test lithium (10 mg/kg i.p.)	Ranitidine	126-136	histamine receptor H2	Mus musculus	93-114
18049114-9	2007	Ranitidine treatment also suppressed the proliferation of splenocytes and production of interleukin (IL)-2 and up-regulated IL-10 production.	Ranitidine	0-10	interleukin 10	Mus musculus	124-129
18049114-10	2007	Adoptive transfer of splenocytes and CD4 cells from ranitidine-treated allograft recipients induced significant prolongation of allograft survival in naive secondary recipients (MST, 71 and &gt;100 days, respectively).	Ranitidine	52-62	CD4 antigen	Mus musculus	37-40
18049114-13	2007	CONCLUSION: In our model, ranitidine treatment induced significantly prolonged survival of fully allogeneic cardiac grafts, generated CD4 regulatory cells, and indefinite survival when combined with FK506 (0.1 mg/kg/day).	Ranitidine	26-36	CD4 antigen	Mus musculus	134-137
17200726-3	2006	According to an earlier report, the postoperative administration of the histamine receptor-2 antagonist ranitidine increases the blood levels of soluble IL2 receptor in humans undergoing abdominal surgery and could thus affect molecular determinants of colonic anastomosis.	Ranitidine	104-114	interleukin 2	Homo sapiens	153-156
17698507-0	2007	The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury.	Ranitidine	62-72	tumor necrosis factor	Rattus norvegicus	12-39
17766108-1	2007	Furan-containing congeners of the histamine H(2) receptor antagonist ranitidine were synthesized and tested for improgan-like antinociceptive activity.	Ranitidine	69-79	histamine receptor H2	Homo sapiens	34-57
17627982-7	2007	The excitatory actions of the agonists were specifically and selectively blocked by the H(1), H(2), H(3) or H(4) receptor antagonists pyrilamine, ranitidine, clobenpropit or J1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine (JNJ 7777120), respectively.	Ranitidine	146-156	H3 clustered histone 14	Homo sapiens	100-121
17532765-7	2007	Higher levels of IL-18 were found in patients treated with ranitidine compared with healthy controls.	Ranitidine	59-69	interleukin 18	Homo sapiens	17-22
17609913-6	2007	RESULTS: (1) Compared with the model group, UI of MP groups (10, 15 and 20 mg.kg(-1).d(-1)) and ranitidine group was lower (P&lt;0.05 or P&lt;0.01), the levels of NO and EGF in the tissue and serum were higher (P&lt;0.05), the thickness of regenerated mucous membrane increased, and the width loss of lamina muscularis mucosa decreased (all P&lt;0.05).	Ranitidine	96-106	epidermal growth factor like 1	Rattus norvegicus	170-173
17614008-5	2007	The [(3)H]-MPP uptake by hOCT1/rOct1 and hOCT3/rOct3 was inhibited by famotidine and ranitidine whereas that by hOCT2/rOct2 was not.	Ranitidine	85-95	solute carrier family 22 member 1	Homo sapiens	25-30
17614008-5	2007	The [(3)H]-MPP uptake by hOCT1/rOct1 and hOCT3/rOct3 was inhibited by famotidine and ranitidine whereas that by hOCT2/rOct2 was not.	Ranitidine	85-95	solute carrier family 22 member 1	Rattus norvegicus	31-36
17614008-5	2007	The [(3)H]-MPP uptake by hOCT1/rOct1 and hOCT3/rOct3 was inhibited by famotidine and ranitidine whereas that by hOCT2/rOct2 was not.	Ranitidine	85-95	solute carrier family 22 member 3	Homo sapiens	41-46
17614008-5	2007	The [(3)H]-MPP uptake by hOCT1/rOct1 and hOCT3/rOct3 was inhibited by famotidine and ranitidine whereas that by hOCT2/rOct2 was not.	Ranitidine	85-95	solute carrier family 22 member 8	Rattus norvegicus	47-52
17478939-0	2007	[Effect of ranitidine on the gastric acid, plasma endothelin, and calcitonin gene-related peptide in patients undergoing the brain operation].	Ranitidine	11-21	calcitonin related polypeptide alpha	Homo sapiens	66-97
17478939-1	2007	OBJECTIVE: To observe the effect of ranitidine on gastric acid, plasma endothelin, and calcitonin gene-related peptide (CGRP) in patients undergoing the brain operation, and to explore the possible pathogenesis of ranitidine on preventing from gastric mucosal injury under the stress.	Ranitidine	36-46	calcitonin related polypeptide alpha	Homo sapiens	120-124
17273750-8	2007	We also found that the cimetidine-mediated down-regulation of NCAM expression in HSG cells did not occur via blocking of the histamine receptor, even though H2R expression was observed on HSG cells, as two other H2R antagonists, famotidine and ranitidine, did not show similar effects.	Ranitidine	244-254	neural cell adhesion molecule 1	Homo sapiens	62-66
17073837-8	2006	However, proton pump inhibitor (PPI) therapy was associated with significantly greater rates of both GU and DU healing than ranitidine; 8-week GU rates were 92% and 88% with esomeprazole 40 mg and 20 mg, respectively (vs. 74% with ranitidine, p &lt; 0.01).	Ranitidine	231-241	ATPase H+/K+ transporting subunit alpha	Homo sapiens	9-20
17478939-9	2007	Ranitidine can obviously decrease the level of intra-gastric acid, and improve the macrocirculation of gastric mucous membrane by decreasing ET and increasing the CGRP level.	Ranitidine	0-10	calcitonin related polypeptide alpha	Homo sapiens	163-167
17200726-4	2006	In this study we examined the effect of blood transfusions, with and without ranitidine administration, on the gene expression of TGFbeta(1) and the specificity-conveying alpha subunit of the receptor for IL2, in rat perianastomotic tissue.	Ranitidine	77-87	transforming growth factor, beta 1	Rattus norvegicus	130-140
16169175-7	2006	However, catalase (CAT), glutathione reductase (GR) and myeloperoxidase (MPx) activities, increased by indomethacin, were found to be lower in the UA- and ranitidine-treated groups.	Ranitidine	155-165	catalase	Rattus norvegicus	9-17
16723495-3	2006	In fact, ranitidine and famotidine antagonized cimetidine-induced IL-18 production.	Ranitidine	9-19	interleukin 18	Homo sapiens	66-71
17109942-7	2006	Intra-CA1 microinjection of ranitidine (H2 receptor antagonist), at the doses of 10, 20 and 40 microg/rat, also reduced the histamine response.	Ranitidine	28-38	carbonic anhydrase 1	Rattus norvegicus	6-9
16946590-9	2006	Ranitidine and nizatidine increased the plasma concentration of motilin.	Ranitidine	0-10	motilin	Homo sapiens	64-71
16946590-10	2006	It is believed that the plasma concentration of Ach is elevated by ranitidine and nizatidine, which possesses an anti-AchE activity, and that the increased the plasma concentration of Ach facilitated release of motilin, elevating the plasma concentration of motilin.	Ranitidine	67-77	acetylcholinesterase (Cartwright blood group)	Homo sapiens	118-122
16488163-3	2006	The facilitatory effect of intra-CA1 histamine was mimicked by the histamine N-methyltransferase inhibitor SKF-91844 as well as by the H2 receptor agonist dimaprit and it was blocked completely by the H2 receptor antagonist ranitidine.	Ranitidine	224-234	carbonic anhydrase 1	Homo sapiens	33-36
16488163-3	2006	The facilitatory effect of intra-CA1 histamine was mimicked by the histamine N-methyltransferase inhibitor SKF-91844 as well as by the H2 receptor agonist dimaprit and it was blocked completely by the H2 receptor antagonist ranitidine.	Ranitidine	224-234	histamine N-methyltransferase	Homo sapiens	67-96
16533576-4	2006	In addition, administration of selective histamine H(2) receptor antagonist ranitidine considerably decreased the animals" endurance time on rota-rod and noticeably increased the passing time on beam, but selective histamine H(1) receptor antagonist triprolidine showed no effect.	Ranitidine	76-86	histamine receptor H 2	Rattus norvegicus	41-64
16741655-7	2006	The ranitidine absorptive permeability increased and secretory permeability decreased upon inhibition of P-gp.	Ranitidine	4-14	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
16741655-11	2006	CONCLUSIONS: Saturable absorptive transport of ranitidine in Caco-2 cells is partially mediated via a pH-dependent uptake transporter for organic cations and is subject to attenuation by P-gp.	Ranitidine	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	187-191
16702623-2	2006	The histamine H2-receptor antagonists (cimetidine, ranitidine and roxatidine), themselves decreased the deoxyribose damage in Fenton-type systems.	Ranitidine	51-61	histamine receptor H2	Homo sapiens	4-25
16534669-7	2006	Histamine caused a fourfold increase in EGFR phosphorylation which was inhibited by both Tyr and ranitidine.	Ranitidine	97-107	epidermal growth factor receptor	Rattus norvegicus	40-44
16169175-7	2006	However, catalase (CAT), glutathione reductase (GR) and myeloperoxidase (MPx) activities, increased by indomethacin, were found to be lower in the UA- and ranitidine-treated groups.	Ranitidine	155-165	catalase	Rattus norvegicus	19-22
16169175-7	2006	However, catalase (CAT), glutathione reductase (GR) and myeloperoxidase (MPx) activities, increased by indomethacin, were found to be lower in the UA- and ranitidine-treated groups.	Ranitidine	155-165	glutathione-disulfide reductase	Rattus norvegicus	25-46
16169175-7	2006	However, catalase (CAT), glutathione reductase (GR) and myeloperoxidase (MPx) activities, increased by indomethacin, were found to be lower in the UA- and ranitidine-treated groups.	Ranitidine	155-165	glutathione-disulfide reductase	Rattus norvegicus	48-50
16169175-7	2006	However, catalase (CAT), glutathione reductase (GR) and myeloperoxidase (MPx) activities, increased by indomethacin, were found to be lower in the UA- and ranitidine-treated groups.	Ranitidine	155-165	myeloperoxidase	Rattus norvegicus	56-71
16169175-7	2006	However, catalase (CAT), glutathione reductase (GR) and myeloperoxidase (MPx) activities, increased by indomethacin, were found to be lower in the UA- and ranitidine-treated groups.	Ranitidine	155-165	myeloperoxidase	Rattus norvegicus	73-76
16169175-9	2006	The administration of UA and ranitidine increased the cNOS activity and lowered the iNOS activity as compared with indomethacin-treated group.	Ranitidine	29-39	nitric oxide synthase 3	Rattus norvegicus	54-58
16169175-9	2006	The administration of UA and ranitidine increased the cNOS activity and lowered the iNOS activity as compared with indomethacin-treated group.	Ranitidine	29-39	nitric oxide synthase 2	Rattus norvegicus	84-88
16898856-1	2006	BACKGROUND: The histamine H(2) receptor antagonist ranitidine is US FDA-approved for the treatment of gastroesophageal reflux disease and healing of erosive esophagitis in children &gt;or=1 month of age.	Ranitidine	51-61	histamine receptor H2	Homo sapiens	16-39
17152347-10	2006	Ranitidine was shown to be a P-gp substrate in vivo in human volunteers and it was found that oral bioavailability of ranitidine was influenced at the intestinal absorption phase.	Ranitidine	0-10	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
17152347-10	2006	Ranitidine was shown to be a P-gp substrate in vivo in human volunteers and it was found that oral bioavailability of ranitidine was influenced at the intestinal absorption phase.	Ranitidine	118-128	ATP binding cassette subfamily B member 1	Homo sapiens	29-33
16141367-0	2005	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).	Ranitidine	52-62	solute carrier family 22 member 1	Homo sapiens	91-119
16397915-5	2006	Ranitidine elicited 24%, 41% and 29% protective effects, respectively.Similarly, kolaviron administered to rats 1 day and for 7 days before IND treatment attenuated the drug-induced inhibition of CAT by 44% and 70%; SOD by 23% and 43% and GSH by 32% and 55%, respectively.	Ranitidine	0-10	catalase	Rattus norvegicus	196-199
16792160-0	2006	[Symptomatic high chromogranin A level associated with rabeprazole and ranitidine].	Ranitidine	71-81	chromogranin A	Homo sapiens	18-32
16141367-0	2005	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).	Ranitidine	52-62	solute carrier family 22 member 1	Homo sapiens	121-126
16141367-0	2005	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).	Ranitidine	52-62	solute carrier family 22 member 1	Homo sapiens	128-135
16141367-0	2005	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).	Ranitidine	52-62	solute carrier family 22 member 2	Homo sapiens	138-143
16141367-0	2005	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).	Ranitidine	52-62	solute carrier family 22 member 2	Homo sapiens	145-152
16141367-0	2005	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).	Ranitidine	52-62	solute carrier family 22 member 3	Homo sapiens	159-164
16141367-0	2005	Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3).	Ranitidine	52-62	solute carrier family 22 member 3	Homo sapiens	166-173
16141367-3	2005	Inhibition and substrate specificity of hOCT1, hOCT2, and hOCT3 for ranitidine and famotidine were elucidated in cRNA-injected Xenopus laevis oocytes.	Ranitidine	68-78	solute carrier family 22 member 1	Homo sapiens	40-45
16141367-3	2005	Inhibition and substrate specificity of hOCT1, hOCT2, and hOCT3 for ranitidine and famotidine were elucidated in cRNA-injected Xenopus laevis oocytes.	Ranitidine	68-78	solute carrier family 22 member 2	Homo sapiens	47-52
16141367-3	2005	Inhibition and substrate specificity of hOCT1, hOCT2, and hOCT3 for ranitidine and famotidine were elucidated in cRNA-injected Xenopus laevis oocytes.	Ranitidine	68-78	solute carrier family 22 member 3	Homo sapiens	58-63
16141367-4	2005	Ranitidine and famotidine exhibited similarly potent inhibition of [3H]1-methyl-4-phenyl pyridinium uptake into hOCT1-expressing (IC50= 33 and 28 microM, respectively) and hOCT2-expressing oocytes (IC50= 76 and 114 microM, respectively).	Ranitidine	0-10	solute carrier family 22 member 1	Homo sapiens	112-117
16141367-4	2005	Ranitidine and famotidine exhibited similarly potent inhibition of [3H]1-methyl-4-phenyl pyridinium uptake into hOCT1-expressing (IC50= 33 and 28 microM, respectively) and hOCT2-expressing oocytes (IC50= 76 and 114 microM, respectively).	Ranitidine	0-10	solute carrier family 22 member 2	Homo sapiens	172-177
16141367-6	2005	[3H]Ranitidine uptake was stimulated by hOCT1 (Km= 70 +/- 9 microM) and to a much smaller extent by hOCT2.	Ranitidine	4-14	solute carrier family 22 member 1	Homo sapiens	40-45
16141367-6	2005	[3H]Ranitidine uptake was stimulated by hOCT1 (Km= 70 +/- 9 microM) and to a much smaller extent by hOCT2.	Ranitidine	4-14	solute carrier family 22 member 2	Homo sapiens	100-105
16141367-9	2005	Thus, hOCT1, which is expressed in the intestine and liver, is likely to play a major role in the intestinal absorption and hepatic disposition of ranitidine and famotidine in humans, whereas hOCT2, the major isoform present in the kidney, may play only a minor role in their renal elimination.	Ranitidine	147-157	solute carrier family 22 member 1	Homo sapiens	6-11
16194053-11	2005	In contrast to SOD and GST activities, CAT activity was increased by indomethacin and reduced by all doses of U. longissima and ranitidine.	Ranitidine	128-138	catalase	Rattus norvegicus	39-42
16708818-6	2005	The combination of Jianweiyuyang granules and ranitidine capsules could significantly upregulate the expression of MUCSAC mRNA (P &lt; 0.01), while downregulate the expression of ETAR mRNA (P &lt; 0.01).	Ranitidine	46-56	endothelin receptor type A	Homo sapiens	179-183
16708818-7	2005	CONCLUSION: There is obvious advantage in treating peptic ulcers by the combination of Jianweiyuyang granules and ranitidine capsules, and its mechanisms may be to protect the gastric mucosal barrier by up-regulating the expression of MUCSAC mRNA and to improve the gastric mucosal blood flow by down-regulating the expression of ETAR mRNA.	Ranitidine	114-124	endothelin receptor type A	Homo sapiens	330-334
16167316-0	2005	Effect of metoclopramide and ranitidine on the inhibition of human AChE by VX in vitro.	Ranitidine	29-39	acetylcholinesterase (Cartwright blood group)	Homo sapiens	67-71
16167316-4	2005	Recently, the clinically used reversible AChE inhibitors metoclopramide (MCP) and ranitidine (RAN) were shown to exhibit some protective effect against the OP pesticide paraoxon in vitro and in vivo.	Ranitidine	82-92	acetylcholinesterase (Cartwright blood group)	Homo sapiens	41-45
16143415-5	2005	The excitatory effect of histamine on the GP neurons was not blocked by selective histamine H1 receptor antagonist triprolidine (n = 16) or chlorpheniramine (n = 6), but was effectively suppressed by ranitidine, a highly selective histamine H2 receptor antagonist (n = 21).	Ranitidine	200-210	histamine receptor H 2	Rattus norvegicus	231-252
16143415-7	2005	The dimaprit-induced GP neuronal excitation was effectively antagonized by selective histamine H2 receptor antagonist ranitidine (n = 14) but not influenced by selective histamine H1 receptor antagonist triprolidine (n = 12).	Ranitidine	118-128	histamine receptor H 2	Rattus norvegicus	85-106
16006492-4	2005	The transport activities (Vmax/Km) of famotidine (Km, 345 microM) by rOat3 were 8- and 15-fold lower than those of cimetidine (Km, 91 microM) and ranitidine (Km, 155 microM), respectively, whereas the activity by hOAT3 (Km, 124 microM) was 3-fold lower than that of cimetidine (Km, 149 microM) but similar to that of ranitidine (Km, 234 microM).	Ranitidine	317-327	solute carrier family 22 member 8	Rattus norvegicus	69-74
16006492-6	2005	Only ranitidine was efficiently transported by hOAT2 (Km, 396 microM).	Ranitidine	5-15	solute carrier family 22 member 7	Homo sapiens	47-52
16006492-7	2005	rOct1 accepts all of the H2 receptor antagonists with a similar activity, whereas the transport activities of ranitidine and famotidine (Km, 61/56 microM) by r/hOCT2 were markedly lower than that of cimetidine (Km, 69/73 microM).	Ranitidine	110-120	POU class 2 homeobox 2	Homo sapiens	160-165
16222740-5	2005	The expression level of VEGF mRNA in gastric tissues during the healing process of JWYY treatment group rats significantly increased compared with other groups (normal group: 0.190+/-0.019, model group: 0.642+/-0.034, ranitidine group: 0.790+/-0.037, P&lt;0.01).	Ranitidine	218-228	vascular endothelial growth factor A	Rattus norvegicus	24-28
16015682-6	2005	RESULTS: Subcutaneous administration of leptin, two PPIs lansoprazole and omeprazole or H(2)-receptor antagonist ranitidine 30 min before AE or Indo produced a dose-dependent and reproducible inhibition of gastric ulcers (GUs).	Ranitidine	113-123	leptin	Rattus norvegicus	40-46
16858644-4	2005	LPS increased protein concentration and neutrophil numbers in the BAL as well as myeloperoxidase (MPO) activity in lungs after 6 h. LPS also increased histamine concentration in BAL after 2 h. Mepyramine and ranitidine attenuated the increased histamine concentrations.	Ranitidine	208-218	myeloperoxidase	Rattus norvegicus	81-96
15909533-12	2005	In addition, the AUC of ranitidine in bile decreased in the treatment of cyclosporine or quinidine, which suggests that the hepatobiliary excretion of ranitidine was partially regulated by P-glycoprotein or organic cation transporter.	Ranitidine	24-34	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	189-203
15909533-12	2005	In addition, the AUC of ranitidine in bile decreased in the treatment of cyclosporine or quinidine, which suggests that the hepatobiliary excretion of ranitidine was partially regulated by P-glycoprotein or organic cation transporter.	Ranitidine	151-161	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	189-203
15698457-5	2005	In a cohort of 6 healthy volunteers, the effect of a 5-day course of ranitidine, cimetidine, and omeprazole on overall CYP, CYP3A4, and PGP activity in vivo was assessed with the (13)C-aminopyrin breath test and the combined per oral and intravenous (14)C-erythromycin breath and urine test.	Ranitidine	69-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
15698457-5	2005	In a cohort of 6 healthy volunteers, the effect of a 5-day course of ranitidine, cimetidine, and omeprazole on overall CYP, CYP3A4, and PGP activity in vivo was assessed with the (13)C-aminopyrin breath test and the combined per oral and intravenous (14)C-erythromycin breath and urine test.	Ranitidine	69-79	ATP binding cassette subfamily B member 1	Homo sapiens	136-139
15322300-0	2004	Histamine H2-receptor antagonist ranitidine protects against neural death induced by oxygen-glucose deprivation.	Ranitidine	33-43	histamine receptor H 2	Rattus norvegicus	0-21
15680274-10	2005	Ranitidine, in combination with histamine, reduced the ulcer area and serum interleukin-1beta to a minimal value, whereas gastric mucosal blood flow and DNA synthesis reached a maximal value.	Ranitidine	0-10	interleukin 1 beta	Rattus norvegicus	76-93
15665623-3	2004	Because antihistamines such as cimetidine and ranitidine are commonly used as prophylaxis against gastrointestinal toxicity commonly seen with IL-2, and, because antihistamines may increase natural killer cell activity, it is reasonable to examine the response rate for this combination.	Ranitidine	46-56	interleukin 2	Homo sapiens	143-147
15363661-6	2004	Furthermore, NO donors (SNP, SNAP, and Sin-1), including the pure NO donor DEA/NO, directly suppressed in vitro FMO activity (N- or S-oxidation of ranitidine, trimethylamine, and thiobenzamide) in human liver microsomal proteins and recombinant human FMO3.	Ranitidine	147-157	MAPK associated protein 1	Homo sapiens	39-44
15322300-9	2004	Caspase 3 activation and alteration of the neuronal cytoskeleton were also prevented by ranitidine pretreatment.	Ranitidine	88-98	caspase 3	Rattus norvegicus	0-9
14634855-2	2004	In addition, preoperative administration of ibuprofen has proved to reduce interleukin-6 (IL-6) release, while that of ranitidine reduced postoperative IL-6-induced C-reactive protein synthesis in patients undergoing abdominal surgery.	Ranitidine	119-129	interleukin 6	Homo sapiens	152-156
15256267-7	2004	Ranitidine stimulated a fourfold increase in plasma gastrin while histamine caused a transient decrease.	Ranitidine	0-10	gastrin	Ovis aries	52-59
15256267-9	2004	Histamine (H2) receptor mRNA expression in the antrum was significantly increased by pentagastrin and decreased by ranitidine.	Ranitidine	115-125	histamine H2 receptor	Ovis aries	0-23
15319347-2	2004	The purpose of the present study is to investigate the role of rat organic anion transporter 3 (rOat3; Slc22a8) in the uptake of H(2)-receptor antagonists (cimetidine, ranitidine, and famotidine) by the isolated rat CP.	Ranitidine	168-178	solute carrier family 22 member 8	Rattus norvegicus	103-110
15319347-3	2004	Saturable uptake of cimetidine and ranitidine was observed in rOat3-LLC with K(m) values of 80 and 120 microM, respectively, whereas famotidine was found to be a poor substrate.	Ranitidine	35-45	solute carrier family 22 member 8	Rattus norvegicus	62-67
14519942-5	2003	The 24 h survival rate after LPS injection was 72.7% in the mice treated with 50 mg/kg of ranitidine, in contrast with 50% in the control group although the treatment did not significantly decrease the plasma ALT activity.	Ranitidine	90-100	glutamic pyruvic transaminase, soluble	Mus musculus	209-212
15031602-2	2004	The effects of histamine and the H2 receptor antagonist ranitidine on renal VEGF and IL-6 synthesis were investigated in a well-established rat model of renal ischemia/reperfusion injury.	Ranitidine	56-66	vascular endothelial growth factor A	Rattus norvegicus	76-80
15031602-11	2004	The beneficial effects of ranitidine were partly mediated by decreased IL-6 and VEGF mRNA expression and significant early increase in renal VEGF abundance.	Ranitidine	26-36	interleukin 6	Rattus norvegicus	71-75
15031602-11	2004	The beneficial effects of ranitidine were partly mediated by decreased IL-6 and VEGF mRNA expression and significant early increase in renal VEGF abundance.	Ranitidine	26-36	vascular endothelial growth factor A	Rattus norvegicus	80-84
15031602-11	2004	The beneficial effects of ranitidine were partly mediated by decreased IL-6 and VEGF mRNA expression and significant early increase in renal VEGF abundance.	Ranitidine	26-36	vascular endothelial growth factor A	Rattus norvegicus	141-145
14660036-4	2003	The initial phase was almost eliminated by the 5-hydroxytryptamine receptor antagonist methysergide, whereas the second phase was sensitive to the histamine H(2) receptor antagonist ranitidine.	Ranitidine	182-192	histamine receptor H 2	Rattus norvegicus	147-170
14744809-7	2004	The suppressive effect of histamine on LT biosynthesis was abrogated by the histamine H(2) receptor antagonists cimetidine, ranitidine, and tiotidine.	Ranitidine	124-134	histamine receptor H2	Homo sapiens	76-99
14550905-3	2003	Histamine H2 receptor antagonist ranitidine effectively blocked the excitatory response of rubral neurons to histamine (n=26), but H1 receptor antagonist triprolidine did not (n=24).	Ranitidine	33-43	histamine receptor H 2	Rattus norvegicus	0-21
14602784-7	2003	CRH-induced dilation of the skin microvasculature was significantly reduced in the presence of the mast cell degranulation inhibitor, sodium cromoglycate, the histamine H(1)-antagonist, promethazine, or the H(2)-antagonist, ranitidine.	Ranitidine	224-234	corticotropin releasing hormone	Homo sapiens	0-3
12854134-7	2003	The expression level of TFF2 mRNA in hydrotalcite group was markedly higher than that in ranitidine group and control group (0.56+/-0.09 vs 0.30+/-0.05, 0.28+/-0.03, P&lt;0.05).	Ranitidine	89-99	trefoil factor 2	Rattus norvegicus	24-28
12966980-1	2003	The photochemical fates of the histamine H2-receptor antagonists cimetidine and ranitidine were studied.	Ranitidine	80-90	histamine receptor H2	Homo sapiens	31-52
12854134-8	2003	The OD value of c-fos protein in hydrotalcite group was higher than that in ranitidine group and control group (0.52+/-0.07 vs 0.31+/-0.04, 0.32+/-0.05, P&lt;0.05).	Ranitidine	76-86	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	16-21
12824943-9	2003	The H2-receptor antagonist, ranitidine, but not the H1-receptor antagonist, diphenhydramine, prevented histamine-induced activation of PDE4 in a concentration-dependent manner.	Ranitidine	28-38	phosphodiesterase 4A	Homo sapiens	135-139
14671421-3	2003	This study aims to characterize how rapidly famotidine and ranitidine, the most widely used histamine H2 receptor antagonists, interact with the human histamine H2 receptor.	Ranitidine	59-69	histamine receptor H2	Homo sapiens	92-113
14671421-3	2003	This study aims to characterize how rapidly famotidine and ranitidine, the most widely used histamine H2 receptor antagonists, interact with the human histamine H2 receptor.	Ranitidine	59-69	histamine receptor H2	Homo sapiens	151-172
14671421-11	2003	CONCLUSION: Ranitidine inhibits the human histamine H2 receptor very rapidly.	Ranitidine	12-22	histamine receptor H2	Homo sapiens	42-63
12388638-8	2002	Thus, we conclude that the secretory transport of ranitidine and famotidine across Caco-2 cell monolayers is mediated by 1) a carrier in the BL membrane that is distinct from the TEA-sensitive organic cation transporter(s) and 2) P-gp in the apical membrane.	Ranitidine	50-60	ATP binding cassette subfamily B member 1	Homo sapiens	230-234
12456431-3	2002	Ranitidine premedication reduces gastric volume, increases gastric pH, and may reduce GER.	Ranitidine	0-10	GER	Homo sapiens	86-89
12456431-4	2002	We used continuous intraluminal esophageal and tracheal pH monitoring probes to investigate the effect of ranitidine on the incidence of GER and tracheal aspiration in 80 adult patients undergoing thoracotomy.	Ranitidine	106-116	GER	Homo sapiens	137-140
12456431-7	2002	The incidence of acid GER in the placebo and ranitidine groups was 28.2% and 2.5%, respectively (P = 0.006).	Ranitidine	45-55	GER	Homo sapiens	22-25
12456431-9	2002	The total number of episodes of GER in the placebo and ranitidine groups was 16 and 1, respectively (P = 0.002).	Ranitidine	55-65	GER	Homo sapiens	32-35
12456431-14	2002	This randomized, double-blinded, placebo-controlled study demonstrates frequent incidences of both acid GER and tracheal acid aspiration during surgery that are significantly reduced by premedication with ranitidine.	Ranitidine	205-215	GER	Homo sapiens	104-107
12063974-7	2002	RESULTS: Mean gastrin levels in patients receiving ranitidine was 56.76 ng/L and in patients not receiving ranitidine 47.16 ng/L on the first day (pNS) remaining stable throughout the course of acute pancreatitis.	Ranitidine	51-61	gastrin	Homo sapiens	14-21
12495560-5	2002	The administration of ranitidine and nizatidine caused significant increases in plasma CGRP and SP levels at 30 to 120 min compared with the placebo group.	Ranitidine	22-32	calcitonin related polypeptide alpha	Homo sapiens	87-91
12495560-5	2002	The administration of ranitidine and nizatidine caused significant increases in plasma CGRP and SP levels at 30 to 120 min compared with the placebo group.	Ranitidine	22-32	tachykinin precursor 1	Homo sapiens	96-98
12495560-6	2002	Peak plasma CGRP levels (39.8+/-3.1 and 40.6+/-3.6 pg mL(-1)) were achieved 60 min after administration of ranitidine and nizatidine, respectively.	Ranitidine	107-117	calcitonin related polypeptide alpha	Homo sapiens	12-16
12495560-7	2002	Maximum plasma SP levels (21.3+/-5.2 and 22.8+/-4.2 pg mL(-1)) were reached 60 min after administration of ranitidine and nizatidine, respectively.	Ranitidine	107-117	tachykinin precursor 1	Homo sapiens	15-17
12495560-9	2002	The released CGRP and SP by ranitidine and nizatidine administration may produce a gastroprotective effect, increase mucosal blood flow, and inhibit acid secretion in the gastrointestinal tract.	Ranitidine	28-38	calcitonin related polypeptide alpha	Homo sapiens	13-17
12495560-9	2002	The released CGRP and SP by ranitidine and nizatidine administration may produce a gastroprotective effect, increase mucosal blood flow, and inhibit acid secretion in the gastrointestinal tract.	Ranitidine	28-38	tachykinin precursor 1	Homo sapiens	22-24
12383956-6	2002	The histamine H(2) receptor antagonist ranitidine effectively blocked the excitatory response of IN cells to histamine (n=23), but the histamine H(1) receptor antagonist triprolidine could not significantly block the histamine-induced excitation, or only very slightly decreased the excitatory effect of histamine on the cells (n=21).	Ranitidine	39-49	histamine receptor H 2	Rattus norvegicus	4-27
12023551-5	2002	Ranitidine inhibited the production of tumor necrosis factor-alpha (TNF-alpha) in monocytes stimulated with lipopolysaccharide in vitro, whereas famotidine did not.	Ranitidine	0-10	tumor necrosis factor	Rattus norvegicus	39-66
12023551-5	2002	Ranitidine inhibited the production of tumor necrosis factor-alpha (TNF-alpha) in monocytes stimulated with lipopolysaccharide in vitro, whereas famotidine did not.	Ranitidine	0-10	tumor necrosis factor	Rattus norvegicus	68-77
12023551-9	2002	These observations strongly suggested that ranitidine could reduce ischemia/reperfusion-induced liver injury by inhibiting neutrophil activation directly, or indirectly by inhibiting the production of TNF-alpha, which is a potent activator of neutrophils.	Ranitidine	43-53	tumor necrosis factor	Rattus norvegicus	201-210
11596859-11	2001	Plasma interleukin-1beta was significantly reduced after administration of omeprazole, ranitidine, or histamine, however, the effect of histamine was less pronounced.	Ranitidine	87-97	interleukin 1 beta	Rattus norvegicus	7-24
12503773-0	2002	Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.	Ranitidine	66-76	gastrin	Homo sapiens	87-94
12503773-9	2002	The pattern of gastrin change in patients administered ranitidine was intermediate between famotidine and cimetidine.	Ranitidine	55-65	gastrin	Homo sapiens	15-22
11557520-5	2001	The histamine H2 antagonist ranitidine potently inhibits PACAP-stimulated acid secretion without affecting histamine release.	Ranitidine	28-38	adenylate cyclase activating polypeptide 1	Rattus norvegicus	57-62
11425876-7	2001	Depletion of Ran--GTP by metabolic poisoning, disruption of the Ran cycle, or in vitro by cell lysis, results in a shift of Nup2p from the nucleoplasm to the cytoplasmic face of the NPC.	Ranitidine	13-16	nucleoporin NUP2	Saccharomyces cerevisiae S288C	124-129
11771855-3	2001	The histamine H2-receptor antagonist ranitidine, a drug with the highest application for stress ulcer prophylaxis, has the ability to helate the copper ion and to influence its tissue distribution and the processes of generation and neutralization of reactive oxygen species (ROS).	Ranitidine	37-47	histamine receptor H 2	Rattus norvegicus	4-25
11595423-12	2001	Ranitidine, that produced achlorhydria and a further increase in plasma gastrin levels, failed to influence the N alpha-MH- and histamine-induced protection and accompanying rise in the GBF.	Ranitidine	0-10	gastrin	Rattus norvegicus	72-79
11332703-1	2001	The effects of the histamine H2 receptor antagonist, ranitidine, on parietal cell lineage was studied in the mouse stomach by using light and electron microscopy techniques.	Ranitidine	53-63	histamine receptor H2	Mus musculus	19-40
11238657-6	2001	Histamine-induced beta-glucuronidase and IL-6 release and [Ca(2+)](i) elevation were inhibited by the selective H(1) antagonist fexofenadine (10(-7)-10(-4) M), but not by the H(2) antagonist ranitidine.	Ranitidine	191-201	interleukin 6	Homo sapiens	41-45
11179434-5	2001	GPCR105 does not bind (i.e., K(D) &gt; 10 microM) all tested H(1) and H(2) receptor antagonists such as diphenhydramine, loratadine, ranitidine, and cimetidine, but has modest affinity for the H(2) receptor agonist, dimaprit (377 nM).	Ranitidine	133-143	histamine receptor H4	Homo sapiens	0-7
11595432-10	2001	Ranitidine showed the anti-AchE activity and increased duodenal HCO(3)(-) secretion, similar to nizatidine, whereas famotidine had any influence on neither AChE activity nor the HCO(3)(-) secretion.	Ranitidine	0-10	acetylcholinesterase	Rattus norvegicus	27-31
10739174-11	2000	Therefore, we concluded that presence of FMO3/Lys158 and FMO3/Gly308 mutant alleles in FMO3 gene is responsible for the low ranitidine N-oxidation (FMO3 activity) in our Korean population.	Ranitidine	124-134	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	41-45
11523209-5	2001	The results showed that HSP70 contents of the mucosa around the gastric ulcer in the model group and ranitidine-treated group were increased as compared with control group (P &lt; 0.01).	Ranitidine	101-111	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	24-29
11523209-6	2001	Jianpiyiqi could increase the expression of HSP70 of the mucosa around the gastric ulcer further as compared with that in the model group and ranitidine-treated group (P &lt; 0.01).	Ranitidine	142-152	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	44-49
11523209-7	2001	The HSP70 contents in the serum and mucosa in the model group and ranitidine-treated group were increased as compared with control group (P &lt; 0.01, P &lt; 0.05 respectively).	Ranitidine	66-76	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	4-9
11523209-8	2001	HSP70 of serum and mucosa in the Jianpiyiqi-treated group was higher than in the model group and ranitidine-treated group (P &lt; 0.05, P &lt; 0.01 respectively).	Ranitidine	97-107	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	0-5
11128045-0	2000	Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450.	Ranitidine	13-23	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-90
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	Ranitidine	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-223
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	Ranitidine	23-33	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-228
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	Ranitidine	171-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	208-223
11128045-2	2000	N- and S-oxidations of ranitidine were inhibited by metimazole [flavin-containing monooxygenase (FMO) inhibitor] to 96-97% and 71-85%, respectively, and desmethylation of ranitidine was inhibited by SKF525A [cytochrome P450 (CYP) inhibitor] by 71-95%.	Ranitidine	171-181	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	225-228
10966262-7	2000	MEASUREMENTS AND MAIN RESULTS: Ranitidine inhibited the release of neutrophil elastase as well as the production of O2-, the increase in the concentrations of intracellular calcium, a second messenger of neutrophil activation, and increases in CD11b and CD18 expression, in activated neutrophils.	Ranitidine	31-41	elastase, neutrophil expressed	Rattus norvegicus	67-86
10966262-7	2000	MEASUREMENTS AND MAIN RESULTS: Ranitidine inhibited the release of neutrophil elastase as well as the production of O2-, the increase in the concentrations of intracellular calcium, a second messenger of neutrophil activation, and increases in CD11b and CD18 expression, in activated neutrophils.	Ranitidine	31-41	integrin subunit alpha M	Rattus norvegicus	244-249
10966262-7	2000	MEASUREMENTS AND MAIN RESULTS: Ranitidine inhibited the release of neutrophil elastase as well as the production of O2-, the increase in the concentrations of intracellular calcium, a second messenger of neutrophil activation, and increases in CD11b and CD18 expression, in activated neutrophils.	Ranitidine	31-41	integrin subunit beta 2	Rattus norvegicus	254-258
10772385-7	2000	Dexamethasone inhibited all cytokines, but ranitidine only TNF-alpha and IL-3.	Ranitidine	43-53	tumor necrosis factor	Homo sapiens	59-68
10772385-7	2000	Dexamethasone inhibited all cytokines, but ranitidine only TNF-alpha and IL-3.	Ranitidine	43-53	interleukin 3	Homo sapiens	73-77
10750671-1	2000	Histamine (H2) receptor antagonists, such as cimetidine and ranitidine, became available in the late 1970s and presently number among the most commonly used drugs.	Ranitidine	60-70	histamine receptor H2	Homo sapiens	0-23
11093918-4	2000	Pretreatment with the H(2)-receptor antagonists cimetidine or ranitidine significantly reduced the dehydration-induced increase in vasopressin levels approximately 40% after 34 and 37 h of dehydration, whereas this was not the case with the H(1)-receptor antagonist mepyramine.	Ranitidine	62-72	arginine vasopressin	Homo sapiens	131-142
10856459-8	2000	Treatment with omeprazole or ranitidine, which completely suppressed gastric acid secretion and significantly raised plasma gastrin level, greatly reduced the formation of erosive lesions preventing the progression of these lesions to chronic gastric ulcers, and this was accompanied by the rise in gastric blood flow and plasma gastrin levels and the significant attenuation of plasma interleukin-1beta levels.	Ranitidine	29-39	gastrin	Rattus norvegicus	124-131
10856459-8	2000	Treatment with omeprazole or ranitidine, which completely suppressed gastric acid secretion and significantly raised plasma gastrin level, greatly reduced the formation of erosive lesions preventing the progression of these lesions to chronic gastric ulcers, and this was accompanied by the rise in gastric blood flow and plasma gastrin levels and the significant attenuation of plasma interleukin-1beta levels.	Ranitidine	29-39	gastrin	Rattus norvegicus	329-336
10856459-8	2000	Treatment with omeprazole or ranitidine, which completely suppressed gastric acid secretion and significantly raised plasma gastrin level, greatly reduced the formation of erosive lesions preventing the progression of these lesions to chronic gastric ulcers, and this was accompanied by the rise in gastric blood flow and plasma gastrin levels and the significant attenuation of plasma interleukin-1beta levels.	Ranitidine	29-39	interleukin 1 beta	Rattus norvegicus	386-403
10772385-2	2000	In order to confirm and expand these studies, we have compared several H1-blockers and the H2-blocker ranitidine for their effect on TNF-alpha, IL-3, 6, 8 and GM-CSF release from human leukemic mast (HMC-1) and basophilic (KU812) cells, compared to dexamethasone.	Ranitidine	102-112	tumor necrosis factor	Homo sapiens	133-142
10772385-2	2000	In order to confirm and expand these studies, we have compared several H1-blockers and the H2-blocker ranitidine for their effect on TNF-alpha, IL-3, 6, 8 and GM-CSF release from human leukemic mast (HMC-1) and basophilic (KU812) cells, compared to dexamethasone.	Ranitidine	102-112	interleukin 3	Homo sapiens	144-154
10772385-2	2000	In order to confirm and expand these studies, we have compared several H1-blockers and the H2-blocker ranitidine for their effect on TNF-alpha, IL-3, 6, 8 and GM-CSF release from human leukemic mast (HMC-1) and basophilic (KU812) cells, compared to dexamethasone.	Ranitidine	102-112	colony stimulating factor 2	Homo sapiens	159-165
10772385-4	2000	All antihistamines caused a dose-dependent inhibition of TNF-alpha release from HMC-1 cells, with maximal effects at 10(-12) M for azelastine, 10(-9) M for loratadine and cetirizine, and 10(-8) M for ranitidine.	Ranitidine	200-210	tumor necrosis factor	Homo sapiens	57-66
10739174-11	2000	Therefore, we concluded that presence of FMO3/Lys158 and FMO3/Gly308 mutant alleles in FMO3 gene is responsible for the low ranitidine N-oxidation (FMO3 activity) in our Korean population.	Ranitidine	124-134	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	57-61
10739174-11	2000	Therefore, we concluded that presence of FMO3/Lys158 and FMO3/Gly308 mutant alleles in FMO3 gene is responsible for the low ranitidine N-oxidation (FMO3 activity) in our Korean population.	Ranitidine	124-134	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	57-61
10739174-11	2000	Therefore, we concluded that presence of FMO3/Lys158 and FMO3/Gly308 mutant alleles in FMO3 gene is responsible for the low ranitidine N-oxidation (FMO3 activity) in our Korean population.	Ranitidine	124-134	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	57-61
10569698-3	1999	The inhibitory effect of histamine could be reversed by the H2 histamine receptor (HR2) antagonists cimetidine and ranitidine both in PMBC and in CD19-depleted cells, but not with triprolidine, an H1 receptor antagonist, suggesting that the inhibition of IFNgamma production is mediated through H2 receptors in these cell populations.	Ranitidine	115-125	CD19 molecule	Homo sapiens	146-150
10678532-6	2000	The histamine H2 receptor antagonist ranitidine effectively blocked the excitatory response of PCs to histamine (n = 20), but triprolidine, an H1 receptor antagonist, could not significantly block the histamine-induced excitation, or only very slightly decreased the excitatory effect of histamine on the cells (n = 13).	Ranitidine	37-47	histamine receptor H 2	Rattus norvegicus	4-25
10569698-3	1999	The inhibitory effect of histamine could be reversed by the H2 histamine receptor (HR2) antagonists cimetidine and ranitidine both in PMBC and in CD19-depleted cells, but not with triprolidine, an H1 receptor antagonist, suggesting that the inhibition of IFNgamma production is mediated through H2 receptors in these cell populations.	Ranitidine	115-125	interferon gamma	Homo sapiens	255-263
10462360-4	1999	Ranitidine and cimetidine reduced markedly, in same concentration, P-selectin levels after induction of aggregation by 5 microm ADP, 1 microg/mL collagen and 3 microM arachidonic acid.	Ranitidine	0-10	selectin P	Homo sapiens	67-77
11499019-4	1999	The excitatory response of PCs to histamine could be blocked by histamine H2 receptor antagonist ranitidine, but not by H1 receptor antagonist triprolidine readily.	Ranitidine	97-107	histamine receptor H 2	Rattus norvegicus	64-85
10424717-6	1999	Pretreatment with H2-receptor antagonist, ranitidine produced a 15.7% reduction in the mucosal damage caused by indomethacin, 29.5% decrease in epithelial cell apoptosis and a 19.6% reduction in ET-1, while the expression of IL-4 increased by 10.8% and that of cNOS showed a 2-fold increase.	Ranitidine	42-52	endothelin 1	Rattus norvegicus	195-199
10424717-6	1999	Pretreatment with H2-receptor antagonist, ranitidine produced a 15.7% reduction in the mucosal damage caused by indomethacin, 29.5% decrease in epithelial cell apoptosis and a 19.6% reduction in ET-1, while the expression of IL-4 increased by 10.8% and that of cNOS showed a 2-fold increase.	Ranitidine	42-52	interleukin 4	Rattus norvegicus	225-229
10424717-6	1999	Pretreatment with H2-receptor antagonist, ranitidine produced a 15.7% reduction in the mucosal damage caused by indomethacin, 29.5% decrease in epithelial cell apoptosis and a 19.6% reduction in ET-1, while the expression of IL-4 increased by 10.8% and that of cNOS showed a 2-fold increase.	Ranitidine	42-52	nitric oxide synthase 3	Rattus norvegicus	261-265
10223772-2	1999	In this study we investigated the inhibition profiles of CYP1A2 (substrate: caffeine) CYP2D6 (substrate: dextromethorphan), and CYP3A4/5 (substrate: dextrorphan) by cimetidine, ranitidine, and the novel H2-receptor antagonist ebrotidine in human liver microsomes.	Ranitidine	177-187	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	57-63
10223772-9	1999	In contrast, the effect of ranitidine or ebrotidine on CYP3A activity in vivo seems to have little clinical significance.	Ranitidine	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	55-60
10221441-3	1999	This study aimed to determine whether major abdominal surgery induced increased serum IgE levels, and whether treatment with ranitidine or prednisolone influenced the IgE response to surgery.	Ranitidine	125-135	immunoglobulin heavy constant epsilon	Homo sapiens	167-170
10067839-6	1999	Furthermore, the increases in OT concentration in dialysates and plasma were prevented by simultaneous administration of chlorpheniramine (an H1 receptor antagonist) or ranitidine (an H2 receptor antagonist) as well as by the adrenergic antagonist phentolamine.	Ranitidine	169-179	oxytocin/neurophysin I prepropeptide	Homo sapiens	30-32
10221441-7	1999	RESULTS: In the ranitidine study, both the control group and the ranitidine-treated group displayed a postoperative increase (P&lt;0.001) of serum IgE.	Ranitidine	16-26	immunoglobulin heavy constant epsilon	Homo sapiens	147-150
10221441-7	1999	RESULTS: In the ranitidine study, both the control group and the ranitidine-treated group displayed a postoperative increase (P&lt;0.001) of serum IgE.	Ranitidine	65-75	immunoglobulin heavy constant epsilon	Homo sapiens	147-150
9746775-4	1998	From the pattern of monoclonal antibody (MoAb) inhibition and the reactions of antibody with Chinese hamster ovary (CHO) cells transfected with GPIX and GPIbbeta, we found that the patient"s antibody is specific for an epitope on GPIX close to, or identical with a site recognized by the MoAb SZ1 that is a common target for antibodies induced by quinine and quinidine, drugs structurally unrelated to ranitidine.	Ranitidine	402-412	glycoprotein IX platelet	Homo sapiens	144-148
9927283-9	1999	The SRIF stimulatory effect of pentagastrin in 28-day-old lambs was abolished by ranitidine, which also reduced this effect in the adult sheep.	Ranitidine	81-91	somatostatin	Ovis aries	4-8
9862768-0	1999	Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2.	Ranitidine	73-83	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	87-101
9862768-4	1999	Ileal ranitidine secretion was concentration dependent and significantly reduced by the P-glycoprotein (P-gp) substrates verapamil and cyclosporin.	Ranitidine	6-16	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	88-102
9862768-4	1999	Ileal ranitidine secretion was concentration dependent and significantly reduced by the P-glycoprotein (P-gp) substrates verapamil and cyclosporin.	Ranitidine	6-16	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	104-108
9862768-8	1999	Caco-2 monolayers, which overexpress P-gp, also showed asymmetric permeability of ranitidine and cimetidine.	Ranitidine	82-92	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	37-41
9862768-11	1999	These data indicate that ranitidine and cimetidine can act as substrates for intestinal P-gp and suggest that the balance between absorptive and secretory mechanisms as a factor in determining intestinal absorption needs to be a routine consideration even for compounds expected to have a predominantly paracellular route of absorption.	Ranitidine	25-35	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	88-92
9716870-3	1998	Enhanced Isc of the rat nasal mucosa resulted from stimulation of substance P (SP) in a dose-dependent manner that could be inhibited by pretreatment with NK1 receptor antagonist CP-96345, the H1 receptor antagonist pyrilamine, the H2 receptor antagonist ranitidine, and the neurotoxin tetrodotoxin, respectively, to different extents.	Ranitidine	255-265	tachykinin receptor 1	Rattus norvegicus	155-167
9754723-7	1998	Base-line salivary EGF output was similar in all groups but increased in the placebo/ranitidine group on day 3 and in the ranitidine group on day 9.	Ranitidine	85-95	epidermal growth factor	Homo sapiens	19-22
9706062-8	1998	CONCLUSIONS: Results support the hypothesis that pancreatico-biliary secretions (present in the intestinal lumen during control or CCK treatment) and gastrointestinal transit time may influence the occurrence of secondary peaks in ranitidine concentration vs. time profiles.	Ranitidine	231-241	cholecystokinin	Homo sapiens	131-134
9754723-7	1998	Base-line salivary EGF output was similar in all groups but increased in the placebo/ranitidine group on day 3 and in the ranitidine group on day 9.	Ranitidine	122-132	epidermal growth factor	Homo sapiens	19-22
9602986-0	1998	Changes in mucosal levels of transforming growth factor-alpha from the oxyntic region and ulcer site during duodenal ulcer healing with ranitidine or sucralfate.	Ranitidine	136-146	tumor necrosis factor	Homo sapiens	29-61
9626585-6	1998	The potentiating effect of smoking on ethanol-induced gastric mucosal lesion and MPO activity was abolished by pretreatment with allopurinol, terfenadine or ranitidine.	Ranitidine	157-167	myeloperoxidase	Rattus norvegicus	81-84
9503217-0	1998	Effect of ranitidine on gastric intramucosal pH in critically ill patients.	Ranitidine	10-20	glucose-6-phosphate isomerase	Homo sapiens	45-47
9505879-2	1998	BACKGROUND: Does the use of the histamine H2 receptor antagonist ranitidine improve the outcome of patients with gastric cancer?	Ranitidine	65-75	histamine receptor H2	Homo sapiens	32-53
9700763-3	1998	PACAP-27 had no effect on basal cells but significantly increased the response to histamine (10(-4) M) at 10(-9) M and to carbachol (10(-4) M) in the presence of ranitidine (10(-4) M) at 10(-7) M and 10(-8) M. PACAP (6-38), an antagonist of PACAP, inhibited the effect of PACAP-27 on carbachol-stimulated cells.	Ranitidine	162-172	LOW QUALITY PROTEIN: pituitary adenylate cyclase-activating polypeptide	Oryctolagus cuniculus	0-5
9503217-7	1998	Ranitidine significantly increased gastric juice pH, but did not affect PCO2i or pHi; pHi was 7.34 +/- 0.14 before ranitidine, and 7.30 +/- 0.12, 7.31 +/- 0.11, 7.31 +/- 0.14 and 7.31 +/- 0.12-2, 4, 6 and 8 h, respectively, after ranitidine administration (p = 0.55).	Ranitidine	0-10	glucose-6-phosphate isomerase	Homo sapiens	49-51
9700763-3	1998	PACAP-27 had no effect on basal cells but significantly increased the response to histamine (10(-4) M) at 10(-9) M and to carbachol (10(-4) M) in the presence of ranitidine (10(-4) M) at 10(-7) M and 10(-8) M. PACAP (6-38), an antagonist of PACAP, inhibited the effect of PACAP-27 on carbachol-stimulated cells.	Ranitidine	162-172	LOW QUALITY PROTEIN: pituitary adenylate cyclase-activating polypeptide	Oryctolagus cuniculus	210-215
9700763-3	1998	PACAP-27 had no effect on basal cells but significantly increased the response to histamine (10(-4) M) at 10(-9) M and to carbachol (10(-4) M) in the presence of ranitidine (10(-4) M) at 10(-7) M and 10(-8) M. PACAP (6-38), an antagonist of PACAP, inhibited the effect of PACAP-27 on carbachol-stimulated cells.	Ranitidine	162-172	LOW QUALITY PROTEIN: pituitary adenylate cyclase-activating polypeptide	Oryctolagus cuniculus	210-215
9700763-3	1998	PACAP-27 had no effect on basal cells but significantly increased the response to histamine (10(-4) M) at 10(-9) M and to carbachol (10(-4) M) in the presence of ranitidine (10(-4) M) at 10(-7) M and 10(-8) M. PACAP (6-38), an antagonist of PACAP, inhibited the effect of PACAP-27 on carbachol-stimulated cells.	Ranitidine	162-172	LOW QUALITY PROTEIN: pituitary adenylate cyclase-activating polypeptide	Oryctolagus cuniculus	210-215
9617379-13	1998	Studies involving ranitidine treatment in association with interleukin-2 for renal carcinoma and metastatic melanoma are also of interest although no statistically significant results are available as yet.	Ranitidine	18-28	interleukin 2	Homo sapiens	59-72
9444664-1	1997	Since some antisecretory drugs such as cimetidine and ranitidine, interfere with ethanol metabolism by inhibition of hepatic and/or gastric alcohol dehydrogenase, we investigated the effect of lansoprazole, a new protonic pump inhibitor, on gastric and hepatic alcohol dehydrogenase activity.	Ranitidine	54-64	alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	Homo sapiens	132-161
9045717-0	1997	Different binding domains for Ran-GTP and Ran-GDP/RanBP1 on nuclear import factor p97.	Ranitidine	30-33	melanotransferrin	Homo sapiens	82-85
9361169-12	1997	CONCLUSION: Nocloprost is superior to ranitidine in the treatment of chronic gastric ulcers, and these effects could be due, at least in part, to higher expression and mucosal content of EGF in the ulcer area.	Ranitidine	38-48	epidermal growth factor	Homo sapiens	187-190
9305407-7	1997	A second reaction, the N-oxidation of ranitidine, exhibited a much higher Km with recombinant FMO3 than did methimazole (2 mM vs. 35 microM).	Ranitidine	38-48	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	94-98
9182905-7	1997	The H2-receptor antagonist ranitidine completely reversed the inhibition of IL-4 and IFN-gamma production, whereas the agonist dimaprit mimicked this effect.	Ranitidine	27-37	interleukin 4	Homo sapiens	76-80
9182905-7	1997	The H2-receptor antagonist ranitidine completely reversed the inhibition of IL-4 and IFN-gamma production, whereas the agonist dimaprit mimicked this effect.	Ranitidine	27-37	interferon gamma	Homo sapiens	85-94
9286814-5	1997	The histamine-induced acceleration of mucin biosynthesis was suppressed by ranitidine, but not pyrilamine.	Ranitidine	75-85	solute carrier family 13 member 2	Rattus norvegicus	38-43
9160923-8	1997	After 2 wks of treatment abnormal "liver enzymes" (ALAT/ASAT) were found in 13/48 (0.27) of the ranitidine group in contrast with 18/36 (0.50) of the placebo group (P = 0.03).	Ranitidine	96-106	ATP binding cassette subfamily B member 7	Homo sapiens	56-60
9471594-5	1997	Ranitidine (10(-2) M) increased 4 times the number of sites of glucocorticoid receptor binding for acetonide triamcinolone and aroused the association constant of hormone-receptor complex.	Ranitidine	0-10	nuclear receptor subfamily 3 group C member 1	Homo sapiens	63-86
9205740-9	1997	In contrast, ranitidine at a single oral dose of 100 mg/kg increased serum gastrin levels more markedly within 2 and 5 h after administration, while after 8 h, this increase still persisted although without significant differences with respect to control, and after 24 h levels returned to normal values.	Ranitidine	13-23	gastrin	Rattus norvegicus	75-82
9205740-10	1997	Both ebrotidine and ranitidine were administered orally at a dose of 100 mg/kg for 26 days showing significant increments in plasma gastrin levels 5 h after administration.	Ranitidine	20-30	gastrin	Rattus norvegicus	132-139
9205740-13	1997	In contrast, ranitidine increased serum gastrin levels significantly and in a dose-dependent manner with respect to control group.	Ranitidine	13-23	gastrin	Rattus norvegicus	40-47
9205757-8	1997	After ranitidine and cimetidine, hypergastrinemia was still present at this time, but normal levels were attained before 24 h. With omeprazole plasma gastrin levels did not return to normal range within 24 h after each administration, and a cumulative effect occurred during treatment.	Ranitidine	6-16	gastrin	Rattus norvegicus	38-45
9471667-8	1997	Two out of three patients received more than 10 doses of H2B, being ranitidine the most frequently prescribed.	Ranitidine	68-78	H2B clustered histone 21	Homo sapiens	57-60
9037573-7	1997	These results suggest that the drop in prolactin levels occurring when cimetidine and ranitidine are suspended may contribute to the development of this syndrome.	Ranitidine	86-96	prolactin	Homo sapiens	39-48
9068463-11	1997	Fasting serum gastrin levels at weeks 4 and 8 were significantly higher in the lansoprazole group compared with the ranitidine group.	Ranitidine	116-126	gastrin	Homo sapiens	14-21
9042599-3	1997	The histamine H2 receptor antagonist ranitidine did not affect the release of prostaglandin F2 alpha, suggesting that its generation may have resulted from histamine H1 receptor activation.	Ranitidine	37-47	histamine receptor H2	Homo sapiens	4-25
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9006348-11	1997	The IL-1 beta-induced increase in permeability could be completely abrogated at 4 and 24 hours PI by treating the animals with the histamine H2-receptor antagonist ranitidine, which also reduced leukocyte infiltration by 47.2%.	Ranitidine	164-174	interleukin 1 beta	Rattus norvegicus	4-13
9006348-11	1997	The IL-1 beta-induced increase in permeability could be completely abrogated at 4 and 24 hours PI by treating the animals with the histamine H2-receptor antagonist ranitidine, which also reduced leukocyte infiltration by 47.2%.	Ranitidine	164-174	histamine receptor H 2	Rattus norvegicus	131-152
9113805-5	1997	RESULTS: Both ranitidine regimens were significantly more effective than placebo in preventing endoscopic and symptomatic relapse of reflux esphagitis (p = 0.003 for ranitidine 150 mg bid; P &lt; 0.001 for ranitidine 300 mg bid).	Ranitidine	14-24	BH3 interacting domain death agonist	Homo sapiens	224-227
8917026-7	1996	Treatment with ranitidine, but not placebo, was associated with a significant increase in CD4+ lymphocytes (33% to 49%; p &lt; .05) and a significant decrease in CD8+ lymphocytes (41% to 27%; p &lt; .05).	Ranitidine	15-25	CD4 molecule	Homo sapiens	90-93
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9113805-7	1997	The percentage of patients with endoscopic relapse (grade 2) after 48 weeks were 60%, 37% and 27% for placebo, ranitidine 150 mg bid and ranitidine 300 mg bid, respectively (P = 0.002 for ranitidine 150 mg bid versus placebo; P &lt; 0.001 for ranitidine 300 mg bid versus placebo).	Ranitidine	137-147	BH3 interacting domain death agonist	Homo sapiens	155-158
9113805-9	1997	CONCLUSIONS: Ranitidine 150 mg bid and 300 mg bid are safe and effective treatments in the prevention of reflux esophagitis relapse.	Ranitidine	13-23	BH3 interacting domain death agonist	Homo sapiens	31-34
9581490-6	1997	It has been shown, that ranitidine modified the gastric mucin components content, what can suggest diminished degradation of mucus directly adhering to the gastric mucosa.	Ranitidine	24-34	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	48-61
9001831-1	1996	Ranitidine 150 mg twice daily (BID) is an approved therapeutic approach for relieving the symptoms of gastroesophageal reflux disease.	Ranitidine	0-10	BH3 interacting domain death agonist	Homo sapiens	31-34
8922739-5	1996	Responses to gastrin were almost completely inhibited by ranitidine (10 microM) at a concentration which abolished the secretory response to dimaprit.	Ranitidine	57-67	gastrin	Rattus norvegicus	13-20
8917026-7	1996	Treatment with ranitidine, but not placebo, was associated with a significant increase in CD4+ lymphocytes (33% to 49%; p &lt; .05) and a significant decrease in CD8+ lymphocytes (41% to 27%; p &lt; .05).	Ranitidine	15-25	CD8a molecule	Homo sapiens	162-165
8917026-8	1996	Also, the mitogen-stimulated interferon-gamma production increased from 121 to 269 pg/mL (p &lt; .05) in patients treated with ranitidine, but not in patients treated with placebo.	Ranitidine	127-137	interferon gamma	Homo sapiens	29-45
8806799-7	1996	A histamine H2 receptor antagonist, ranitidine, did not affect the histamine-induced expression of cell adhesion molecules.	Ranitidine	36-46	histamine receptor H2	Homo sapiens	2-23
8982295-4	1996	The effect of histamine was completely blocked by the histamine H2-receptor (H2R) antagonist ranitidine but not by its chemical control AH20399AA.	Ranitidine	93-103	histamine receptor H2	Homo sapiens	54-75
8616026-4	1996	The effect of histamine was apparently mediated by H2-type histamine receptors (H2R), since the H2R antagonist ranitidine completely blocked the response.	Ranitidine	111-121	histamine receptor H2	Homo sapiens	51-78
8774841-5	1996	Cimetidine and ranitidine decreased the activity of NAT significantly, no effect on this enzyme was observed after nizatidine.	Ranitidine	15-25	N-acetyltransferase 1	Rattus norvegicus	52-55
8638714-4	1996	Ranitidine, omeprazole, and NaHCO3 raised the serum gastrin concentration and activated ODC and HDC.	Ranitidine	0-10	histidine decarboxylase	Rattus norvegicus	96-99
8711434-3	1996	The protective effect of histamine was blocked by the H2-receptor (H2R) antagonist ranitidine but not by AH202399 A, a chemical control to ranitidine devoid of H2R affinity.	Ranitidine	83-93	histamine receptor H2	Homo sapiens	54-70
8836631-6	1996	), attenuated the hypothermic effect of morphine (10 mg/kg), a histamine H2 receptor antagonist, ranitidine (100 mg/kg, i.p.	Ranitidine	97-107	histamine receptor H2	Mus musculus	63-84
8652190-10	1996	Furthermore, blockage of H2 receptors with ranitidine increased the release of TNF alpha from PMC stimulated with antigen, suggesting that histamine released by MC within 10 min of antigen stimulation downregulates the subsequent release of TNF alpha from the same MC population.	Ranitidine	43-53	tumor necrosis factor	Rattus norvegicus	79-88
8652190-10	1996	Furthermore, blockage of H2 receptors with ranitidine increased the release of TNF alpha from PMC stimulated with antigen, suggesting that histamine released by MC within 10 min of antigen stimulation downregulates the subsequent release of TNF alpha from the same MC population.	Ranitidine	43-53	tumor necrosis factor	Rattus norvegicus	241-250
8767354-2	1996	In previous studies measuring intragastric pH in healthy volunteers it was shown that there was a faster onset of action with ranitidine (CAS 66357-35-5) 300 mg effervescent tablets (Zantac) compared to standard tablets.	Ranitidine	126-136	BCAR1 scaffold protein, Cas family member	Homo sapiens	138-141
8767354-2	1996	In previous studies measuring intragastric pH in healthy volunteers it was shown that there was a faster onset of action with ranitidine (CAS 66357-35-5) 300 mg effervescent tablets (Zantac) compared to standard tablets.	Ranitidine	183-189	BCAR1 scaffold protein, Cas family member	Homo sapiens	138-141
8804870-17	1996	The mean increase in gastrin levels after 12 months" treatment was significantly greater for patients in the lansoprazole group (124.2 pg/ml, P = 0.0056) than those in the ranitidine group (31.9 pg/ml).	Ranitidine	172-182	gastrin	Homo sapiens	21-28
8708169-1	1996	OBJECTIVE: To study the effect of nasogastric suction and ranitidine on the determination of gastric intramucosal pH (pHi).	Ranitidine	58-68	glucose-6-phosphate isomerase	Homo sapiens	118-121
8708169-9	1996	Compared to control and nasogastric suction periods, after ranitidine mean gastric pHi was higher (control 7.22 +/- 0.08; nasogastric suction 7.23 +/- 0.07; after ranitidine 7.31 +/- 0.06, p &lt; 0.001) mean gastric PCO2 lower (control 6.4 +/- 1.3; nasogastric suction 6.5 +/- 1.3; after ranitidine 5.3 +/- 0.9, p &lt; 0.001) and pH gap lower (control 0.18 +/- 0.08; nasogastric suction 0.17 +/- 0.05; after ranitidine 0.09 +/- 0.06, p &lt; 0.01).	Ranitidine	59-69	glucose-6-phosphate isomerase	Homo sapiens	83-86
8638714-4	1996	Ranitidine, omeprazole, and NaHCO3 raised the serum gastrin concentration and activated ODC and HDC.	Ranitidine	0-10	gastrin	Rattus norvegicus	52-59
8638714-4	1996	Ranitidine, omeprazole, and NaHCO3 raised the serum gastrin concentration and activated ODC and HDC.	Ranitidine	0-10	ornithine decarboxylase 1	Rattus norvegicus	88-91
8616026-4	1996	The effect of histamine was apparently mediated by H2-type histamine receptors (H2R), since the H2R antagonist ranitidine completely blocked the response.	Ranitidine	111-121	histamine receptor H2	Homo sapiens	80-83
8616026-4	1996	The effect of histamine was apparently mediated by H2-type histamine receptors (H2R), since the H2R antagonist ranitidine completely blocked the response.	Ranitidine	111-121	histamine receptor H2	Homo sapiens	96-99
8657447-0	1996	[Effect of the histamine H2-receptor antagonist zantac on lipid peroxidation an antioxidant system in patients with gastroduodenal hemorrhage of ulcer etiology].	Ranitidine	48-54	histamine receptor H2	Homo sapiens	15-36
8657447-2	1996	The administration of zantac, a histamine H2-receptor blocker, considerably reduced lipid peroxidation and enhanced antioxidative activity, which positively affected the clinical course of diseases.	Ranitidine	22-28	histamine receptor H2	Homo sapiens	32-53
8927936-13	1996	Histamine-stimulated secretion was unaffected by alpha-FMH and abolished by the histamine H2-receptor antagonist ranitidine.	Ranitidine	113-123	histamine receptor H 2	Rattus norvegicus	80-101
8927936-14	1996	The acid response to gastrin-17 was almost abolished in histamine-depleted rats and abolished by ranitidine.	Ranitidine	97-107	gastrin	Rattus norvegicus	21-28
8560202-2	1996	The effect of histamine was apparently mediated by H2-type histamine receptors (H2R) since it was blocked by ranitidine, and H2R antagonist.	Ranitidine	109-119	histamine receptor H2	Mus musculus	51-78
9275711-9	1996	It is suggested that the histamine H2 receptor antagonist Ranit has, to some extent, potential in the treatment of myeloid leukemia, especially when combined with antineoplastic agent Ara-C at suboptimal doses.	Ranitidine	58-63	histamine receptor H2	Homo sapiens	25-46
8560202-2	1996	The effect of histamine was apparently mediated by H2-type histamine receptors (H2R) since it was blocked by ranitidine, and H2R antagonist.	Ranitidine	109-119	histamine receptor H2	Mus musculus	80-83
8603673-3	1995	The 3795-bp open reading frame of the cDNA encodes a polypeptide consisting of 1265 amino acids with three Ran-GTP binding domains (RanBD) that are almost identical with published partial amino acid sequences of human RanBP2 as deduced from several partial cDNA clones of other authors.	Ranitidine	107-110	RAN binding protein 2	Homo sapiens	218-224
7483087-1	1995	The histamine H-2-receptor antagonist ranitidine hydrochloride has been shown to alleviate trauma-, blood transfusion- and sepsis-induced immunosuppression.	Ranitidine	38-62	histamine receptor H2	Homo sapiens	4-26
8564521-5	1995	The histamine H2-receptor antagonist, ranitidine shifted the histamine concentration effect curve to the left and attenuated the dose dependent relaxations elicited at high concentrations.	Ranitidine	38-48	histamine H2 receptor	Cavia porcellus	4-25
7589599-5	1995	Recombinant IL-2-induced NK-cell activity was 37.1% (11.1-71.7) (P &lt; 0.05 compared to spontaneous activity), and rIL-2 plus ranitidine-induced NK-cell activity was 52.7% (18.9-85.6) (P &lt; 0.05 compared to spontaneous and to rIL-2-induced activity, respectively).	Ranitidine	127-137	interleukin 2	Rattus norvegicus	229-234
7589599-6	1995	These results suggest a synergistic increase of low-dose rIL-2-induced NK-cell activity by ranitidine.	Ranitidine	91-101	interleukin 2	Rattus norvegicus	57-62
7616440-6	1995	Ranitidine and H1-receptor antagonist chlorpheniramine had similar inhibitory effects on ODC activity induced by gastrin.	Ranitidine	0-10	ornithine decarboxylase 1	Rattus norvegicus	89-92
7627386-0	1995	Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis.	Ranitidine	0-10	interleukin 6	Homo sapiens	33-46
7627386-0	1995	Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis.	Ranitidine	0-10	C-reactive protein	Homo sapiens	55-73
7627386-4	1995	STUDY DESIGN: The effect of perioperative ranitidine on postoperative change in plasma interleukin-6 (IL-6) and serum C-reactive protein (CRP) levels was assessed in 23 women undergoing elective abdominal hysterectomy.	Ranitidine	42-52	interleukin 6	Homo sapiens	87-100
7627386-4	1995	STUDY DESIGN: The effect of perioperative ranitidine on postoperative change in plasma interleukin-6 (IL-6) and serum C-reactive protein (CRP) levels was assessed in 23 women undergoing elective abdominal hysterectomy.	Ranitidine	42-52	interleukin 6	Homo sapiens	102-106
7627386-9	1995	C-reactive protein levels were also significantly increased in all patients after 24, 48, and 120 hours, respectively; however, at 48 hours, CRP was significantly reduced in ranitidine-treated patients compared with non-ranitidine-treated patients (p = 0.02).	Ranitidine	174-184	C-reactive protein	Homo sapiens	141-144
7627386-11	1995	However, the reduced CRP level in ranitidine-treated patients suggests that H2RAs modulate IL-6 signal transduction in hepatic cells.	Ranitidine	34-44	C-reactive protein	Homo sapiens	21-24
7627386-11	1995	However, the reduced CRP level in ranitidine-treated patients suggests that H2RAs modulate IL-6 signal transduction in hepatic cells.	Ranitidine	34-44	interleukin 6	Homo sapiens	91-95
8748234-9	1995	The production of rare nonproliferating preparietal cells is enhanced after blocking the secretory activity of their mature forms by continuous infusion of the histamine H2-receptor antagonist, ranitidine, for 42 h. Thus, the presence of active mature parietal cells is necessary to maintain the normal cellular proliferation and commitment program in the gastric epithelium.	Ranitidine	194-204	histamine receptor H2	Homo sapiens	160-181
7636452-2	1995	This study is the first large, prospective, nationwide family practice outpatient evaluation of the effectiveness of the histamine (H2)-receptor antagonist ranitidine as medical therapy for this disorder.	Ranitidine	156-166	histamine receptor H2	Homo sapiens	121-144
7616440-6	1995	Ranitidine and H1-receptor antagonist chlorpheniramine had similar inhibitory effects on ODC activity induced by gastrin.	Ranitidine	0-10	gastrin	Rattus norvegicus	113-120
7664171-6	1995	Treatment with the histamine H2 receptor antagonist ranitidine alone reduced survival time in i.v.-infected animals and blocked the protective effect of histamine.	Ranitidine	52-62	histamine receptor H2	Homo sapiens	19-40
7698188-2	1994	Ranitidine, a histamine H2 receptor blocking agent, given intraperitoneally 30 min prior to ischemia, exerted a dose-dependent protective effect on water accumulation and ion shifts in the brain (Na+, K+ and Ca2+).	Ranitidine	0-10	histamine receptor H 2	Rattus norvegicus	14-35
7696266-5	1995	Inhibition of the alcohol dehydrogenase isoenzymes by the H2-receptor antagonists nizatidine, ranitidine, and famotidine was negligible.	Ranitidine	94-104	aldo-keto reductase family 1 member A1	Homo sapiens	18-39
7713139-8	1995	However, the selective histamine H2 receptor antagonist, ranitidine, selectively inhibited the synthesis of prostaglandin E2 alone.	Ranitidine	57-67	histamine receptor H2	Homo sapiens	23-44
7697902-7	1995	The histamine H2-receptor antagonist ranitidine has been shown to be effective in preventing NSAID-induced duodenal ulcers, but has no efficacy in preventing NSAID-induced gastric ulcers.	Ranitidine	37-47	histamine receptor H2	Homo sapiens	4-25
7827929-0	1994	Effect of ranitidine on soluble interleukin 2 receptors and CD8 molecules in surgical patients.	Ranitidine	10-20	CD8a molecule	Homo sapiens	60-63
7827929-1	1994	The effect of perioperative immunomodulation with the H2-receptor antagonist ranitidine on postoperative changes in soluble interleukin (IL) 2 receptor and soluble CD8 levels was assessed in 24 patients undergoing major elective abdominal surgery.	Ranitidine	77-87	CD8a molecule	Homo sapiens	164-167
7827929-5	1994	In patients treated with ranitidine, the serum level of soluble IL-2 receptor increased from day 0 to day 9 (P &lt; 0.01); in control patients it decreased from day 0 to day 1, did not change significantly by day 3 and increased by day 9.	Ranitidine	25-35	interleukin 2 receptor subunit beta	Homo sapiens	64-77
7827929-9	1994	The postoperative change in soluble IL-2 receptor level may reflect lymphocyte activation status; ranitidine appears to promote activation of mainly CD4-positive lymphocytes since serum levels of CD8 were unchanged.	Ranitidine	98-108	CD4 molecule	Homo sapiens	149-152
7535606-1	1994	Nontoxic doses of the histamine H2 antagonists ranitidine, cimetidine, lamtidine and mifentidine rapidly and reversibly increased tyrosinase activity in an amelanotic human melanoma cell line (MM96L) with low constitutive activity.	Ranitidine	47-57	tyrosinase	Homo sapiens	130-140
7809839-12	1995	Ranitidine delayed the LPS-induced ventilation-perfusion imbalance and attenuated the peak increase in the proinflammatory cytokine, tumor necrosis factor, without altering its antiinflammatory opponent, cortisol.	Ranitidine	0-10	tumor necrosis factor	Homo sapiens	133-154
7931667-5	1994	He received pentagastrin as before, but this time was also given a histamine H2 receptor blocker (zantac).	Ranitidine	98-104	histamine receptor H2	Homo sapiens	67-88
7870664-1	1994	We investigated the effect of acute renal and hepatic dysfunction on the neurotoxicity of ranitidine, a histamine H2 receptor antagonist.	Ranitidine	90-100	histamine receptor H2	Mus musculus	104-125
8063004-10	1994	The activities of debrisoquine 4-hydroxylase and bufuralol 1"-hydroxylase were inhibited in vitro by cimetidine or ranitidine at a higher concentration than that on in vivo administration of either H2 blocker.	Ranitidine	115-125	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	18-44
8053433-9	1994	Ranitidine increased fasting serum gastrin levels (22%; p &lt; 0.05 vs. placebo), whereas both lansoprazole regimens produced more marked rises in serum gastrin (54% and 60%; p &lt; 0.05 vs. placebo and ranitidine).	Ranitidine	0-10	gastrin	Homo sapiens	35-42
8033816-8	1994	Dehydration-induced AVP secretion was lowered when neuronal HA synthesis was inhibited by the administration of (S) alpha-fluoromethylhistidine or when the animals were pretreated with the H3-receptor agonist R(alpha)methylhistamine, which inhibits the release and synthesis of HA, the H1-receptor antagonists mepyramine and cetirizine, or the H2-receptor antagonists cimetidine and ranitidine.	Ranitidine	383-393	arginine vasopressin	Homo sapiens	20-23
7958721-9	1994	This inhibition caused by ketamine seems to be associated with the protection of acetylcholinesterase against the inhibition by ranitidine and physostigmine.	Ranitidine	128-138	acetylcholinesterase	Cavia porcellus	81-101
10147354-1	1994	Ranitidine is a histamine H 2-receptor antagonist which, on the basis of its well established tolerability and efficacy profile, has been widely prescribed for the treatment of ulcer disease and mild to moderate reflux oesophagitis.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	16-38
7925615-4	1994	It has been shown that histamine H2 receptor antagonists such as cimetidine, ranitidine and famotidine are good hydroxyl radical scavengers.	Ranitidine	77-87	histamine receptor H2	Homo sapiens	23-44
8063004-4	1994	In vivo administration of cimetidine and ranitidine decreased the contents of P450 isozymes and the activities of P450-linked monooxygenase systems; i.e., benzphetamine N-demethylase, aminopyrine N-demethylase, 7-ethoxycoumarin O-deethylase, debrisoquine 4-hydroxylase and bufuralol 1"-hydroxylase.	Ranitidine	41-51	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	242-268
8063004-12	1994	The kinetic parameters for cimetidine or ranitidine as to the activities of debrisoquine 4-hydroxylase and bufuralol 1"-hydroxylase in liver microsomes were determined by means of Lineweaver-Burk plots.	Ranitidine	41-51	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	76-102
7511596-10	1994	Cimetidine and ranitidine, H2 receptor antagonists structurally unrelated to each other, completely reversed the histamine-mediated increase in IL-1 alpha-induced IL-6 synthesis.	Ranitidine	15-25	interleukin 1 alpha	Homo sapiens	144-154
7916447-0	1994	Effects of a histamine H2-receptor antagonist, ranitidine on the vasopressin and oxytocin responses to novelty stress in the rat.	Ranitidine	47-57	arginine vasopressin	Rattus norvegicus	65-76
7916447-2	1994	administered histamine H2-receptor antagonist, ranitidine, on plasma levels of vasopressin and oxytocin were studied in male rats under unstressed or stressed conditions.	Ranitidine	47-57	histamine receptor H 2	Rattus norvegicus	13-34
7916447-2	1994	administered histamine H2-receptor antagonist, ranitidine, on plasma levels of vasopressin and oxytocin were studied in male rats under unstressed or stressed conditions.	Ranitidine	47-57	arginine vasopressin	Rattus norvegicus	79-90
7967226-6	1994	Ranitidine, a histamine H2-receptor antagonist with AChE inhibitory activity and ACh release facilitatory activity, enhanced the motor activity but decreased blood pressure at 1 to 10 mg/kg, i.v.	Ranitidine	0-10	histamine receptor H2	Canis lupus familiaris	14-35
7967226-6	1994	Ranitidine, a histamine H2-receptor antagonist with AChE inhibitory activity and ACh release facilitatory activity, enhanced the motor activity but decreased blood pressure at 1 to 10 mg/kg, i.v.	Ranitidine	0-10	acetylcholinesterase	Canis lupus familiaris	52-56
8174779-6	1994	In vivo, the IgE-independent MC secretagogues, compound 48/80 and ACTH, induced anagen in mouse telogen follicles after intracutaneous administration, while inhibitors of mast cell degranulation (cromoglycate, tiacrilast) and antagonists of selected MC products (clemastin, ranitidine, ketanserin) significantly retarded the induced development of anagen follicles in these mice.	Ranitidine	274-284	pro-opiomelanocortin-alpha	Mus musculus	66-70
7912509-10	1994	Ranitidine inhibited gastric ADH to a similar extent on a molar basis, but its effect on alcohol levels in vivo was less constant in various studies.	Ranitidine	0-10	aldo-keto reductase family 1 member A1	Homo sapiens	29-32
7511596-10	1994	Cimetidine and ranitidine, H2 receptor antagonists structurally unrelated to each other, completely reversed the histamine-mediated increase in IL-1 alpha-induced IL-6 synthesis.	Ranitidine	15-25	interleukin 6	Homo sapiens	163-167
8120456-7	1994	The indirect effect of histamine on ADCC of NK cells and the effect of histamine on ADCC of monocytes/neutrophils were completely antagonized by the specific H2 receptor (H2R) blocker ranitidine.	Ranitidine	184-194	histamine receptor H2	Homo sapiens	158-169
8129609-1	1994	BACKGROUND: The histamine H2-receptor antagonist ranitidine hydrochloride has been shown to improve trauma-, blood transfusion-, and sepsis-induced immunosuppression.	Ranitidine	49-73	histamine receptor H2	Homo sapiens	16-37
8120456-7	1994	The indirect effect of histamine on ADCC of NK cells and the effect of histamine on ADCC of monocytes/neutrophils were completely antagonized by the specific H2 receptor (H2R) blocker ranitidine.	Ranitidine	184-194	histamine receptor H2	Homo sapiens	171-174
8025518-4	1994	A similar observation has been made with the use of ranitidine after marrow transplantation suggesting that histamine H2-receptor antagonists should be used very cautiously, if at all, in the setting of bone marrow transplantation.	Ranitidine	52-62	histamine receptor H2	Homo sapiens	108-129
7907797-6	1994	In all these gastric secretory models ranitidine, as expected, antagonized histamine H2-receptor-mediated responses, showing a potency comparable to that found in cardiac preparations (pA2 values were 6.84, 6.38 and 6.78 in the atria, papillary muscle and gastric fundus, respectively).	Ranitidine	38-48	histamine receptor H 2	Rattus norvegicus	75-96
8180296-14	1994	serum gastrin levels were already elevated during the initial high-dose ranitidine treatment (128 +/- 23 pg/ml).	Ranitidine	72-82	gastrin	Homo sapiens	6-13
7976661-3	1994	Mepyramine and ranitidine given 2 h before the induction of EBP prevented the accumulation of water, sodium and albumin in samples taken from the parietal cortex.	Ranitidine	15-25	EBP, cholestenol delta-isomerase	Rattus norvegicus	60-63
7975647-0	1994	[Activity of lysozyme in serum and selected granulocytic cytoenzymatic markers evaluated in patients with duodenal ulcer treated with ranitidine].	Ranitidine	134-144	lysozyme	Homo sapiens	13-21
7975647-3	1994	In the group of patients with duodenal ulcer after two weeks of treatment with ranitidine, a statistically significant increase was found of diluted serum lysozyme activity as compared to the activity of this enzyme before the treatment.	Ranitidine	79-89	lysozyme	Homo sapiens	155-163
7975647-5	1994	On the basis of the obtained results of studies the conclusions were formulated: 1) The increase of diluted serum lysozyme activity in the patients with duodenal ulcer after two weeks of treatment with ranitidine may evidence the presence of inhibitors of the enzyme in the serum of the studied group.	Ranitidine	202-212	lysozyme	Homo sapiens	114-122
8101695-6	1993	Increases in serum gastrin concentrations between the baseline and the 8-wk visit were greater in lansoprazole-treated than in ranitidine-treated patients.	Ranitidine	127-137	gastrin	Homo sapiens	19-26
8039538-10	1994	It is recommended that the dose of ranitidine is halved in patients with GFR &lt; or = 20 ml min-1.	Ranitidine	35-45	Rap guanine nucleotide exchange factor 5	Homo sapiens	73-76
8039538-10	1994	It is recommended that the dose of ranitidine is halved in patients with GFR &lt; or = 20 ml min-1.	Ranitidine	35-45	CD59 molecule (CD59 blood group)	Homo sapiens	93-98
8070507-2	1994	Ranitidine 150 mg.l-1 was perfused at 10 ml.min-1 for 180 min in different sites of the small intestine between 65-250 cm beyond the teeth.	Ranitidine	0-10	CD59 molecule (CD59 blood group)	Homo sapiens	44-49
7875420-0	1994	[Variations of plasma gastrin (basal and postprandial) in ththtreatmentof duodenal ulcer with either enprostil or ranitidine.	Ranitidine	114-124	gastrin	Homo sapiens	22-29
7875420-3	1994	This is at variance with the elevation of plasma gastrin observed with ranitidine.	Ranitidine	71-81	gastrin	Homo sapiens	49-56
7904426-5	1993	An intraperitoneal injection of galanin (an inhibitor of gastrin release) or ranitidine (a blocker of histamine H2-receptor) also suppressed the calcium-lowering effect of IBM, whereas omeprazole (an inhibitor of the proton pump) had no effect.	Ranitidine	77-87	histamine receptor H 2	Rattus norvegicus	102-123
8314361-5	1993	Cimetidine, ranitidine and famotidine all reduced significantly the t1/2 beta of naproxen by 50% from 25 h to 13 h and the t1/2 alpha from 4.0 h to 1.1 h. No effect of the H2 antagonists was observed on the absorption of naproxen.	Ranitidine	12-22	CD6 molecule	Homo sapiens	123-151
8281874-4	1994	The mean integrated 24-hr plasma gastrin concentration during dosing with ranitidine 150 mg four times a day was 904 pmol/hr/liter compared with placebo (410 pmol/hr/liter)--an increase of 122%.	Ranitidine	74-84	gastrin	Homo sapiens	33-40
8285777-5	1993	Serum gastrin concentration was &gt; 150 ng/l in four patients on omeprazole and in three patients on ranitidine.	Ranitidine	102-112	gastrin	Homo sapiens	6-13
8288442-8	1993	The inhibitory effects of histamine on [Ca2+]i accumulation in differentiated cells were partially reversed by histamine H2 receptor antagonist ranitidine, whereas in undifferentiated cells, the effects of histamine on Ca2+ mobilization were not affected by ranitidine.	Ranitidine	144-154	histamine receptor H2	Homo sapiens	111-132
8364260-10	1993	CONCLUSIONS: This study shows that treatment with ranitidine, in a dose up to 300 mg bid, has no significant effect on serum ethanol concentrations, even when ethanol was given in divided doses to simulate normal patterns of social drinking.	Ranitidine	50-60	BH3 interacting domain death agonist	Homo sapiens	85-88
8317406-7	1993	In a group of 34 patients studied prospectively, high dosage (300 mg orally bid) therapy with the H2-antagonist ranitidine for 8 wk significantly improved symptoms and endoscopic appearance (p &lt; 0.05).	Ranitidine	112-122	BH3 interacting domain death agonist	Homo sapiens	76-79
8377843-5	1993	In all the experimental models amthamine was more potent than dimaprit (from 3 to 10 fold) and approximately equipotent with histamine, and its effect was competitively antagonized by the histamine H2 receptor antagonists famotidine or ranitidine.	Ranitidine	236-246	histamine receptor H 2	Rattus norvegicus	188-209
8315550-0	1993	Ranitidine treatment in newborn infants: effects on gastric acidity and serum prolactin levels.	Ranitidine	0-10	prolactin	Homo sapiens	78-87
8473547-0	1993	Effect of concomitantly administered cimetidine or ranitidine on the pharmacokinetics of the 5-HT2-receptor antagonist ritanserin.	Ranitidine	51-61	5-hydroxytryptamine receptor 2A	Homo sapiens	93-107
8223837-1	1993	This was an open, randomized study of the cardiovascular effects of the histamine H2 receptor antagonists ranitidine, famotidine, and nizatidine after single oral doses alone or in combination in healthy volunteers.	Ranitidine	106-116	histamine receptor H2	Homo sapiens	72-93
8097411-9	1993	The histamine H2-receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine and roxatidine acetate) continue as first-line therapy for peptic ulcer disease and are effective in preventing relapse.	Ranitidine	51-61	histamine receptor H 2	Rattus norvegicus	4-25
8472980-5	1993	The expected rise in meal stimulated plasma gastrin with ranitidine was seen in the 12 patients who received ranitidine but, despite suppression of H pylori urease activity in 10 of 12 patients taking ranitidine bismuth citrate, there was no attenuation of the meal stimulated gastrin rise.	Ranitidine	57-67	gastrin	Homo sapiens	44-51
8472980-5	1993	The expected rise in meal stimulated plasma gastrin with ranitidine was seen in the 12 patients who received ranitidine but, despite suppression of H pylori urease activity in 10 of 12 patients taking ranitidine bismuth citrate, there was no attenuation of the meal stimulated gastrin rise.	Ranitidine	109-119	gastrin	Homo sapiens	44-51
8095692-12	1993	The production of pro-IL-1 alpha in bone marrow stromal cells stimulated by histamine was inhibited not only by H2 antagonists, such as cimetidine, ranitidine, and famotidine, but also by the protein kinase A antagonist KT-5720.	Ranitidine	148-158	interleukin 1 alpha	Mus musculus	22-32
8095031-5	1993	Pretreatment with atropine or ranitidine inhibited the development of stress ulcers, reduced changes in ir-TRH concentrations in the gastric wall and gastric juice, and induced an increase in gastric pH.	Ranitidine	30-40	thyrotropin releasing hormone	Rattus norvegicus	107-110
8441926-3	1993	The mainstay for pharamacological management of gastric ulceration exists in reduction or neutralization of gastric acid secretion through administration of histamine H2 receptor blockers such as cimetidine and ranitidine.	Ranitidine	211-221	histamine receptor H2	Homo sapiens	157-178
8381053-1	1993	The hypothesis that the histamine H2 receptor blocker ranitidine potentiates neuromuscular paralysis during anaesthesia was tested in vivo in urethane anaesthetised and mechanically ventilated rats.	Ranitidine	54-64	histamine receptor H 2	Rattus norvegicus	24-45
8496937-1	1993	Ranitidine (1), the histamine H2-receptor antagonist, has been previously reported to increase gastric emptying and gastric motility by inhibition of acetylcholinesterase (AChE) and enhancement of acetylcholine (ACh) release.	Ranitidine	0-10	histamine H2 receptor	Oryctolagus cuniculus	20-41
8496937-1	1993	Ranitidine (1), the histamine H2-receptor antagonist, has been previously reported to increase gastric emptying and gastric motility by inhibition of acetylcholinesterase (AChE) and enhancement of acetylcholine (ACh) release.	Ranitidine	0-10	ACE-1	Oryctolagus cuniculus	150-170
8496937-1	1993	Ranitidine (1), the histamine H2-receptor antagonist, has been previously reported to increase gastric emptying and gastric motility by inhibition of acetylcholinesterase (AChE) and enhancement of acetylcholine (ACh) release.	Ranitidine	0-10	ACE-1	Oryctolagus cuniculus	172-176
8435440-7	1993	In the presence of the histamine H2-receptor antagonist ranitidine, histamine was ineffective but pentagastrin and gastrin-17 (G17) maintained their capacity to induce the morphological transformations.	Ranitidine	56-66	histamine receptor H 2	Rattus norvegicus	23-44
8424425-6	1993	Ranitidine 300 mg bid provides an alternative therapeutic approach for patient populations at risk for ulcer complications.	Ranitidine	0-10	BH3 interacting domain death agonist	Homo sapiens	18-21
8490080-8	1993	Basal serum gastrin concentrations, which were already elevated by the previous high-dose ranitidine treatment (125 +/- 25 pg/ml), rose to four times the normal values after 4 weeks of treatment with lansoprazole (255 +/- 65 pg/ml).	Ranitidine	90-100	gastrin	Homo sapiens	12-19
8425242-1	1993	Continuous gastroesophageal pH monitoring was used to evaluate the effect of ranitidine on gastroesophageal reflux (GOR) in 60 patients scheduled for elective non-gastrointestinal abdominal or gynaecological surgery.	Ranitidine	77-87	GER	Homo sapiens	116-119
8481359-3	1993	Most trials utilizing high dose IL-2 employ indomethacin and ranitidine in order to alleviate or prevent IL-2 toxicity, but only administer these medications concurrently with IL-2 therapy.	Ranitidine	61-71	interleukin 2	Homo sapiens	105-109
8481359-3	1993	Most trials utilizing high dose IL-2 employ indomethacin and ranitidine in order to alleviate or prevent IL-2 toxicity, but only administer these medications concurrently with IL-2 therapy.	Ranitidine	61-71	interleukin 2	Homo sapiens	105-109
1284190-0	1992	The effects of histamine, pyrilamine, cimetidine, and ranitidine on secretion of lingual lipase and amylase from rat von Ebner"s glands.	Ranitidine	54-64	lipase F, gastric type	Rattus norvegicus	81-95
7510793-0	1993	The anti-ulcer drug ranitidine hydrochloride and its synthetic intermediates are inactivators of monoamine oxidase-B.	Ranitidine	20-44	monoamine oxidase B	Homo sapiens	97-116
8016577-7	1993	In a study in 30 H. pylori-negative patients with functional dyspepsia ranitidine (150 mg bid) significantly reduced the severity of heartburn.	Ranitidine	71-81	BH3 interacting domain death agonist	Homo sapiens	90-93
8249388-0	1993	[Changes of IgA, IgG and IgM immunoglobulins and of 10 other plasma proteins in patients with duodenal ulcer treated with ranitidine].	Ranitidine	122-132	CD79a molecule	Homo sapiens	12-15
1481550-8	1992	The corresponding values in the piroxicam/ranitidine 150 mg bid group (group B) were 3.3 +/- 1.2 (stomach) (p &gt; 0.05 vs. group A) and 1.4 +/- 0.7 (duodenum) (p &lt; 0.05 vs. group A).	Ranitidine	42-52	BH3 interacting domain death agonist	Homo sapiens	60-63
1481550-9	1992	The values in the piroxicam/ranitidine 300 mg bid group (group C) averaged 1.0 +/- 0.0 (stomach) and 0.3 +/- 0.1 (duodenum) (for both p &lt; 0.05 vs. group A).	Ranitidine	28-38	BH3 interacting domain death agonist	Homo sapiens	46-49
8429117-5	1993	In these time windows also the time spent above 3.0 pH units was significantly shorter for the former regimen than for 300 mg bid of both nizatidine (P &lt; .01) and ranitidine (P &lt; .05).	Ranitidine	166-176	BH3 interacting domain death agonist	Homo sapiens	126-129
1284190-6	1992	The H2 receptor inhibitors, cimetidine and ranitidine, stimulated secretion of only amylase, but not lingual lipase.	Ranitidine	43-53	lipase F, gastric type	Rattus norvegicus	101-115
1362604-0	1992	A histaminergic H2-receptor antagonist, ranitidine, blocks the suppressive vasopressin response to fear-related emotional stress in the rat.	Ranitidine	40-50	arginine vasopressin	Rattus norvegicus	75-86
1362604-8	1992	Ranitidine blocked the suppressive vasopressin and the facilitative prolactin responses to the associatively applied emotional stress, but the drug did not change the facilitative oxytocin or ACTH response to the stress.	Ranitidine	0-10	arginine vasopressin	Rattus norvegicus	35-46
1358393-8	1992	The contractile response to histamine was antagonized by the histamine H1-receptor antagonist, clemizole (0.1 microM) but was potentiated by the histamine H2-receptor antagonist, ranitidine (10 microM).	Ranitidine	179-189	histamine receptor H2	Homo sapiens	145-166
1455167-4	1992	Ranitidine was found to present non-competitive inhibition only on low Km gastric ADH with a Ki of 12 mmol l-1.	Ranitidine	0-10	alcohol dehydrogenase 1C (class I), gamma polypeptide	Rattus norvegicus	82-85
1355465-10	1992	The histamine H2-receptor antagonists (cimetidine, ranitidine, famotidine, and nizatidine) continue as first-line therapy for peptic ulcer disease and are effective in preventing relapse.	Ranitidine	51-61	histamine receptor H 2	Rattus norvegicus	4-25
1362971-8	1992	The histamine H2-receptor antagonists cimetidine and ranitidine inhibited both in vitro parameters, whereas the gastric proton pump inhibitor omeprazole only affected aminopyrine accumulation.	Ranitidine	53-63	histamine receptor H2	Homo sapiens	4-25
1364175-2	1992	H2 antagonists, cimetidine, famotidine and ranitidine were used to inhibit cytochrome P-450 in rat liver.	Ranitidine	43-53	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	75-91
1353559-0	1992	Effect of indomethacin plus ranitidine in advanced melanoma patients on high-dose interleukin-2.	Ranitidine	28-38	interleukin 2	Homo sapiens	82-95
1353559-5	1992	Indomethacin and ranitidine may be responsible for some responses in melanoma patients previously attributed to IL-2.	Ranitidine	17-27	interleukin 2	Homo sapiens	112-116
1527233-4	1992	Ranitidine, a histamine H2-receptor antagonist, is also excreted renally and may compete with NDMAD for renal secretion.	Ranitidine	0-10	histamine receptor H2	Homo sapiens	14-35
1534659-5	1992	Loss of tyrosinase activity could be prevented by cimetidine and ranitidine, an H2 antagonist.	Ranitidine	65-75	tyrosinase	Homo sapiens	8-18
1427586-0	1992	Gastric acid secretion and plasma gastrin during short-term treatment with omeprazole and ranitidine in duodenal ulcer patients.	Ranitidine	90-100	gastrin	Homo sapiens	34-41
1427586-7	1992	The increase in fasting plasma gastrin observed after ranitidine and omeprazole was 86% and 242%, respectively, on day 7, and 13% and 103% twenty-four hours after final dose.	Ranitidine	54-64	gastrin	Homo sapiens	31-38
1433852-4	1992	The biological half life of serum ranitidine in Group 1 was 98.9 +/- 13.8 (M +/- SD) min, which was not significantly different from that of Group 2.	Ranitidine	34-44	MSD	Homo sapiens	75-83
1371435-1	1992	This investigation examined the effect of cimetidine, famotidine, and ranitidine on rat liver acetyl CoA:arylamine N-acetyltransferase (NAT) activity.	Ranitidine	70-80	N-acetyltransferase 1	Rattus norvegicus	136-139
1552502-1	1992	The histaminergic H2 antagonist, ranitidine, has also been found to significantly inhibit acetylcholinesterase (AChE) in vitro.	Ranitidine	33-43	acetylcholinesterase (Cartwright blood group)	Homo sapiens	90-110
1552502-1	1992	The histaminergic H2 antagonist, ranitidine, has also been found to significantly inhibit acetylcholinesterase (AChE) in vitro.	Ranitidine	33-43	acetylcholinesterase (Cartwright blood group)	Homo sapiens	112-116
1347778-1	1992	Following a recent report that epithelial cells of the choroid plexus possess histamine H2 receptors, the effect of cimetidine and ranitidine, histamine H2 receptor antagonists, on the secretion and electrolyte content of CSF was examined.	Ranitidine	131-141	granulocyte-macrophage colony-stimulating factor	Felis catus	222-225
1347778-5	1992	Whereas the secretion of CSF did not change over 6 h in the control group, it decreased significantly by 30-60 min after injection of cimetidine or ranitidine and remained low for the following 6 1/2 h in all experimental groups except the 10-mg ranitidine group.	Ranitidine	148-158	granulocyte-macrophage colony-stimulating factor	Felis catus	25-28
1347778-5	1992	Whereas the secretion of CSF did not change over 6 h in the control group, it decreased significantly by 30-60 min after injection of cimetidine or ranitidine and remained low for the following 6 1/2 h in all experimental groups except the 10-mg ranitidine group.	Ranitidine	246-256	granulocyte-macrophage colony-stimulating factor	Felis catus	25-28
1347778-6	1992	Peak cimetidine and ranitidine concentrations in CSF in the 50-mg experimental groups were noted 60 and 90 min, respectively, after intravenous injection.	Ranitidine	20-30	granulocyte-macrophage colony-stimulating factor	Felis catus	49-52
1347778-8	1992	We conclude that intravenous cimetidine or ranitidine can significantly reduce CSF secretion in the cat, possibly by competitive inhibition of the histamine effect on H2 receptors located on the choroid plexus epithelial cell, or by a direct effect on the capillaries of the choroid plexus.	Ranitidine	43-53	granulocyte-macrophage colony-stimulating factor	Felis catus	79-82
1371435-3	1992	At an inhibitor:substrate ratio of 2:1, ranitidine, cimetidine, and famotidine reduced NAT II activity by 9, 48, and 75%, respectively.	Ranitidine	40-50	N-acetyltransferase 1	Rattus norvegicus	87-90
1748040-3	1991	The effects of inhibition of basal and pentagastrin-stimulated acid secretion by ranitidine on the deep histological gastric damage induced by 30 min of infusion of PAF (100 ng/kg/min) were assessed by using a histological score.	Ranitidine	81-91	PCNA clamp associated factor	Rattus norvegicus	165-168
1727201-2	1992	OBJECTIVE: To determine whether the H2-receptor antagonist, ranitidine, which is a potent inhibitor of gastric alcohol dehydrogenase activity in vitro, increases the bioavailability of orally administered ethanol (0.3 g/kg of body weight) and to compare the resulting blood alcohol concentrations with those of two other H2-antagonists, cimetidine and famotidine, the latter of which does not inhibit gastric alcohol dehydrogenase.	Ranitidine	60-70	alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	Homo sapiens	103-132
1727201-2	1992	OBJECTIVE: To determine whether the H2-receptor antagonist, ranitidine, which is a potent inhibitor of gastric alcohol dehydrogenase activity in vitro, increases the bioavailability of orally administered ethanol (0.3 g/kg of body weight) and to compare the resulting blood alcohol concentrations with those of two other H2-antagonists, cimetidine and famotidine, the latter of which does not inhibit gastric alcohol dehydrogenase.	Ranitidine	60-70	alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	Homo sapiens	401-430
1736336-0	1992	Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet-activating factor, pepsinogen A, and gastrin in duodenal ulcer patients.	Ranitidine	59-69	gastrin	Homo sapiens	165-172
1687371-9	1991	Ranitidine inhibited pentagastrin-, bethanechol-, and histamine-induced acid secretion, whereas the CCKB/gastrin antagonists inhibited only the secretory response to pentagastrin.	Ranitidine	0-10	gastrin	Rattus norvegicus	26-33
1353465-6	1992	Administration of ranitidine resulted in a similar rate of ulcer healing and in a similar accumulation of EGF in the ulcer area to that observed after ebrotidine, but the increments in plasma gastrin levels in rats treated with ranitidine were observed at lower doses than in tests with ebrotidine.	Ranitidine	18-28	gastrin	Rattus norvegicus	192-199
1353465-6	1992	Administration of ranitidine resulted in a similar rate of ulcer healing and in a similar accumulation of EGF in the ulcer area to that observed after ebrotidine, but the increments in plasma gastrin levels in rats treated with ranitidine were observed at lower doses than in tests with ebrotidine.	Ranitidine	228-238	gastrin	Rattus norvegicus	192-199
1471315-0	1992	Effects of omeprazole and ranitidine on plasma gastrin concentration and stomach gastrin content in rats.	Ranitidine	26-36	gastrin	Rattus norvegicus	47-54
1471315-2	1992	After 28 days omeprazole (80 mumol/kg x 2) or ranitidine (375 mumol/kg x 4) that produced corresponding inhibition of acid secretion, increased the tissue gastrin content by 114 and 59%.	Ranitidine	46-56	gastrin	Rattus norvegicus	155-162
1748040-5	1991	Stimulation of gastric acid secretion by pentagastrin significantly increased PAF-induced gastric damage, and this effect was reversed by a dose of ranitidine that returns acid secretion to baseline levels.	Ranitidine	148-158	PCNA clamp associated factor	Rattus norvegicus	78-81
1810260-2	1991	Volunteers were pretreated with ranitidine (CAS 66357-35-5) (150 mg b.d.)	Ranitidine	32-42	BCAR1 scaffold protein, Cas family member	Homo sapiens	44-47
1811991-2	1991	Adenosine deaminase activity was studied in the gastric mucosa of patients with peptic ulcer in relation to ulcer localisation and treatment with ranitidine or sucralfate.	Ranitidine	146-156	adenosine deaminase	Homo sapiens	0-19
1811991-4	1991	A significant decrease in adenosine deaminase activity was found after treatment with ranitidine but not with sucralfate.	Ranitidine	86-96	adenosine deaminase	Homo sapiens	26-45
1680932-1	1991	In cultured human melanoma cells, histamine H1 (mepyramine) and H2 receptor antagonists (cimetidine, ranitidine, impromidine) increased tyrosinase activity, whereas H2 agonists (dimaprit, nordimaprit) decreased activity.	Ranitidine	101-111	tyrosinase	Homo sapiens	136-146
1803344-3	1991	The respiratory stimulating effect of TRH remained unchanged after pretreatments with histamine H1-receptor antagonist diphenhydramine or H2-receptor antagonists cimetidine and ranitidine, while the TRH-induced hypertension and tachycardia were attenuated by cimetidine.	Ranitidine	177-187	thyrotropin releasing hormone	Rattus norvegicus	38-41
1664503-7	1991	Intracerebroventricular infusion of the H1 receptor antagonist mepyramine (0.37 mumol) or the H2 receptor antagonists cimetidine (0.40 mumol) or ranitidine (0.40 mumol) inhibited or prevented the alpha-MSH response to intracerebroventricular administration of HA (0.27 mumol), restraint or ether stress.	Ranitidine	145-155	proopiomelanocortin	Rattus norvegicus	196-205
1889719-8	1991	Either intermittent or continuous dosing with ranitidine was associated with an elevation of plasma gastrin concentration, which remained constant throughout the 5-month study.	Ranitidine	46-56	gastrin	Homo sapiens	100-107
1765356-0	1991	Omeprazole 20 mg uid and ranitidine 150 mg bid in the treatment of benign gastric ulcer.	Ranitidine	25-35	BH3 interacting domain death agonist	Homo sapiens	43-46